
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_enob_enochianbio.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20200701_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001527728 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_06/30 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_e3109__10k.xdxs -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001527728</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">06/30</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0102" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0128" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0129" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0134" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0135" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0217" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0230" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0263" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0264" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0271" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0272" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0279" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0280" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0287" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0288" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0295" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0296" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0297" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0303" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0304" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0307" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0308" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0310" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0313" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0314" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0315" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0329" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0330" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0331" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0337" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0338" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0345" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0346" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0353" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0354" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0361" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0362" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0369" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0370" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0377" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0378" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0383" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0384" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0385" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0386" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0387" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0393" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0394" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0399" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0401" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0402" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0405" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0406" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0408" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0411" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0412" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0413" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0449" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0464" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0468" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0491" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0498" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0507" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0510" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0513" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0537" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0540" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0548" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0555" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0658" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0659" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0666" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0667" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0670" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0671" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0814" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0948" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0954" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0955" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0963" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0965" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0966" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0972" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0980" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0983" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1003" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1009" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1010" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1246" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1248" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1250" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1252" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1254" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1256" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1258" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1260" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1262" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1266" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1268" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1270" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1302" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1304" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1306" xs:nil="true"></ix:nonnumeric>
  <ix:nonnumeric id="xdx2ixbrl1312" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1316" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1318" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1359" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1363" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1365" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1367" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1371" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1373" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1375" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1377" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1379" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1381" xs:nil="true"></ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1383" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1391" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="enob-20210630.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2020-07-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EnochianBiopharmaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">enob:EnochianBiopharmaIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_EnochianBiopharmaIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">enob:EnochianBiopharmaIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">enob:EmployeeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_custom_EmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">enob:EmployeeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_LabEquipmentAndInstrumentsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_LabEquipmentAndInstrumentsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">enob:AccumulatedAmortizationMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">enob:AccumulatedAmortizationMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">enob:AccumulatedAmortizationMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-012018-11-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2018-11-01</xbrli:startdate>
        <xbrli:enddate>2018-11-13</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-06-01</xbrli:startdate>
        <xbrli:enddate>2019-06-19</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ConvertibleNotesPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">enob:ConvertibleNotesPayablesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ConvertibleNotesPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">enob:ConvertibleNotesPayablesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_NotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">enob:NotePayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_NotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">enob:NotePayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-02-01</xbrli:startdate>
        <xbrli:enddate>2021-02-11</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-04</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_UnitedStatesTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">enob:UnitedStatesTaxMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_UnitedStatesTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">enob:UnitedStatesTaxMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-07-01</xbrli:startdate>
        <xbrli:enddate>2021-07-08</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-08_us-gaap_SubsequentEventMember_custom_LincolnParksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">enob:LincolnParksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-21_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">enob:PurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">enob:LincolnParkMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-09_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-152021-07-09_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-03-15</xbrli:startdate>
        <xbrli:enddate>2021-07-09</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-06-01</xbrli:startdate>
        <xbrli:enddate>2021-06-14</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-06-01</xbrli:startdate>
        <xbrli:enddate>2021-06-16</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-06-01</xbrli:startdate>
        <xbrli:enddate>2020-06-16</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-14_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">enob:LincolnParkMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-14_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">enob:LincolnParkMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-06-01</xbrli:startdate>
        <xbrli:enddate>2021-06-14</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-11_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">enob:LincolnParkMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-11_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">enob:LincolnParkMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-06-01</xbrli:startdate>
        <xbrli:enddate>2021-06-11</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-182021-06-09_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-03-18</xbrli:startdate>
        <xbrli:enddate>2021-06-09</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-02-01</xbrli:startdate>
        <xbrli:enddate>2021-02-18</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-12-01</xbrli:startdate>
        <xbrli:enddate>2021-12-14</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-27_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-03_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-27_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-12-01</xbrli:startdate>
        <xbrli:enddate>2019-12-27</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">enob:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">enob:EBIAndWeirdScienceLLCMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_DanDritDenmarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:DanDritDenmarkMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_DanDritDenmarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:DanDritDenmarkMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">enob:EnochianBiosciencesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">enob:EnochianBiosciencesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EnochianBiosciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">enob:EnochianBiosciencesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-012017-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2017-10-01</xbrli:startdate>
        <xbrli:enddate>2017-10-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-02-06_custom_EquityIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">enob:EquityIncentivePlan2014Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">enob:N2019EquityIncentivePlanMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:EmployeesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">enob:N2019EquityIncentivePlanMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:EmployeesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:BoardOfDirectorsAndScientificAdvisoryMembersMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:BoardOfDirectorsAndScientificAdvisoryMembersMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_PlanOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:PlanOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_BlackScholesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">enob:BlackScholesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EmployeeStockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:EmployeeStockOptionOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:CommonStockPurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:CommonStockPurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:CommonStockPurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:CommonStockPurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange4Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange4Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-07_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange5Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange5Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-09_custom_ConsultingAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">enob:ConsultingAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2019-07-09</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ConsultingAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">enob:ConsultingAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012020-06-30_custom_ConsultingAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">enob:ConsultingAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-07-01</xbrli:startdate>
        <xbrli:enddate>2020-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_LicenseAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">enob:LicenseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_LicenseAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">enob:LicenseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-06_custom_LicenseAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">enob:LicenseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-02-01</xbrli:startdate>
        <xbrli:enddate>2021-02-06</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-012021-08-25_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-08-01</xbrli:startdate>
        <xbrli:enddate>2021-08-25</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-10-10_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-10-01</xbrli:startdate>
        <xbrli:enddate>2021-10-10</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 10pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>United
states</b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20200701__20210630_zUiiAxeB466e"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:DocumentType" inside-table="false" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--DocumentAnnualReport_c20200701__20210630_zm6Vo0MtLKmk"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span><span style="text-transform: uppercase"><b>&nbsp;ANNUAL
report under section 13 Or 15(</b></span><b>d<span style="text-transform: uppercase">) of the securities exchange act of 1934
</span></b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_90D_edei--DocumentPeriodEndDate_c20200701__20210630_zyPlFfyfdYdb"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">June 30, 2021</ix:nonnumeric></span></span></span></b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--DocumentTransitionReport_c20200701__20210630_zHnZXtV0xSr7"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="false" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span><span style="text-transform: uppercase"><b>&nbsp;TRANSITION
report under section 13 Or 15(</b></span><b>d<span style="text-transform: uppercase">) of the securities exchange act of 1934
</span></b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the transition period from</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
file number <b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityFileNumber_c20200701__20210630_ztsUqbslUfae"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">000-54478</ix:nonnumeric></span></span></span></b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; font: 10pt/107% Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font: 24pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityRegistrantName_c20200701__20210630_zbsO7dj0HdHa"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityRegistrantName" inside-table="true" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ENOCHIAN BIOSCIENCES INC</ix:nonnumeric></span></span>. </b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Name
of registrant in its charter) </span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 50%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20200701__20210630_zpgqYapcLnp6"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span>
</span></td>
<td style="vertical-align: top; width: 1%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 49%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20200701__20210630_z5dbZSyVtWPb"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45-2559340</ix:nonnumeric></span></span>
</span></td></tr>
<tr>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(State
or other jurisdiction of </span><span style="font-family: Times New Roman, Times, Serif"><br><span style="font-size: 10pt"> incorporation
or organization) </span></span></td>
<td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
Employer </span><span style="font-family: Times New Roman, Times, Serif"><br><span style="font-size: 10pt"> Identification No.)
</span></span></td></tr>
<tr>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20200701__20210630_znDCx1cgTMu3"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2080 Century Park East</ix:nonnumeric></span></span> &nbsp; <span id="xdx_902_edei--EntityAddressAddressLine2_c20200701__20210630_zs80ZfnzpK7f"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityAddressAddressLine2" inside-table="true" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Suite 906</ix:nonnumeric></span></span> &nbsp; <span id="xdx_903_edei--EntityAddressCityOrTown_c20200701__20210630_z7SjX2i8kqc6"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Los Angeles</ix:nonnumeric></span></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20200701__20210630_zeU01ATcRbV2"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">CA</ix:nonnumeric></span></span></span></td>
<td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20200701__20210630_zE0WXx3lmVP7"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90067-2012</ix:nonnumeric></span></span></span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(Address of principal
executive offices) </span></td>
<td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code) </span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">+1<span id="xdx_90E_edei--CityAreaCode_c20200701__20210630_zYq4LHNg1V8h"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">(305)</ix:nonnumeric></span></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20200701__20210630_zIJXrqVDsBJk"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">918-1980</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Registrant’s
telephone number, including area code)</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom; background-color: white">
<td style="border-bottom: black 1pt solid; padding: 0; width: 34%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
of Each Class</b></span></td>
<td style="padding: 0; width: 1%; line-height: 107%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0; width: 32%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
Symbol</b></span></td>
<td style="padding: 0; width: 1%; line-height: 107%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0; width: 32%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
of Each Exchange on Which Registered</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding: 0; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--Security12bTitle_c20200701__20210630_zNgzFqfbfsB3"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:Security12bTitle" inside-table="true" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock,
par value $0.0001 per share</ix:nonnumeric></span></span></span></td>
<td style="padding: 0; line-height: 107%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--TradingSymbol_c20200701__20210630_z9HIdHTiiFwa"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:TradingSymbol" inside-table="true" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ENOB</ix:nonnumeric></span></span></span></td>
<td style="padding: 0; line-height: 107%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_903_edei--SecurityExchangeName_c20200701__20210630_zQJzV01TvF46"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" inside-table="true" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span></span>
Stock Market LLC</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(g) of the Act: Common Stock, $0.0001 par value</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;☐ Yes
☒ <span id="xdx_900_edei--EntityWellKnownSeasonedIssuer_c20200701__20210630_zXFTNpd5n8D6"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span> </span></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&nbsp;☐
Yes ☒&nbsp;<span id="xdx_901_edei--EntityVoluntaryFilers_c20200701__20210630_zkhtZPBTuBnf"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> </span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act
during the last 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. <span id="xdx_901_edei--EntityCurrentReportingStatus_c20200701__20210630_zRgH5OBsfMee"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;☒ No&nbsp;☐</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).&nbsp;<span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20200701__20210630_zP9vDLAicz55"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;☒ No&nbsp;☐</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 30%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer </span></td>
<td style="width: 20%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">☐</span></td>
<td style="width: 30%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated filer </span></td>
<td style="width: 20%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">☐</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityFilerCategory_c20200701__20210630_zzuajoLdk4il"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span> </span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">☒</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company </span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntitySmallBusiness_c20200701__20210630_zw3PQ1PLQrn2"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span> </span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth company</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20200701__20210630_zZaw7sXAM1Qg"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_905_edei--IcfrAuditorAttestationFlag_c20200701__20210630_znIgnM8srwn3"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ <span id="xdx_900_edei--EntityShellCompany_c20200701__20210630_zE2MaW19QPXc"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> </span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
December 31, 2020, the aggregate market value of the voting and non-voting common equity held by non-affiliates was $<span id="xdx_90F_edei--EntityPublicFloat_iI_c20201231_zGZK8vbYuTDa"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,506,916</ix:nonfraction></span></span>.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 24, 2021, the number
of shares outstanding of the registrant’s common stock, par value $0.0001 per share (the “Common Stock”) was
<span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20210924_zsUTdSXOqITk"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2021-09-24" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,219,661</ix:nonfraction></span></span>.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Portions of the registrant’s Proxy
Statement for its 2021 Annual Meeting of stockholders are incorporated by reference into Part III of this Annual Report on Form
10-K or will be filed by amendment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CONTENTS</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="vertical-align: top; width: 10%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; width: 80%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><i>Page</i></span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_029" tabindex="18">Forward-Looking Statements</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">ii</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Part I</b></span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 1 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_030" tabindex="18">Business</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 1A </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_031" tabindex="18">Risk Factors</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">18</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 1B</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_032" tabindex="18">Unresolved Staff Comment</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 2 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_033" tabindex="18">Properties</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 3 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_034" tabindex="18">Legal Proceedings</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 4 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_035" tabindex="18">Mine Safety Disclosures</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Part II</b></span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 5 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_036" tabindex="18">Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 6 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_037" tabindex="18">Selected Financial Data</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 7 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_038" tabindex="18">Management’s Discussion and Analysis of Financial Condition and Results Of Operations</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 7A </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_039" tabindex="18">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 8 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_040" tabindex="18">Financial Statements and Supplementary Data</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-1</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 9 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_041" tabindex="18">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 9A </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_042" tabindex="18">Controls and Procedures</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 9B </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_043" tabindex="18">Other Information</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Part III </b></span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 10 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_044" tabindex="18">Directors, Executive Officers and Corporate Governance</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 11 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_045" tabindex="18">Executive Compensation</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 12 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_046" tabindex="18">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 13 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_047" tabindex="18">Certain Relationships and Related Transactions and Director Independence</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 14 </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_048" tabindex="18">Principal Accountant Fees and Services</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Part IV</b></span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Item 15</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_049" tabindex="18">Exhibits, Financial Statement Schedules</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">45</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_050" tabindex="18">Signatures and Certifications</a></span></td>
<td style="vertical-align: bottom; text-align: right; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">47</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Cautionary Language Regarding Forward-Looking Statements
and Industry Data</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report
on Form 10-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act
of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking
statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements
are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our
business. In some cases, you can identify forward-looking statements by the following words: “may,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “anticipate,”
“believe,” “approximately,” “estimate,” “predict,” “project,” “potential”
or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that
a statement is not forward-looking.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Forward-looking
statements include, but are not limited to, statements concerning:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our potentially continuous incurrence of losses as a pre-clinical-stage
biotechnology company with no products that have achieved regulatory approval;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our ability to generate revenue if we fail to develop marketable product;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our dependence on substantial additional financing to support the research,
development, licensing, manufacture, and marketing of product candidates and products, and the possibility that unforeseen operational
costs will arise;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The dilutive effect on stockholders’ ownerships interests of
the Company raising capital through an equity issuance in connection with future equity financing or equity debt agreements;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our dependence on the services of experts, including Dr. Serhat Gümrükcü,
and third parties to research and develop product candidates in cooperation with our employees, officers, scientific advisory
board, and research institutions;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The difficulty or impossibility of predicting future clinical trial
results and regulatory outcomes of our products based upon our pre-clinical or earlier clinical trial performance;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The application of heightened regulatory and commercial scrutiny to
our gene, cell, and immunotherapy products given their novel nature and concomitant potential for actual or perceived safety issues;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our ability to compete in a rapidly developing field, and the potential
impact to our financial condition, product marketability, and operational capacities of a competitor receiving regulatory approval
before us, or a competitor developing a more advanced or efficacious therapy than our product;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Potential delays or total failures of third parties, such as universities,
non-profits, and clinical research centers, to perform obligations on which our product research and development rely;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Potential interruption or delay of our and our third-party contractors’
business operations due to COVID-19, which may prevent the timely initiation and conclusion of pre-clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The impact on our competitive position, business operations, and financial
condition of implementation of amended healthcare laws and regulations related to healthcare pricing and reimbursement;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The dependence of our research and development platform on intellectual
property licensed from licensors, and the severe adverse impact to our business operations of a disruption of one of our licensing
relationships;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The potential monetary costs of defending our intellectual property
rights in a dispute, and the possibility that an intellectual property dispute will not be settled in our favor;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The possibility that our patents and patent applications, even if unchallenged,
will not sufficiently protect or provide exclusive use of our intellectual property, which could jeopardize our ability to commercialize
our product and dissuade companies from subsequently collaborating with us;</span></td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The negative impact to our competitive position and the value of our
technology of our failure to protect trade secrets through the use of non-disclosure and confidentiality agreements, or the unavailability
of adequate recourse for breach of such agreements;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The fluctuation and volatility of the market price of our Common Stock
due to its limited public market, and the possibility that these issues will compound and strain our stockholders’ ability
to resell their Common Stock;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The ability of our principal stockholders and management, through their
ownership of a majority of our outstanding Common Stock, to exert significant control over matters requiring stockholder approval;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our significant dependence on sophisticated management with highly
technical expertise to oversee business operations, and our ability to attract and retain qualified personnel to sustain growth;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our ability to adapt to future growth by training an expanding employee
base and shifting away from reliance on third-party contractors;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The risk of liability arising from claims of environmental damage,
personal injury, and property damages in connection with our research and development activities, including those that involve
the use of hazardous materials;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The possibility that enforcement actions to suspend or severely restrict
our business operations will be brought against the Company for our failure to comply with laws or regulations and the potential
costs of defending against such actions;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Our reliance on adequate maintenance of the security and integrity
of our information technology systems to effectively operate our business; and</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Such other factors
as discussed throughout Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
and in Part I, Item 1A. Risk Factors herein.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="a_029"></span>A forward-looking
statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may
not occur. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Annual Report.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors, including without limitation the
risks and uncertainties described below the heading “Item 1.A. Risk Factors” in this report, that may cause our actual
results, performance, or achievements to be materially different from any future results, performance or achievements expressed
or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations
and assumptions that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving
the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things,
future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond our control. This is especially emphasized by the anticipated impacts from the COVID-19
pandemic on the Company, including the related effects to our business operations, results of operations, cash flows, and financial
position. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions
could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this Annual Report
will prove to be accurate. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction
of actual results. Any or all of the forward-looking statements contained in this Annual Report and any other public statement
made by us, including by our management, may turn out to be incorrect. We are including this cautionary note to make applicable
and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Information regarding
market and industry statistics contained in this report is included based on information available to us that we believe is accurate.
It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic
analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and
the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services.
Except as required by U.S. federal securities laws, we have no obligation to update forward-looking information to reflect actual
results or changes in assumptions or other factors that could affect those statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART I</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Unless otherwise
indicated or the context otherwise requires, all references in this prospectus to “we,” “us,” “our”
or the “Company” are to Enochian BioSciences Inc., a Delaware corporation (“Registrant”), together with
its wholly owned subsidiaries, Enochian Biopharma, Inc., a Delaware corporation (“Enochian Biopharma”) Enochian Biosciences
Denmark ApS, a Danish limited company, organized under the Danish Act on Limited Companies of the Kingdom of Denmark (“DanDrit
Denmark”), and Enochian Technology, Inc., a Nevada corporation (“Enochian Technology”). </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_030"></span>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are a pre-clinical stage biotechnology company committed to using our genetically modified cell, gene, and immune therapy technologies
to potentially prevent or cure HIV, HBV, influenza and coronavirus infections, as well as to provide potentially long-term or life-long
cancer remission in some of the deadliest cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Over the past several
years, Enochian BioSciences has expanded the pipeline from a single potential cure for HIV (autologous transplantation with gene-modified
cells; ENOB-HV-01) to three additional potential cures for HIV, a potential cure for Hepatitis B Virus (HBV), potential inhaled
treatment and prophylaxis/prevention of all variants of SARS-CoV-1 and -2 (the cause of the COVID-19 pandemic), and potential cures
for many solid tumors, beginning with pancreatic cancer.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our integrated platforms
encompass innovative interventions in gene and immune therapies that provide hope for cures or life-long remissions for devastating
diseases. Our platforms can potentially streamline and accelerate pre-clinical, regulatory, clinical, and production pathways.
Because of the relative ease of administration, our potentially groundbreaking interventions could be used throughout the world.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Platforms:
</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><i>Hijack RNA</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Our novel approach
tricks the virus into sending suicide signals to the infected cell instead of turning the cell into a virus factory. The technology
is delivered by vectors that would allow it to rapidly treat an infection, or to lay and wait in ambush until a cell becomes infected,
which would prevent (prophylaxis, similar to taking drugs to protect from becoming infected with malaria or HIV) future infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The delivery
mechanism can be adapted for aerosol (e.g., respiratory infections like the virus that causes COVID-19 and influenza), intravenous
or other delivery mechanisms (e.g. for Hepatitis B Virus and HIV).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.25in"><i>Allogeneic
Cell Therapy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.25in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The human immune
system is designed to recognize “self” and destroy “otherness” or “non-self”, such as bacteria,
viruses and cancer cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Alloreactivity
(reacting against another person’s cells) is the most powerful response the immune system generates. Several of our technologies
take advantage of the alloreactivity to hyperstimulate a person’s immune response to better attack a chronic infection (e.g.
HIV) or solid tumors. In certain treatments (e.g. HIV and cancer), cells taken from healthy donors are sometimes genetically modified
to further boost the immune system to seek and kill diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: center">*********</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">In addition to
those platforms, Enochian BioSciences has an innovative approach to remove cells from a person living with HIV and genetically
modify them so they cannot be infected with HIV. The unique innovation is an additional genetic alteration to increase the ability
of those cells to survive and expand when they are given back to the same person (autologous transplantation).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in; background-color: white">To
date, our operations have been funded by sales of our securities and the issuance of debt. We have never generated any sales revenue,
and we expect this to continue until our therapies or products are approved for marketing in the United States and/or Europe. Even
if we are successful in having our therapies or products approved for sale in the United States and/or Europe, we cannot guarantee
that a market for the therapies or products will develop. We may never be profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Respiratory Diseases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">In
June 2021, Enochian BioSciences acquired the exclusive license to a potential pan-SARS-Cornavirus-1 and-2 (SARS-CoV) and pan-Influenza
inhaled treatment and prophylaxis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">SARS-CoV-2
has caused the most devastating global pandemic in a century – COVID-19. Using the Hijack RNA platform technology, <i>in
vitro</i> and <i>in vivo </i>results showing rapid killing of infected cells but not uninfected cells were presented at the important
Conference on Retroviruses and Opportunistic Infections in March 2021. Since that time, there has been substantial progress with
a Pre-IND (as defined below) submission expected in the near term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">Influenza
has caused dozens of major global pandemics; the most notable in 1918 that killed 50 to 100 million people. There was an H1N1 threat
as recently as 2009. The Hijack RNA also has shown promising <i>in vitro</i> results that were presented at the Annual Conference
of the American Society of Gene and Cell Therapy (ASGCT) in May 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">Two
leading scientists and public health experts were announced as members of our newly formed Scientific Advisory Board focused on
respiratory diseases on August 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Human Immunodeficiency
Virus (HIV), and Acquired Immunodeficiency Syndrome (AIDS)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">HIV
attacks the human immune system, specifically killing off CD4+ cells, or T cells, which play a central, controlling role in the
immune system. Left untreated, HIV dramatically reduces the number of T cells in the body, devastates the immune system, leading
to AIDS, a condition where the immune system cannot fight off life-threatening infections and cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Currently
there are over 30 antiretroviral drugs, or ART, approved by the U.S. Food and Drug Administration (“FDA”) to treat
HIV but these drugs are expensive, require daily adherence, and can have significant side effects over time. In addition, on a
global basis, as many as 1 million people, including persons in high-income countries, continue to die each year from HIV/AIDS
due to drug-resistant HIV or lack of access to treatment. To date, there are no treatments that can eliminate the reservoir of
immune cells that are infected with HIV from the body. Consequently, treatment for HIV is life-long.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">There
have been several efforts to cure HIV by re-engineering a person’s own T-cells so that these cells no longer express a special
protein (C-C chemokine co-receptor type 5 or CCR5), which HIV uses to gain entry to them. A naturally occurring mutation that blocks
expression of CCR5 on T cells occurs in ~1% of persons living in or from Northern Europe with no known adverse effects. The “Berlin
patient”, and more recently the “London patient” were HIV-positive persons who developed cancer and were treated
with a bone marrow transplant with cells donated from persons with this naturally occurring mutation of CCR5. The Berlin and London
patients seem to have been effectively cured from HIV providing proof-of-concept that HIV can be cured. However, because the transplanted
cells come from another person, such transplants carry high risk and can result in death in a significant proportion of patients.
Given the success with these two patients, several researchers and companies have attempted to replicate this experience by genetically
modifying T cells of HIV-positive patients to render them unable to be infected by HIV and then returning them to the patient.
Because the transplanted cells are from the same person, the risks to the patient are much lower. The uptake, or engraftment of
the modified T cells, however, has not been optimal, leading to failure to achieve a cure. In addition, the transplant pre-treatment
that has been used is bone marrow-destroying chemotherapy, which wipes out the patient’s immune system and can have long-term
side effects including the risk of developing cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">ENOB-HV-01
is a novel, proprietary approach with the potential to overcome the failures of recent efforts to develop a cure for HIV. The intervention
provides gene-modified T cells with a competitive advantage over non-modified cells in the HIV-positive person, with the potential
to significantly increase engraftment; and avoids the need for chemotherapy that substantially depletes the bone marrow and could
potentially be given as an outpatient treatment. The Company met with the FDA INTERACT team on June 2, 2020. INTERACT is the first
available FDA interaction and is a key step in the process towards a potential Investigational New Drug Application (IND) to study
First-in-Human products potentially leading to marketing authorization via Biologics License Application (BLA). The FDA Center
for Biologics Evaluation and Research (CBER) has numerous INTERACT requests and grants meetings that are deemed appropriate for
this early FDA engagement. The Enochian management team considered the meeting to be successful with strong alignment between Enochian
BioSciences’s approach to developing ENOB-HV-01 and the comments of the FDA reviewers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Initial
scientific findings from a mouse study on the ENOB-HV-01 approach were presented at the annual ASCGT conference in May 2020. Additional
<i>in vitro</i> and <i>in vivo</i> studies are ongoing and/or planned. We hope to make a Pre-IND submission to the US FDA by end
of 2021 or early 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are also developing ENOB-HV-11 and ENOB-HV-12 that will utilize a novel cellular- and immunotherapy approach that could potentially
provide both preventative and therapeutic vaccines for HIV. A non-human primate study is in process and on schedule. Preliminary
results could potentially be available by the end of 2021 or early 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our co-founder and
inventor, Dr. Serhat Gumrukcu, who is also the Director of Seraph Research Institute (SRI), submitted Pre-IND for ENOB-HV-21 an
innovative treatment of Natural Killer (NK) and Gamma Delta T-Cells (GDT) collected from another person. It is believed that the
GDT cells, a small subset of immune cells that can be infected with HIV, could be a key factor in controlling the virus. The initial
scientific findings were presented during the ASCGT Conference this past May. Written comments on the submission are expected this
Fall. Enochian BioSciences has an exclusive license to use the underlying patent to develop HV-21 for the prevention, treatment,
and/or amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in
humans.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are in the development phase of additional product candidates related to our HIV pipeline. ENOB-HV-31, which is an <i>in vivo </i>gene
therapy, and ENOB-HV-32, which is a peptide drug for packaging and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Hepatitis B (HBV) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Despite the availability
of an effective vaccine and treatment that can control infection if it is taken daily for life, hepatitis B virus (HBV) is the
world’s most common serious liver infection. While vaccines are increasingly required for children, many adults have not
been vaccinated. Life-long treatment can be difficult for certain people and access can be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In that regard, HBV remains
the leading cause of liver cancer and the second leading cause of cancer deaths in the world. Two billion people have been infected
with HBV, approximately 350 million have chronic HBV infection, and nearly one million people die every year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current efforts to develop
novel treatment or cure largely focus on approaches to deplete the pool of a certain type of HBV DNA. Enochian BioSciences has
collaborated with SRI to develop an innovative approach to co-opt HBV polymerase, a key expanding factor that the virus needs to
reproduce itself, to induce the death of liver cells infected with the virus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial <i>in vitro
</i>and <i>in vivo </i>work was presented at the biannual HEP DART meeting in December of 2019, where it was selected as one of
the best new therapies/novel strategies. Additional data was presented at the annual ASCGT conference in May 2020. A proof-of-concept,
<i>in vivo</i> cure study is in advanced stages. A Pre-IND request was accepted. FDA comments are expected in the near term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 27, 2020, Enochian
BioSciences announced the creation of an HBV Scientific Advisory Board comprised of distinguished leaders in HBV disease, treatment
and cure. On August 23, 2021, we announced the addition of a third leading expert with substantial experience in HBV clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cancer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
on learning from peer-reviewed publications of Phase I/IIa trials, we have designed an innovative therapeutic vaccination platform
that could potentially be used to induce life-long remissions from some of the deadliest solid tumors. Initial preclinical <i>in
vitro</i> studies have been encouraging. We initially plan to target pancreatic cancer, triple-negative breast cancer, glioblastoma,
and renal cell carcinoma. The platform might also allow for non-specific immune enhancement that could have impact against a broad
array of solid tumors. As with HIV, our approach would potentially allow for outpatient therapy without ablating or significantly
impairing the patient’s immune system, as many current approaches require.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Through a collaboration
with a leader in the field of pancreatic cancer, our first cancer-related therapeutic target, we are&nbsp;developing the pipeline
with&nbsp;<i>in vitro</i>&nbsp;and&nbsp;<i>in vivo</i>&nbsp;proof-of-concept studies to evaluate the potential to induce long-term
remission or cure. Results are expected in late 2021or early 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Product Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1527728/000173112221001565/img001.jpg" src="https://www.sec.gov/Archives/edgar/data/1527728/000173112221001565/img001.jpg"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>ENOB-HV-01: Autologous Transplant with Genetically Modified
Cells</b>:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>FDA INTERACT Meeting Held February 2020 - Advanced Pre-Clinical
Stage</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It has been proven
that gene editing to knock down the expression of CCR5 — a door HIV needs to enter and kill CD4+ T cells — in autologous
human stem cells (HSC) combined with transplantation can lead to a cure of HIV. However, the approaches currently available require
an expensive and risky ablation of the immune system. Even with that drastic intervention, an insufficient number of gene-modified
cells survive to achieve durable control of HIV.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have pioneered
a novel approach that we believe will allow sufficient engraftment of the gene-modified HSC to eliminate the need for Antiretroviral
Treatment (ART.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In a transgenic
mouse model, the technology increased engraftment in bone marrow by 163%. For context, a 10% increase is often thought to be successful.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management considered
the FDA INTERACT Meeting to be successful and in alignment with Enochian’s experimental plan. Additional in vitro and in
vivo experiments are underway. Pre-IND submission is possible by the first part of 2022 with human studies potentially beginning
in 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>ENOB-HV-11 and 12: Preventive and Therapeutic Vaccines</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Allogeneic Cell Therapy Platform
- Advanced Pre-Clinical Stage; Non-Human Primate Studies Begun</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Boosting a person’s
immune system through vaccination can lead to protection from HIV infection in people who are not living with HIV. In persons living
with HIV who are controlling the spread of virus with antiretroviral (ARV) treatment, boosting the immune system in a different
way than the virus already has through infection, could allow control of HIV after stopping ARVs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Enochian BioSciences’
technology uses the powerful induction of an immune response created by cells from another person potentially to induce such a
response. Based on promising in vitro results, a study in non-human primates was begun by the renowned HIV and cancer researcher
Dr. Hans Peter Kiem of the Fred Hutchinson Cancer Research Center, Seattle, Washington.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Preliminary results
are expected by the end of 2021 or early 2022. If successful, human studies could potentially begin in 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>ENOB-HV-21: Immunotherapy with Allogeneic NK/GDT Cells</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>Allogeneic Cell Therapy Platform -Pre-IND Scheduled -
Advanced Pre-Clinical with Human Data through a Collaboration</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 14, Enochian
BioSciences announced that the FDA has accepted a Pre-IND request for a potential functional cure or treatment of HIV. Written
comments are expected this Fall.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Serhat Gumrukcu,
co-founder and inventor of Enochian BioSciences, and Director of SRI, submitted the Pre-IND. The request was based on the results
of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy. The patient subsequently achieved
viral control for 360 days with an innovative treatment of Natural Killer (NK) and Gamma Delta T cells (GDT) collected from another
person. During the entire period, no antiviral drugs were given. It is believed that the GDT cells, a small subset of immune cells
that can be infected with HIV, could be a key factor in controlling the virus.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This innovative cellular therapy could
be an important approach to achieve a “functional cure” of HIV, potentially allowing persons with the virus to stop
antiviral treatment for extended periods. The Pre-IND submission requested that the novel strategy be extended to persons with
HIV who have achieved suppression of the virus with antiviral treatment. Enochian BioSciences has an exclusive license to use the
underlying patent to develop HV-21 for the prevention, treatment, and/or amelioration of and/or therapy exclusively for HIV in
humans, and research and development exclusively relating to HIV in humans.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ENOB-HV-31: In Vivo Gene Therapy</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Hijack RNA Platform - Early Pre-Clinical</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">HIV is an RNA virus.
Based on the Hijack RNA Platform, an approach to “seek and kill” HIV-infected cells has been developed<i>. In vivo</i>
and <i>in vitro</i> studies should begin in the near term.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ENOB-HB-01: Potential Cure for HBV</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Hijack RNA Platform - Advanced Pre-Clinical</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current efforts
to develop a novel treatment or cure largely focus on approaches to deplete the pool of a certain type of HBV DNA. Enochian has
collaborated with SRI to develop an innovative approach to co-opt HBV polymerase to induce the death of liver cells infected with
the virus.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ENOB-CV-01: Aerosol/Inhaled Treatment
Potentially for All Coronaviruses that Cause Human Disease</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Hijack RNA Platform - Pre-IND Submission
Expected in Near-term - Advanced Pre-Clinical</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The technology tricks
– or hijacks – the polymerase of Coronaviruses to trigger infected cells to commit suicide instead of becoming virus-producing
factories. The code recognized by the Hijack RNA is similar in SARS-CoV-1 and all variants of SARS-CoV-2 (that cause COVID-19)
as well as those known to cause 20 percent of common colds.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Modeled on the approach
taken by operation Warp Speed, production, distribution, and reimbursement potential partners have been identified. Based on promising
experiments in mice, a Pre-IND application is expected in the near term.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ENOB-CV-11: Aerosol/Inhaled Prophylaxis
Potentially for All Coronaviruses that Cause Human Disease</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Hijack RNA Platform - Pre-IND Submission
Expected in Near-term - Advanced Pre-Clinical</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The technology is
delivered by an AAV particle or nanoparticle, allowing it to wait in ambush for a cell to become infected or until the cells die
due to natural turnover. Because target cells of the Coronavirus – respiratory epithelial cells - live up to 6 to 20 months
in human airways, it is possible that a single inhalation could protect against infection for relatively long periods of time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The code recognized
by the Hijack RNA is similar in SARS-CoV-1 and all variants of SARS-CoV-2 (that cause COVID-19) as well as those known to cause
20 percent of common colds. Therefore, a single inhaled dose every 6 to 20 months could potentially prevent all variants of Coronaviruses.
Based on promising experiments in mice, a Pre-IND application is expected in the near term.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ENOB-FL-01: Aerosol/Inhaled Treatment
Potentially for All Influenza Viruses</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Hijack RNA Platform - Early Pre-Clinical</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Influenza viruses
are also RNA viruses. Therefore, a similar approach to that for Coronaviruses has been developed. The code targeted by the Hijack
RNA is similar in all pandemic variants since 1918. In vitro experiments demonstrated rapid killing of infected cells without damage
to uninfected cells.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ENOB-FL-11: Aerosol/Inhaled Prophylaxis
Potentially for All Influenza Viruses</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Hijack RNA Platform - Early Pre-Clinical</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The approach taken
will be similar to that described for ENOB-CV-11 above.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ENOB-DC-11: Genetically modified
Allogeneic Dendritic Cells as Potential Cure</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Allogeneic Cell Therapy Platform
- Moderately Advanced Pre-Clinical</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted in the
Allogeneic Cell Therapy Platform Section, allogeneic cells are a potent stimulant to the immune system. Our technology genetically
modifies dendritic cells, the conductor of the immune system, to enhance their already powerful ability to activate and orchestrate
the immune response to tumors. Combined with fragments of, or fragments from, specific tumors, preliminary <i>in vitro</i> data
is promising.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Enochian BioSciences
has initiated a collaboration with Dr. Anahid Jewett from UCLA to study further the <i>in vitro</i> and <i>in vivo</i> effectiveness
of the approach in pancreatic cancer. The survival rate in pancreatic cancer is only 5 to 10 percent at 5 years. Dr. Jewett created
an innovative pancreatic cancer mouse model to study the impact of potential therapy. Results are expected by the end of 2021 with
potential Pre-IND submission by the end of the year. The technology is a platform in itself that could potentially be used for
other solid tumors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Collaborations</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;We have established
strategic partnerships with leading scientists and centers, such as The Scripps Institute, Fred Hutchinson Cancer Research Center,
the Texas Biomedical Research Institute, the University of California, Los Angeles and The Hepatitis B Foundation and Baruch S.
Blumberg Institute, for several of our programs. We will continue to pursue partnerships when appropriate with selected philanthropic,
pharmaceutical and biotechnology companies to fund internal research and development activities, and to assist in product development
and commercialization. We are applying our technology platform to several commercial applications in which our products provide
us and our strategic partners and collaborators with potential technical, competitive and economic advantages.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Our Intellectual Property</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Patents and licenses
are important to our business. Our strategy is to file license patent applications to protect technology, inventions and improvements
to inventions that we consider important for the development of our business. We rely on a combination of patent, copyright, trademark,
and trade secret laws, as well as continuing technological innovations, proprietary knowledge, and various third party agreements,
including, without limitation, confidentiality agreements, materials transfer agreements, research agreements and licensing agreements,
to establish and protect our proprietary rights. We aim to take advantage of all of the intellectual property rights that are available
to us and seek protection of those rights so that we can fully exploit our innovations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also protect
our proprietary information by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and
assignment of invention agreements upon commencement of their respective employment or engagement. Our patent filings are discussed
briefly below.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Pharmaceutical composition for inducing an immune response
in a human or animal (2001 Denmark (DK), 2002 PCT)</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;This patent
family, owned by the Company, is directed to certain melanoma cell lines and the use of an allogenic melanoma cell lysate (MCL)-pulsed
autologous dendritic cell vaccine expressing at least one of six MAGE-A antigens to induce an immune response. This patent has
been granted in: Europe, USA, China, Australia, Singapore, Russia, and Hong Kong and is pending in Japan. The issued patents relating
to ENOB-DB-01 (previously known as “MCV”) begin to expire in November 2022, subject to any applicable patent term extension,
patent term adjustment, or supplementary protection certificates that may be available in a country or jurisdiction.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Protocol for generating dendritic cells (2005 DK, 2008
PCT)</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This patent family
is directed to the generation of dendritic cells based on a blood sample by culturing monocytes at reduced temperatures. Dendritic
cells exposed to tumor antigens followed by treatment with T(h) 1-polarizing differentiation signals have paved the way for the
development of dendritic cell-based cancer vaccines. Issued claims are directed to a method of generating immature dendritic cells
under certain temperature settings, which by further activation has been shown to give a high yield of homogeneous and fully matured
dendritic cells. The patent expiration date is December 2026 subject to any applicable patent term extension, patent term adjustment,
or supplementary protection certificates that may be available in a country or jurisdiction. This patent has been issued in the
USA, Canada, China, Eurasia, Russia, Europe, Israel, Mexico, Malaysia, and New Zealand. This patent is owned by the Company and
was not licensed from third parties.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;<b>Trade Secrets and Proprietary
Know-How</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to intellectual
property protected by patents and copyrights, we have trade secrets and proprietary know-how relating to our products, production
processes, and future strategies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>In-Licensed Technology</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 16,
2018, Enochian Biopharma, the Registrant’s wholly owned subsidiary, entered into a License Agreement (the “HIV License
Agreement”) with Weird Science, LLC (“Weird Science”). The License Agreement contains, among other things, the
following terms: (a) a perpetual, fully paid-up, royalty-free, sublicensable, and exclusive (including to the exclusion of Weird
Science) worldwide license from Weird Science to Enochian Biopharma to use Weird Science’s intellectual property and technology
for the prevention, treatment, and/or amelioration of and/or therapy for HIV in humans, and research and development exclusively
relating to HIV in humans (the “Field”) worldwide; (b) a nonexclusive, royalty-free, sublicensable license from Enochian
Biopharma to Weird Science to use the Enochian Technology to commercialize products outside of the Field worldwide; (c) a nonexclusive,
royalty-free license from Enochian Biopharma to Weird Science to use the results of a study with syngeneic and humanized mice models
outside the Field and, at Weird Science’s own expense, to prosecute patents relating to the results of the study, which Weird
Science will own, and (d) a perpetual, fully paid-up, royalty-free, sublicensable, and sole and exclusive (including to the exclusion
of Weird Science) worldwide license from Weird Science to Enochian Biopharma (which will be part of the license described in (a)
above) to use patent applications and patents related to the study results disclosed in (d) above solely in the Field, and to make,
have made, use, sell, offer to sell and import inventions claimed in such patent applications and patents solely in the Field.
Our current product candidates covered by this license include ENOB-HV-01: Autologous HIV Curative Treatment, ENOB-HV-11: Preventative
HIV Vaccine; ENOB-HV-12: Therapeutic HIV Vaccine, (See Note 8 in the Financial Statements)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020,
the Company entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company,
G Tech Bio, LLC “(G-Tech”), and G Health Research Foundation, a not for profit entity organized under the laws of California
doing business as Seraph Research Institute (“SRI”), whereby the Company acquired a perpetual, sublicensable, exclusive
license (the “HBV License”) for a treatment under development (aimed to treat Hepatitis B Virus (HBV) infections in
accordance with its agreement in principle with G-Tech and SRI announced by the Company on November 25, 2019. The HBV License Agreement
states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain
other in-kind funding related to the Treatment over a 24-month period. The Company paid an upfront payment of $1.2 million on February
6, 2020. Our current product candidate under this license is ENOB-HB-01 Hijacking HBV Polymerase. (See Note 8 in the Financial
Statements)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 18, 2021, the
Company entered into a Statement of Work and License Agreement (the “Influenza and Coronavirus Indications Agreement”)
by and among G Tech and SRI, whereby the Company acquired a perpetual, sublicensable, exclusive license (the “Development
License”) to research, develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus
or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and
pan-influenza (the “Prevention and Treatment”). The Influenza and Coronavirus Indications License Agreement states
that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. The Company paid an upfront payment
of $10 million on June 18, 2021. Our current product candidates under this license are ENOB-CV-01: Coronavirus Treatment, ENOB-CV-11:
Coronavirus Prophylaxis, ENOB-FL-01: Influenza Treatment, and ENOB-FL-11: Influenza Prophylaxis. (See Note 8 in the Financial Statements)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 25, 2021, the
Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”)
with Dr. Gumrukcu and SRI whereby Dr. Gumrukcu granted the Company an exclusive, worldwide, perpetual, fully paid-up, royalty-free
license, with the right to sublicense, his proprietary technology subject to a U.S. patent application, to make, use, offer to
sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively for HIV in humans,
and research and development exclusively relating to HIV in humans; provided Dr. Gumrukcu retained the right to conduct HIV research
in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to Dr. Gumrukcu and SRI,
under any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License,
to make, use offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of
any (i) HIV Comorbidities and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment
to SRI of $600,000 and agreed to fund future HIV research conducted by Dr. Gumrukcu and SRI, as mutually agreed to by the parties.
Our current product candidate under this license is ENOB-HV-21: HIV Natural Killer and Gamma Delta T Cell Treatment or Cure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Competition</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The biotechnology
and pharmaceutical industries, including in the field of gene therapy, are characterized by rapidly advancing technologies, intense
competition and a strong emphasis on intellectual property. While we believe that our technology platforms, strong intellectual
property portfolio and scientific expertise in the gene therapy field provide us with competitive advantages, we face potential
competition from many different sources, including larger and better-funded pharmaceutical and biotechnology companies, new market
entrants and new technologies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;We are aware
of several companies focused on other methods for editing genes and regulating gene expression, and a limited number of commercial
and academic groups pursuing the development of gene regulation and genome editing technology. The field of applied gene regulation
and genome editing is highly competitive, and we expect competition to persist and intensify in the future from several different
sources, including pharmaceutical and biotechnology companies; academic and research institutions; and government agencies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, our
competitors may succeed in obtaining patent protection, receiving FDA approval, or commercializing competitive products before
us. If we commence commercial product sales, we may be competing against companies with greater marketing and manufacturing capabilities,
areas in which we have limited or no experience. In addition, any product candidate that we successfully develop may compete with
existing products that have long histories of safe and effective use.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The competitive
landscape that we are facing is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<b><i>Gene
therapy companies developing gene-based products in clinical trials</i></b>. uniQure N.V.’s product for lipoprotein lipase
deficiency and GlaxoSmithKline plc’s, or GSK, product for severe combined immunodeficiency due to adenosine deaminase deficiency
are approved in Europe. No other gene therapy products have yet been approved. Our competitors in this category may include, but
not be limited to, Sangamo Therapeutics, Inc., uniQure N.V., bluebird bio, Inc., Regenxbio Inc., Shire, Pfizer Pharmaceutical,
and GlaxoSmithKline.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Cell therapy
companies developing cell-based products</i></b>. Our competitors in this category may include Novartis AG, Adaptimmune Therapeutics
PLC, Atara Biotherapeutics, Inc., bluebird bio, Inc., Cellectis S.A., Juno Therapeutics, Inc., Kite Pharma, and Iovance Biotechnologies,
Inc.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>For ENOB-HV-01</i></b>,
we are aware of two companies developing a gene therapy for HIV/AIDS: Sangamo and American Gene Technology.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;<b><i>For ENOB-HV-11 and ENOB-HV-12</i></b>,
we are aware of a few biotech companies developing an HIV vaccine such as Geovax, Biosantech SA, and FIT Biotech, among a few others.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;	<b><i>For ENO-DC-11</i></b>,
the competitive landscape is more complex.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Immunotherapy is
an active area of research and a number of immune-related products have been identified in recent years that are alleged to modulate
the immune system. Many of these products utilize dendritic cells, a form of immune cell that presents cancer target peptides to
T cells and that can in turn result in T cell activation. More recently, bi-specific antibodies and checkpoint inhibitors (for
instance PD-1/PD-L1 antibodies) have been identified as having utility in the treatment of cancer. Bi-specific antibodies commonly
target both the cancer peptide and the T cell receptors (“TCR”), thus bringing both cancer cells and T cells into close
proximity to maximize the chance of TCR binding and hence an immune response to the cancer cells. Checkpoint inhibitors on the
other hand work by targeting receptors that inhibit T cell effectiveness and proliferation and essentially activate T cells. Other
immunotherapies that are being actively investigated include antibody-drug complexes, TCR-mimic antibodies, oncolytic viruses,
and cancer vaccines. A variety of cell-based autologous and allogeneic approaches are also being researched and developed.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">CAR-T in solid tumors</span></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to hematological
malignancies, there are a growing number of pharmaceutical, biotechnology, and academic institutions researching and developing
autologous and allogeneic chimeric antigen receptor T cell (“CAR-T”) therapies in the solid tumor setting. These CAR-T
cell therapies are at a variety of stages of preclinical and clinical development, as well as directed towards a broad target spectrum.
Two Car-T therapies have been approved for treatment of leukemia.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">CARsand TCR-mimics tar</span>g<span style="text-decoration: underline">etin</span>g <span style="text-decoration: underline">peptide-HLA
complexes</span></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Most CAR-T therapies
in development are directed towards antigen targets. However, competitors are also developing a CAR-T that selectively binds to
the peptide-HLA (pHLA) complex (the natural binding site for endogenous TCR). Furthermore, competitors are also looking at pHLA
antibodies or TCR mimic antibodies that can either be engineered in T cells or developed as standalone antibody therapies in cancer
indications (including solid tumors).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">TCR Tcells</span></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Competitors are
developing TCR T cells (including affinity engineered T cells) that are directed towards a multitude of targets. Juno Therapeutics
has developed an engineered TCR therapeutic candidate where the end TCR is purported to have enhanced affinity through stem-cell
selection.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">Other cell-based approaches</span></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to all
the adoptive cell therapy approaches above, our competitors are also investigating the potential of GammaDelta T cell, CAR-NK cell,
NK cell, NKT cell and CTLs either in a preclinical or clinical setting (both hematologic malignancies and solid tumors). In addition,
Bristol Myers Squibb’s Abraxane is used for pancreatic cancer.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">For ENOB-CV-01 and -11; SARS-CoV:</span></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Treatment: </i>There
are currently several products with FDA EUA for treatment of COVID including, but not limited to Remdesivir (Gilead) and monoclonal
antibodies (Elly Lily and Regeneron). In addition, other system anti-virals are in advanced clinical trials. SaNOtize Research
and Development Corp. has reported data on an aerosolized therapy and its intention to seek EUA at least in Canada and Europe.
Virpax Pharmaceuticals, Inc. has announced the conclusion of a Pre-IND with the FDA for an aerosolized treatment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Prevention:
</span></i>Four vaccines have received FDA EUA (Pfizer, Moderna, Johnson and Johnson and Novavax). One, Pfizer has received full approval.
Several companies have announced plans for, and/or are conducting clinical trials of aerosolized vaccines.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">For ENOB-FL-01 and -11; Influenza:</span></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Treatment:</i>
Current treatments are largely to manage symptoms. Tamiflu is approved for use within the first few days of symptoms.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Prevention:</i>
Annual vaccines are approved for use. Several companies have announced plans to develop new vaccines, e.g. mRNA.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">For ENOB-HBV-01:</span></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is an approved
vaccine to prevent HBV infection. In addition, several approved combination antivirals can suppress replication, but do not cure
HBV. Several companies are pursuing cures, mostly targeting the depletion of ccc-DNA.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Manufacturing</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34pt">Our intent is to
rely on contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs), to help develop
and produce our preclinical and clinical product candidates in accordance with FDA and EMA mandated regulations, also known as
current good manufacturing practices, (“cGMPs”). We employ a technical operations staff in the areas of process development,
analytical development, quality control, quality assurance, project management, and manufacturing, which will facilitate appropriate
oversight of our CMOs, support of our regulatory filings and execution of clinical trials.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Government Regulation</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<b><i>FDA
Review and Approval </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;Government
authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping,
promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such
as those we are developing. Any products we develop will require regulatory review and allowance to proceed prior to conducting
clinical trials and additional regulatory approvals prior to commercialization. In the United States, the FDA regulates drugs under
the Federal Food, Drug and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA) and their implementing regulations govern,
among other things, biopharmaceutical testing, manufacturing, safety, efficacy, labeling, storage, recordkeeping, advertising,
and other promotional practices.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Obtaining FDA approval
is a costly and time-consuming process. Generally, FDA approval requires that preclinical studies be conducted in the laboratory
and in animal model systems to gain preliminary information on efficacy and to identify any major safety concerns. The results
of these studies are then submitted as a part of an IND, which the FDA must review and allow before human clinical trials can start.
The IND includes a detailed description of the proposed clinical investigations. An independent Institutional Review Board (“IRB”)
must also review and approve the clinical protocol and each clinical site.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;A company
must submit an IND for each investigational medical product and specific indication(s), and must conduct clinical studies to demonstrate
the safety and efficacy of the product necessary to obtain FDA approval. The FDA receives reports on the progress of each phase
of clinical testing and may require the modification, suspension, or termination of clinical trials if an unwarranted risk is presented
to patients.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Obtaining FDA approval
prior to marketing a biopharmaceutical product in the United States typically requires several phases of clinical trials to demonstrate
the safety and efficacy of the product candidate. Clinical trials are the means by which experimental treatments are tested in
humans and are conducted following preclinical testing. Clinical trials may be conducted within the United States or in foreign
countries. If clinical trials are conducted in foreign countries, the products under development as well as the trials are subject
to regulations of the FDA and/or its regulatory counterparts in the other countries. Upon successful completion of clinical trials,
approval to market the treatment for a particular patient population may be requested from the FDA in the United States and/or
its counterparts in other countries.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical trials
for therapeutic products are normally conducted in three phases. Phase 1 clinical trials are typically conducted with a small number
of patients to evaluate safety, determine a safe dosage range, identify side effects, and, if possible, gain early evidence of
effectiveness. Phase 2 clinical trials are conducted with a larger group of patients to evaluate effectiveness of an investigational
product for a defined patient population, and to determine common short-term side effects and risks associated with the drug. Phase
3 clinical trials involve large scale, multi-center, comparative trials that are conducted to evaluate the overall benefit-risk
relationship of the investigational product and to provide an adequate basis for product labeling. In some special cases where
the efficacy testing of a product may present a special challenge to testing in humans, such as in the case of a vaccine to protect
healthy humans from a life-threatening disease that is not a naturally occurring threat, effectiveness testing may be required
in animals. For certain advanced therapies that meet eligibility criteria for expedited program Designations, clinical development
may be expedited.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical trials
involve the administration of the biologic product candidate to healthy volunteers or patients under the supervision of qualified
investigators which generally are physicians not employed by, or under, the control of the trial sponsor. Clinical trials are conducted
under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection
and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical
trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted
to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA’s regulations comprising
the Good Clinical Practice (“GCP”) requirements, and any additional requirements for the protection of human research
subjects and their health information including the requirement that all research subjects provide informed consent.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, each clinical
trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An
IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves
the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative,
reviews and approves the study protocol, and must monitor the clinical trial until completed. Clinical trials involving recombinant
DNA also must be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees
basic and clinical research that utilizes recombinant DNA at that institution. The IBC assesses the safety of the research and
identifies any potential risk to public health or the environment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After completion
of clinical trials of a new product, FDA marketing approval must be obtained. If the product is regulated as a biologic, a Biologics
License Application, or BLA, is required. If the product is classified as a new drug, a New Drug Application, or NDA is required.
The NDA or BLA must include results of product development activities, preclinical studies, and clinical trials in addition to
detailed chemistry, manufacturing and control information.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Applications submitted
to the FDA are subject to an unpredictable and potentially prolonged approval process. Despite good-faith communication and collaboration
between the applicant and the FDA during the development process, the FDA may ultimately decide, upon final review of the data,
that the application does not satisfy its criteria for approval or requires additional product development or further preclinical
or clinical studies. Even if FDA regulatory approval(s) are obtained, a marketed product is subject to continual review, and later
discovery of previously unknown problems or failure to comply with the applicable regulatory requirements may result in restrictions
on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before marketing
approval can be secured for a product, the facility in which the product is manufactured must be inspected by the FDA and must
comply with the FDA’s current Good Manufacturing Practices, (“cGMP”) regulations. In addition, after marketing
approval is secured, the manufacturing facility must be inspected periodically for cGMP compliance by FDA inspectors, and, if the
facility is located in California, by inspectors from the Food and Drug Branch of the California Department of Health Services.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical
trials are required to register, and report results for, all controlled, clinical investigations, other than Phase 1 investigations,
of a product subject to FDA regulation. Trial registration may require public disclosure of certain confidential commercial development
data.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at
any time during the product development process, approval process or after approval, may subject an applicant to administrative
or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of
an approval, a clinical he hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial
suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil
or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial
condition, results of operations and cash flows</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Orphan Drug Designation</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the Orphan
Drug Act, the FDA may grant orphan designation to a product intended to treat a rare disease or condition, which is generally a
disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the
United States and for which there is no reasonable expectation that the cost of developing and making a product available for this
type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting
an NDA or BLA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval
process. If a product that has orphan designation subsequently receives the first FDA approval for such product for the disease
or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA
may not approve any other applications to market a product containing the same active moiety for the same use or indication for
seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity.
A product is clinically superior if it is safer, more effective or makes a major contribution to patient care. Any claims of clinical
superiority could require a head-to-head clinical trial between such drugs. Competitors may receive approval of different products
for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication
for which the orphan product has exclusivity. If a product designated as an orphan product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan product exclusivity.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify"><i>Other Healthcare Laws and
Compliance Regulations</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we currently
do not have any products on the market, we may also be subject to additional healthcare regulation and enforcement by the federal
government and by authorities in the states and foreign jurisdictions in which we conduct our business. In the United States, among
other things, the research, manufacturing, distribution, sale and promotion of pharmaceutical and biological products are potentially
subject to regulation and enforcement by various federal, state and local authorities in addition to the FDA, including the Centers
for Medicare and Medicaid Services (“CMS”), other divisions of the United States Department of Health and Human Services
(e.g., the Office of Inspector General), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal
Trade Commission, the Occupational Safety and Health Administration, the Environmental Protection Agency, state Attorneys General
and other state and local government agencies. Our current and future business activities, including for example, sales, marketing
and scientific/educational grant programs, must comply with health care regulatory laws, as applicable, including, without limitation:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span><span style="font-family: Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the federal anti-kickback statute, which
is a criminal statute that makes it a felony for individuals or entities to knowingly and willfully offer or pay, or to solicit
or receive, direct or indirect remuneration, in order to induce the purchase, order, lease, or recommending of items or services,
or the referral of patients for services, that are reimbursed under a federal health care program, including Medicare and Medicaid;
</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the federal False Claims Act, which prohibits,
among other things, individuals and entities from knowingly submitting, or causing to be submitted, false or fraudulent claims
for payment of government funds, with penalties that include three times the government’s damages plus civil penalties for
each false claim; in addition, the False Claims Act permits a person with knowledge of fraud, referred to as a qui tam plaintiff,
to file a lawsuit on behalf of the government against the person or business that committed the fraud, and, if the action is successful,
the qui tam plaintiff is rewarded with a percentage of the recovery; </span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">federal criminal laws that prohibit executing
a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the Health Insurance Portability and Accountability
Act of 1996, or HIPAA, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy
of protected health information; </span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the federal Physician Payment Sunshine
Act, which requires certain manufacturers of drugs, devices, biologics and medical suppliers to report annually to CMS information
related to payments and other transfers of value to physicians, other healthcare professionals and teaching hospitals, and ownership
and investment interests held by physicians and other healthcare professionals and their immediate family members; and</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">state and foreign law equivalents of each
of the above federal laws, such as state anti-kickback and false claims laws which may impose more strict requirements than federal
law and may apply to items or services reimbursed by any payor (including commercial insurers and cash-paying patients); state
laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to
healthcare professionals and other potential referral sources; state laws that require drug manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare professionals or marketing expenditures; and
state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other
in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our operations
are found to be in violation of any of such laws or any other governmental laws or regulations that apply, they may be subject
to penalties, including, without limitation, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring
of operations, exclusion from participation in federal and state healthcare programs, additional program integrity obligations,
individual imprisonment, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal
of product approvals, refusal to permit us to enter into supply contracts, including government contracts, contractual damages,
reputational harm, administrative burdens, diminished profits, and future earnings, any of which could have a material adverse
effect on our business, financial condition, result of operations, and cash flows. These additional healthcare regulations could
affect our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party
payors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, the introduction
of legislation, implementation of new regulations, or enforcement of existing regulations that have a negative impact on the commercial
prospects for the types of products we are developing could negatively impact our share price and our ability to raise capital.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify"><i>Coverage and Reimbursement</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Significant uncertainty
exists as to the coverage and reimbursement status of any product candidate that receives regulatory approval. In the United States
and markets in other countries, sales of our product candidates, if approved, will depend, in part, on the extent to which third-party
payors provide coverage and establish adequate reimbursement levels.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the United States,
third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private
health insurers and other organizations. Third-party payors are increasingly challenging the price, examining the medical necessity
and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and
efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might
not include all the FDA-approved drugs for a particular indication. Third-party payor coverage may be more limited than the purposes
for which the product is approved by the FDA or foreign regulatory authorities. Further, one payor’s determination to provide
coverage for a drug product does not assure that other payors will also provide coverage for the drug product.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, the process
for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting
the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor’s
decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved or that the
product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and
distribution. There may be significant delays in obtaining reimbursement for approved products, and reimbursement rates may fluctuate
over time or vary according to the use of the product or clinical setting in which a product is used. Net prices for products may
be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation
of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, third-party
payers are increasingly challenging the price of medical products and services, and there is increasing pressure on biotechnology
companies to reduce healthcare costs. If purchasers or users of our products are not able to obtain adequate reimbursement for
the cost of using our products, they may forego or reduce their use. Significant uncertainty exists as to the reimbursement status
of newly approved healthcare products, and whether adequate third-party coverage will be available. Our inability to promptly obtain
coverage and profitable payment rates from both government funded and private payors for future products we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize potential products, and
our overall financial condition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify"><i>Healthcare Reform</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2010, former
President Obama Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of
2010 (collectively, the “Affordable Care Act”),, which substantially changed the way healthcare is financed by both
governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The Affordable
Care Act contains a number of provisions, including those governing enrollments in federal healthcare programs, reimbursement adjustments
and fraud and abuse changes. Additionally, the Affordable Care Act increases the minimum level of Medicaid rebates payable by manufacturers
of brand name drugs; requires collection of rebates for drugs paid by Medicaid managed care organizations; requires manufacturers
to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s
outpatient drugs to be covered under Medicare Part&nbsp;D; and imposes a non-deductible annual fee on pharmaceutical manufacturers
or importers who sell “branded prescription drugs” to specified federal government programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since its enactment,
there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be
additional challenges and amendments to the Affordable Care Act in the future. Other legislative changes have been proposed and
adopted since the Affordable Care Act was enacted, including aggregate reductions of Medicare payments to providers and reduced
payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner
in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed
bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in
the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing&nbsp;cost
disclosure and transparency measures, and, in some cases, proposing to encourage importation from other countries and bulk purchasing.&nbsp;We
cannot predict what healthcare reform initiatives may be adopted in the future.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also are subject
to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and
manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances,
including radioactive compounds and infectious disease agents, used in connection with our research. The extent of government regulation
that might result from any future legislation or administrative action cannot be accurately predicted.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify"><i>Foreign Corrupt Practices
Act</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business activities
may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or
rules of other countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to
give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action,
or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately
and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.
Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of
non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed
by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers
and purchasers are subject to regulation under the FCPA. There is no certainty that all of our employees, agents, suppliers, manufacturers,
contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given
the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions
against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers,
requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance
programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer
our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could
materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees,
and our business, prospects, operating results, and financial condition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Employees</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2021,
we had 11 full-time employees. We believe that we have good relations with our employees.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Corporate Information</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 16,
2018, we completed our acquisition of Enochian Biopharma pursuant to an acquisition agreement, dated January 12, 2018, by and among
the Registrant, its wholly owned subsidiary DanDrit Acquisition Sub, Inc., Enochian Biopharma and Weird Science (the “Acquisition
Agreement”), with Enochian Biopharma surviving as a wholly owned subsidiary of the Registrant. As consideration for the acquisition,
the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock and (ii) the right to receive Contingent
Shares pro rata upon the exercise or conversion of warrants, which were outstanding at closing (See Note 1 to the Financial Statements).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We trade on the
NASDAQ Capital Market under the ticker “ENOB.”</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our website is http://www.enochianbio.com.
We make available free of charge, on or through our internet site, our annual, quarterly, and current reports and any amendments
to those reports filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC. Information contained in our website is not part of, nor incorporated by reference
into, this report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_031"></span>Item 1A. Risk Factors</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RISK FACTORS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Investing in our common stock involves
a high degree of risks. Investors should carefully consider all of the risk factors and uncertainties described below, in addition
to the other information contained in this Annual Report on Form 10-K, including the section of this report titled “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related
notes, before investing in our common stock. </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The risks described below may not
be the only ones relating to our Company and additional risks that we currently believe are immaterial may also affect us. If any
of these risks, including those described below, materialize, our business, competitive position, reputation, financial condition,
results of operations, cash flows and future prospects could be seriously harmed. In these circumstances, the market price of our
common stock could decline, and investors may lose all or a part of their investment.</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Financial Results
and Capital Needs</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred
substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the
foreseeable future.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a pre-clinical-stage
biotechnology company. Investment in biotechnology related to genetically modified cells is highly speculative because it entails
substantial upfront capital expenditures and significant risk that a product candidate will fail to prove effective, gain regulatory
approval or become commercially viable. We do not have any products approved by regulatory authorities and have not generated any
revenues from product sales or otherwise to date, and have incurred significant research, development and other expenses related
to our ongoing operations and expect to continue to incur such expenses. As a result, we have not been profitable and have incurred
significant operating losses in every reporting period since our inception. For the years ended June 30, 2021 and 2020, respectively,
we reported a net loss of $26.7 million and $11.4 million. We had an accumulated deficit of $90.9 million and $64.2 million as
of June 30, 2021 and 2020, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not expect
to generate revenues for the foreseeable future. We expect to continue to incur significant expenses and operating losses for the
foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for
our product candidates and any additional product candidates we may acquire, in-license or develop, and potentially begin to commercialize
product candidates that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays
and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the
rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical
studies or does not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable.
Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. We anticipate
that our expenses will increase in the future as we continue to invest in research and development of our existing product candidates,
investigate and potentially acquire new product candidates and expand our manufacturing and commercialization activities.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We are a pre-clinical
biotechnology company and may never be able to successfully develop marketable products or generate any revenue. We have a very
limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance
that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are an early
stage biotechnology company and have not generated any revenues to date. All of our product candidates are in the discovery stage
or pre-clinical development stage. Moreover, we cannot be certain that our research and development efforts will be successful
or, if successful, that our potential treatments will ever be approved for sales to generate commercial revenues. Our pipeline
includes cell, gene and immunotherapy involving genetically modified cells targeted to treat HIV, Hepatitis B, pan-coronavirus
and influenza, and cancer, and we rely on third parties under contract in the development of product candidates in our pipeline.
There is no guarantee that we will be able to manage and fund the development of a pipeline with multiple target conditions, nor
that third parties will meet their obligations to us in connection with our research and development. We and certain third parties,
on which we rely, have no relevant operating history upon which an evaluation of our performance and prospects can be made. We
are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen capital
requirements, failure of treatments either in non-clinical testing or in clinical trials, failure to establish business relationships,
failure of our third parties to meet their obligations to us and competitive disadvantages against larger and more established
companies. If we fail to become profitable, we may suspend or cease operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We will require
substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us
to delay, limit, reduce or terminate our product development or commercialization efforts.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to expend
substantial resources for the foreseeable future to continue the pre-clinical development of our cell, gene and immunotherapy product
candidates, and the advancement and potential expansion of our pre-clinical research pipeline. We also expect to continue to expend
resources for the development and manufacturing of product candidates and the technology we have licensed or have a right to license
from our licensors.&nbsp;These expenditures will include costs associated with research and development, potentially acquiring
or licensing new product candidates or technologies, conducting pre-clinical and clinical studies and potentially obtaining regulatory
approvals and manufacturing products, as well as marketing and selling products approved for sale, if any. Under the terms of certain
of our license agreements, we are obligated to make payments upon the achievement of certain development, regulatory and commercial
milestones.&nbsp;We will also need to make significant expenditures to develop a commercial organization capable of sales, marketing
and distribution for any products, if any that we intend to sell ourselves in the markets in which we choose to commercialize on
our own. In addition, other unanticipated costs may arise. Because the design and outcome of our ongoing, planned and anticipated
pre-clinical and clinical studies is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully
complete the development and commercialization of our product candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future capital
requirements depend on many factors, including:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="white-space: nowrap; width: 48px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the costs and payments
associated with license agreements for our product and technologies;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the costs of conducting
pre-clinical and clinical studies and the cost of manufacturing our product candidates</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the timing of, and the
costs involved in, obtaining regulatory approvals for our product candidates, if clinical studies are successful, including any
costs from post-market requirements;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the cost of commercialization
activities for our product candidates, if any of these product candidates is approved for sale, including marketing, sales and
distribution costs;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">our ability to establish
and maintain strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the costs involved in
preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and
the outcome of such litigation; and</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the timing, receipt
and amount of sales of, or royalties on, our future products, if any.</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additional funds
may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us
on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical studies or other development
activities for one or more of our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing
and distribution capabilities or other activities that may be necessary to commercialize our product candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Raising additional
capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.
</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until such time
as we can generate substantial product revenues, we may attempt to finance our cash needs through equity offerings, debt financings,
government and/or other third-party grants or other third-party funding, marketing and distribution arrangements and other collaborations,
strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, our investors’ ownership interest will be diluted. Debt financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. If we are unable to obtain funding on a timely basis, we may be required to significantly
curtail one or more clinical research or development programs, which would adversely impact our potential revenues, results of
operations and financial condition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Risks Related to the Development of Our Product Candidates</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We are highly
dependent on the services of third parties to conduct research and development of our pipeline, and our failure to maintain the
services of such third parties could harm our business</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are highly dependent
on third parties working in conjunction with our officers, employees, scientific advisory board and research institutions in the
research and development of product candidates in our pipeline. Many of the techniques utilized in the development of our product
candidates have been developed by Dr. Serhat Gumrukcu, and we rely on the services of Dr. Gumrukcu, and of G-Tech Bio LLC and SRI,
in the continued development of our pipeline. Our future performance will depend on our ability to retain the services of Dr. Gumrukcu,
G-Tech Bio LLC and SRI. The loss of the services of any of the foregoing, or of any of our key employees or scientific advisory
board members could impede the achievement of our research, development, regulatory approvals and commercialization objectives.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>The results
of pre-clinical studies or earlier clinical studies are not necessarily predictive of future results, and if we fail to demonstrate
efficacy in our pre-clinical studies and/or clinical trials in the future our future business prospects, financial condition and
operating results will be materially adversely affected.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The success of our
research and development efforts will depend upon our ability to demonstrate the efficacy of the treatments in our pipeline in
pre-clinical studies, as well as in clinical trials following IND approval by the FDA. Pre-clinical studies involve testing potential
product candidates in appropriate non-human disease models to demonstrate efficacy and safety.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Success in pre-clinical
studies does not ensure that later clinical studies will generate adequate data to demonstrate the efficacy and safety of an investigational
drug. Currently, several of our product candidates, including ENOB-HV-01, our autologous HIV curative treatment, ENOB-HV-11, our
preventative HIV vaccine, ENOB-HV-12, our therapeutic HIV vaccine and ENOB-HB-01, our coopting HBV polymerase, our co-opting of
virus machinery for SARS-Coronaviruses, including the cause of COVID-19, and Influenza viruses are all currently in various stages
of pre-clinical development with ongoing and planned pre-clinical studies in conjunction with research institutions and third parties.
We presented pre-clinical data on ENOB-HV-01 in May 2020 at the annual conference of the American Society of Gene and Cell Therapy,
and participated in an INTERACT meeting with the FDA related to ENOB-HB-01 in June 2020. Additionally, we presented results on
ENOB-HB-01 and ENOB-FL-01 in May 2020 at the annual conference of the American Society of Gene and Cell Therapy, and SARS-Coronavirus
at the Conference on Retroviruses and Opportunistic Infections in March 2021. Despite preliminary data we believe is positive,
this does not guarantee that any of these products will proceed to the clinical stage or to approval for commercial use. A number
of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us,
have suffered significant setbacks in clinical studies, even after seeing promising results in earlier preclinical studies or clinical
studies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Regulatory agencies
evaluate these data carefully before they will approve clinical testing in humans. If certain non-clinical data reveals potential
safety issues or the results are inconsistent with an expectation of the potential product candidates’ efficacy in humans,
the regulatory agencies may require additional more rigorous testing before allowing human clinical trials. This additional testing
will increase program expenses and extend timelines. We may decide to suspend further testing on our product if, in the judgment
of our management and advisors, the pre-clinical test results do not support further development.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Our novel
gene, cell and immunotherapy product candidates and new therapeutic approaches could result in heightened regulatory scrutiny,
delays in clinical development or delays in or our inability to achieve regulatory approval or commercialization of our product
candidates.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future success
is dependent on the successful development of novel gene, cell and immunotherapy product candidates. Because these programs, particularly
our pipeline of allogeneic T-cell product candidates that are bioengineered from sick patients, represent a new approach to immunotherapy
for the treatment of cancer and other diseases, developing and commercializing our product candidates subject us to a number of
challenges.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, actual
or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the
willingness of subjects to participate in clinical studies, or if approved by applicable regulatory authorities, of physicians
to subscribe to the novel treatment mechanics. The FDA or other applicable regulatory authorities may ask for specific post-market
requirements, and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory
approval.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We face significant
competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval
before us or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition
and our ability to successfully market or commercialize our product candidates. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The development
of treatments in the fields of HIV, Hepatitis B, COVID-19 and Influenza prevention and treatment and cancer is highly competitive
and many pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private
research organizations may pursue the research and development of technologies, drugs or other therapeutic products for the treatment
of some or all of the diseases we are targeting. Nearly all of our competitors have greater capital resources, larger overall research
and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval and
pharmaceutical product manufacturing and marketing than we do. Techniques in gene, cell and immunotherapy are subject to rapid
technological change and development and is significantly affected by existing rival products and medical procedures, new product
introductions and the market activities of other participants. With additional resources, our competitors may be able to respond
to the rapid and significant technological changes faster than we can. Our future success will depend in large part on our ability
to maintain a competitive position with respect to these technologies. We may also face competition from products, which have already
been approved and accepted by the medical community for the treatment of these same indications. If we are unable to compete effectively
with any existing products, new treatment methods and new technologies, we may be unable to commercialize therapeutic products
that we may develop in the future, which could adversely impact potential revenues, results of operations and financial condition
or lead to abandonment of product candidates in our pipeline.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Our reliance
on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research organizations,
may result in delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under
our agreements with them.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the course of
the development of our pipeline, we have and expect to continue to engage university laboratories, non-profit organizations, independent
contractors, other biotechnology companies or contract or clinical manufacturing organizations to conduct and manage research and
development, pre-clinical and clinical studies and to manufacture materials for us to be used in pre-clinical and clinical testing.
Due to engagements with these organizations, many important aspects of our research have been and will be out of our direct control.
If any of these organizations we may engage in the future, fail to perform their obligations under our agreements with them or
fail to perform non-clinical testing and/or clinical trials in a satisfactory manner, we may face delays in completing our clinical
trials, as well as commercialization of any of our product candidates. Furthermore, any loss or delay in obtaining contracts with
such entities may also delay the completion of our clinical trials, regulatory filings and the potential market approval of our
product candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Business interruptions
resulting from the coronavirus disease 2019 (COVID-19) outbreak or similar public health crises could cause a disruption of the
development of our product candidates and adversely impact our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Public health crises
such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a new strain of coronavirus surfaced
in Wuhan, China and has reached multiple other regions and countries, including Los Angeles where our primary office and laboratory
facilities are located. The COVID-19 pandemic continues to evolve, and to date has led to the implementation of various mitigation
responses, including government-imposed quarantines, travel restrictions and other public health safety measures, as well as leading
to reported adverse impacts on healthcare resources, facilities and providers across the United States and in other countries.
COVID-19 may cause delays in our research activities. COVID-19 has not materially affected our operations to date, it has caused
delays in the conduct of experiments due to limitations of various organizations, in particular those conducting experiments related
to COVID-19. There have also been increases in the cost to conduct animal studies due to staffing and other limitations. The full
extent to which COVID-19 may impact our operations or those of our third-party partners, including research organizations and suppliers
will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration
of the outbreak, effectiveness of vaccines, additional or modified government actions, new information that will emerge concerning
the severity and impact of COVID-19 and the actions to contain COVID-19 or address its impact in the short and long term, among
others.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Additionally, timely
initiation and completion of planned preclinical studies is dependent upon the availability of, for example, preclinical study
sites, university researchers and investigators, regulatory agency personnel, and materials, which may be adversely affected by
global health matters, such as pandemics. We plan to conduct preclinical studies in geographies that are currently being affected
by COVID-19.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Further, in the event
that governmental authorities were to further modify current restrictions, our employees conducting research and development activities
may not be able to access our laboratory offices, and our core activities may be significantly limited or curtailed, possibly for
an extended period of time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Changes in
healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare
policy, may negatively impact our ability to generate revenues.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><span style="background-color: white">In
the United States and some foreign jurisdictions, there have been a number of proposed legislative and regulatory changes related
to the healthcare system that could affect our ability to profitably sell or commercialize our product candidates for which we
obtain marketing approval in the future. The potential pricing and reimbursement environment for our product candidates may change
in the future and become more challenging due to, among other reasons, policies advanced by the current or any new presidential
administration, federal agencies, healthcare legislation passed by Congress, or fiscal challenges faced by all levels of government
health administration authorities, or by similar changes in foreign countries.</span> The implementation of any such changes could
have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects,
including our share price and ability to raise capital.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>We have limited
experience in drug development and may not be able to successfully develop any drugs, which would cause us to cease operations.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We have never successfully
developed a new drug and brought it to market. Our management and clinical teams have experience in drug development but they may
not be able to successfully develop any drugs. Our ability to achieve revenues and profitability in our business will depend on,
among other things, our ability to develop products internally or to obtain rights to them from others on favorable terms; complete
laboratory testing and human studies; obtain and maintain necessary intellectual property rights to our products; successfully
complete regulatory review to obtain requisite governmental agency approvals; enter into arrangements with third parties to manufacture
our products on our behalf; and enter into arrangements with third parties to provide sales and marketing functions. If we are
unable to achieve these objectives we will be forced to cease operations and you will lose all of your investment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire,
retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved
or commercialized in a timely manner or at all, which could negatively impact our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The ability of the
FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average
review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies
that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Disruptions at the
FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would harm our business. For example, over the last several years, including for 35 days beginning on December 22, 2018,
the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical
FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability
of the FDA to timely review and process our regulatory submissions, which could harm our business.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The COVID-19 pandemic
has also resulted in the FDA imposing preventive measures, including postponements of non-U.S. manufacturing and product inspections.
If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections,
reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to
timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Our gene therapy
product candidates are still in development and will require extensive clinical testing before we are prepared to submit an application
for marketing approval to regulatory authorities. We cannot predict with any certainty if or when we might submit any such application
for regulatory approval for our product candidates or whether any such application will be approved by the applicable regulatory
authority in our target markets. Human clinical trials are expensive and difficult to design and implement, in part because they
are subject to rigorous regulatory requirements. For instance, regulatory authorities may not agree with our proposed endpoints
for any clinical trials of our gene therapy product candidates, which may delay the commencement of our clinical trials. The clinical
trial process is also time-consuming. We estimate that clinical trials of our product candidates will take at least several years
to complete.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Clinical trials
are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Our product candidates
are still in development and will require extensive clinical testing before we are prepared to submit an application for marketing
approval to regulatory authorities. We cannot predict with any certainty if or when we might submit any such application for regulatory
approval for our product candidates or whether any such application will be approved by the applicable regulatory authority in
our target markets. Human clinical trials are expensive and difficult to design and implement, in part because they are subject
to rigorous regulatory requirements. For instance, regulatory authorities may not agree with our proposed endpoints for any clinical
trials of our product candidates, which may delay the commencement of our clinical trials. The clinical trial process is also time-consuming.
We estimate that clinical trials of our product candidates will take at least several years to complete.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">A number of companies
in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse
safety profiles, notwithstanding promising results in earlier trials, and in the regulatory approval process. In addition, the
design of a clinical trial, such as endpoints, inclusion and exclusion criteria, statistical analysis plans, data access protocols
and trial sizing, can determine whether its results will support approval of a product and flaws in the design of a clinical trial
may not become apparent until the clinical trial is well advanced. If we experience delays in the commencement or completion of
our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates
could be harmed, and our ability to generate revenues may be delayed. In addition, any delays in our clinical trials could increase
our costs, cause a drop in our stock price, slow down the approval process and jeopardize our ability to commence product sales
and generate revenues. Further, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such
difficulties or delays in commencing or completing clinical trials. Any of these occurrences may harm our business, financial condition
and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Enrollment
and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside our control.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We may encounter
delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once
enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention
in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the
effectiveness of our patient recruitment efforts, delays in enrollment due to travel or quarantine policies, or other factors,
related to COVID-19, the existing body of safety and efficacy data with respect to the study candidate, the perceived risks and
benefits of gene therapy approaches for the treatment of certain diseases, the number and nature of competing existing treatments
for our target indications, the number and nature of ongoing trials for other product candidates in development for our target
indications, perceived risk of the delivery procedure, patients with pre-existing conditions that preclude their participation
in any trial, the proximity of patients to clinical sites and the eligibility criteria for the study. Furthermore, the results
we have reported in clinical trials to date and any other results we may report in clinical trials of any of our gene therapy product
candidates in the future may make it difficult or impossible to recruit and retain patients in other clinical trials of those gene
therapy product candidates. Similarly, negative results reported by our competitors about their product candidates may negatively
affect patient recruitment in our clinical trials. Delays or failures in planned patient enrollment or retention may result in
increased costs, program delays or both, which could have a harmful effect on our ability to develop our gene therapy product candidates
or could render further development impossible. In addition, we expect to rely on clinical trial sites to ensure proper and timely
conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited
in our ability to control their actual performance.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Intellectual
Property</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have licensed
a significant portion of our intellectual property from our licensors. If we breach any of our license agreements with these licensors,
or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights
that are important to our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We hold rights under
license agreements with our licensors, including Weird Science and G-Tech, , SRI and Dr. Serhat Gumrukcu that are important to
our business. Our research and development platform is built, in part, around patent rights licensed from such licensors. Under
our existing license agreements, we are subject to various obligations, including diligence obligations with respect to development
and commercialization activities, provision of support with respect to development of licensed intellectual property, prosecution
of intellectual property protection, payment obligations upon achievement of certain milestones and royalties on product sales.
In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements
and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products
and technology covered by these license agreements. If any of these licenses are terminated, or if the underlying patents fail
to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of,
and to market, products identical to ours and we may be required to cease our development and commercialization of product candidates
covered by any such licenses. Any of the foregoing could have a material adverse effect on our competitive position, business,
financial condition, results of operations, and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, disputes
may arise regarding intellectual property subject to a licensing agreement, including:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="width: 48px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the
scope of rights granted under license agreements and other interpretation-related issues;</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="vertical-align: top">
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">payment obligations due to licensors
        under license agreements and other disputes related to the obligations for payment related to intellectual property protection;</p>
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></td></tr>
<tr>
    <td style="text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the extent to which our product candidates, technology and processes infringe on intellectual property of a licensor that is not subject to a licensing agreement;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">our diligence obligations under license agreements and what activities satisfy those diligence obligations; </span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us; and</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the priority of invention of patented technology.</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the
agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The resolution of
any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement,
either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our licensing
arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we do not obtain
required intellectual property licenses or rights, we could encounter delays in our product development efforts while we attempt
to design around other patents or even be prohibited from developing, manufacturing or selling products requiring these rights
or licenses. There is also a risk that legal disputes may arise as to the rights to technology developed in collaboration with
other parties, all with attendant risk, distraction, expense, and lack of predictability.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>If we are
unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual
property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete
effectively may be adversely affected.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely upon a combination
of patents, trademarks, trade secrets and confidentiality agreements – either that we own or possess or that are owned or
possessed by our licensors that are licensed to us – to protect the intellectual property related to our technology and product
candidates. When we refer to “our” technologies, inventions, patents, provisional patents, patent applications or other
intellectual property rights, we are referring to both the rights that we own or possess as well as those that we license, many
of which are critical to our intellectual property protection and our business. For example, the product candidates and platform
technology we have licensed from our licensors are protected primarily by patent or patent applications of our licensors that we
have licensed and as confidential know-how and trade secrets. If the intellectual property that we rely on is not adequately protected,
competitors may be able to use our technologies and erode or negate any competitive advantage we may have.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The patentability
of inventions and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves
complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation. Moreover,
the standards applied by the U.S. Patent and Trademark Office, or USPTO, and non-U.S. patent offices in granting patents are not
always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter
or the scope of claims allowable in biotechnology patents.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance
that all potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the
instances where searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent
a pending patent application from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe
affects the validity or enforceability of a claim of one of our patents or patent applications, which may, nonetheless, ultimately
be found to affect the validity or enforceability of such claim. We also may not be able to obtain full patent protection from
provisional patents for which we have sought or will seek further patent protection. As a consequence of these and other factors,
our patent applications may fail to result in issued patents with claims that cover our product candidates in the U.S. or in other
countries.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if patents
have issued or do successfully issue from patent applications, and even if these patents cover our product candidates, third parties
may challenge the validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held
to be unenforceable. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if unchallenged,
our patents and patent applications or other intellectual property rights may not adequately protect our intellectual property,
provide exclusivity for our product candidates or prevent others from designing around our claims. The possibility exists that
others will develop products on an independent basis which have the same effect as our product candidates and which do not infringe
our patents or other intellectual property rights, or that others will design around the claims of patents that we have had issued
that cover our product candidates. If the breadth or strength of protection provided by our patents and patent applications with
respect to our product candidates is threatened, it could jeopardize our ability to commercialize our product candidates and dissuade
companies from collaborating with us.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may also desire
to seek a license from a third party who owns intellectual property that may be useful for providing exclusivity for our product
candidates, or for providing the ability to develop and commercialize a product candidate in an unrestricted manner. There is no
guarantee that we will be able to obtain a license from such a third party on commercially reasonable terms, or at all.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the
United States Patent and Trademark Office (USPTO) and various foreign governmental patent agencies require compliance with a number
of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We and our licensors
have filed a number of patent applications covering our product candidates or methods of using or making those product candidates.
We cannot offer any assurances about which, if any, patents will be issued with respect to these pending patent applications, the
breadth of any such patents that are ultimately issued or whether any issued patents will be found invalid and unenforceable or
will be threatened by third parties. Because patent applications in the U.S. and most other countries are confidential for a period
of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any
patent application related to a product candidate. We or our licensors may also become involved in proceedings regarding our patents,
including patent infringement lawsuits, interference or derivation proceedings, oppositions, and <i>inter partes </i>and post-grant
review proceedings before the USPTO, the European Patent Office and other non-U.S. patent offices.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>If we are
unable to protect the confidentiality of our trade secrets, the value of our technology could be negatively impacted and our business
would be harmed.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the
protection afforded by patents we hold rights to, we also rely on trade secret protection for certain aspects of our intellectual
property. However, trade secrets are difficult to protect. We seek to protect these trade secrets, in part, by entering into non-disclosure
and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent contractors,
advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent
assignment agreements with employees and certain consultants. Any party with whom we have executed such an agreement may breach
that agreement and disclose our proprietary information, including our trade secrets, and we might not be able to obtain adequate
remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult,
expensive and time-consuming, and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets
are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. Further,
if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to
prevent such third party, or those to whom they communicate such technology or information, from using that technology or information
to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, it could have
a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success will
depend in part on our ability to commercialize our product candidates without infringing the proprietary rights of others. Much
of the intellectual property utilized in our product candidates is licensed from our licensors, who hold patents and provisional
patents in their names. We have not conducted extensive freedom of use patent searches and no assurance can be given that patents
do not exist or could be issued which would have an adverse effect on our ability to market our technology or maintain our competitive
position with respect to our technology. We also cannot be sure that patents or provisional patents filed by others are valid or
will be upheld if challenged. It is possible that there are additional patents that may cover certain other aspects of technology
used in our product candidates that is not covered by our licensed intellectual property. If our licensed technology or other subject
matter are claimed under other United States patents or other international patents or are otherwise protected by third party proprietary
rights, we or our licensors may be subject to infringement actions. In such event, we may challenge the validity of such patents
or other proprietary rights or we may be required to obtain licenses from such companies in order to develop, manufacture or market
our technology. There can be no assurances that we would be successful in a challenge or be able to obtain such licenses or that
such licenses, if available, could be obtained on commercially reasonable terms. Furthermore, the failure to succeed in a challenge,
develop a commercially viable alternative or obtain needed licenses could have significant adverse consequences to the development
of our pipeline. Adverse consequences include delays in marketing some or all of our product candidates based on our technology
or the inability to proceed with the development, manufacture or sale of products requiring such licenses. If we defend ourselves
against charges of patent infringement or to protect our proprietary rights against third parties, substantial costs will be incurred
regardless of whether we are successful. Such proceedings are typically protracted with no certainty of success. An adverse outcome
could subject us to significant liabilities to third parties and force us to curtail or cease the research and development of our
technology.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Parties making claims
against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize
our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would
be a substantial diversion of resources from our business. In the event of a successful claim of infringement against us, we may
have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign
our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time
and monetary expenditure. Additionally, parties making claims against us may be able to sustain the costs of complex patent litigation
more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some
of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation
and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have
a material adverse effect on our business, results of operations, financial condition and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We may not
be able to protect our intellectual property rights throughout the world.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting
and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States can be less extensive than those in the United States.
In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state
laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their
own products and may also export infringing products to territories where we have patent protection, but enforcement is not as
strong as that in the United States. These products may compete with our products and our patents or other intellectual property
rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<b>Risks Related
to our Common Stock</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Our stock price has been and will likely continue to
be volatile and may decline regardless of our operating performance.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our stock price
has fluctuated in the past and can be expected to be volatile in the future. From July 1, 2020 through June 30, 2021, the reported
sale price of our Common Stock has fluctuated between $6.79 and $2.82 per share. The stock market in general and the market for
biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance
of particular companies. As a result of this volatility, investors may experience losses on their investment in our Common Stock.
The market price of our Common Stock may be influenced by many factors, including the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the success of competitive
products or technologies;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">regulatory actions with
respect to our product candidates or products or our competitors’ product candidates or products;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">actual or anticipated
changes in our growth rate relative to our competitors;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">announcements by us
or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">results
of clinical studies of our product candidates or those of our competitors;</span></td></tr>
<tr>
<td style="line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">regulatory
or legal developments in the U.S. and other countries;</span></td></tr>
<tr>
<td style="line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">developments
or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr>
<tr>
<td style="line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the
recruitment or departure of key personnel;</span></td></tr>
<tr>
<td style="line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the level of expenses
related to any of our product candidates or clinical development programs;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the results of our efforts
to in-license or acquire additional product candidates or products;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">actual or anticipated
changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">variations in our financial
results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">fluctuations in the
valuation of companies perceived by investors to be comparable to us;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">inconsistent trading
volume levels of our shares;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">announcement or expectation
of additional financing efforts;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">sales of our Common
Stock by us, our insiders or our other stockholders;</span></td></tr>
<tr style="vertical-align: top">
<td style="white-space: nowrap; line-height: 107%">&nbsp;</td>
<td style="white-space: nowrap; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="text-align: justify; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="width: 48px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">market conditions in
the pharmaceutical and biotechnology sectors;</span></td></tr>
<tr>
<td style="line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">general economic, industry
and market conditions; and</span></td></tr>
<tr>
<td style="line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">the other risks described
in this “Risk Factors” section.</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the
stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have experienced significant
volatility that has often been unrelated to the operating performance of particular companies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;	<b><i>Our principal stockholders
and management own a significant percentage of our stock and could exert significant control over matters subject to stockholder
approval.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our executive officers,
directors, affiliates, and entities they control own approximately 62.9% of our outstanding Common Stock and voting power. These
stockholders, should they act in concert, could determine the outcome of all matters requiring stockholder approval. For example,
these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any
merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals
or offers for our Common Stock. The interests of our significant stockholders who are also affiliates may not always coincide with
the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of
other stockholders, including seeking a premium value for their Common Stock, and might affect the market price for our Common
Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Sales of a substantial number of
shares of our Common Stock in the public market could cause our stock price to fall.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A significant portion
of our Common Stock is held in restricted form, and consequentially a minority of our outstanding Common Stock actively trades
in the public markets. Sales of a substantial number of such shares of our Common Stock in the public market could occur at any
time. While a large majority of such shares are unregistered and subject to volume restrictions on sale pursuant to Rule 144 under
the Securities Act, these restrictions could be lifted if any of our stockholders ceased to be bound by such restrictions. These
sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market
price of our Common Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Trading of
our Common Stock may be volatile and sporadic, which could depress the market price of our Common Stock and make it difficult for
our stockholders to resell their shares.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is currently
a limited market for our Common Stock and the volume of our Common Stock traded on any day may vary significantly from one period
to another. Trading in our stock is often thin and characterized by wide fluctuations in trading prices, due to many factors that
may have little to do with our operations or business prospects. The availability of buyers and sellers represented by this volatility
could lead to a market price for our Common Stock that is unrelated to operating performance. There is no assurance that a sufficient
market will develop in the stock, in which case it could be difficult for our stockholders to resell their stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred
and will continue to incur increased costs as a result of being a public company and our management expects to devote substantial
time to public company compliance programs.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a public company,
we have incurred and will continue to incur significant legal, accounting and other expenses. We are subject to the reporting requirements
of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect
to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC
and The NASDAQ Stock Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies,
including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance
practices. As a Smaller Reporting Company and Non-accelerated Filer, we are able to take advantage of certain accommodations afforded
to such companies, including being exempt from the requirement to conduct an audit of our internal controls. In the event we no
longer qualify as a Smaller Reporting Company and Non-accelerated Filer, we will lose such accommodations, which could involve
significant costs that could affect our operations. Changes in reporting requirements, the current political environment and the
potential for future regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional
compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The rules and regulations
applicable to public companies have substantially increased our legal and financial compliance costs and make some activities more
time-consuming and costly. To the extent these requirements divert the attention of our management and personnel from other business
concerns, they could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Because we
do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will
be the sole source of potential gain for our stockholders.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never declared
or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth
and development of our business. As a result, capital appreciation, if any, of our Common Stock will be the sole source of gain
for our stockholders for the foreseeable future.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Future sales
and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result
in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect that significant
additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts
of Common Stock or securities convertible into or exchangeable for Common Stock in one or more transactions at prices and in a
manner we determine from time to time. These future issuances of Common Stock or Common Stock-related securities, together with
the exercise of outstanding options or warrants, and any additional shares that may be issued in connection with acquisitions or
licenses, if any, may result in material dilution to our investors. Such sales may also result in material dilution to our existing
stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our Common Stock. Pursuant
to our equity incentive plans, our compensation committee is authorized to grant equity-based incentive awards to our employees,
non-employee directors and consultants. Future grants of RSUs, options and other equity awards and issuances of Common Stock under
our equity incentive plans will result in dilution and may have an adverse effect on the market price of our Common Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Some terms
of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others,
even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove
our current management.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Certificate
of Incorporation, and our Bylaws, as well as Delaware law, could make it more difficult for a third party to acquire us or increase
the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include terms
that:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="white-space: nowrap; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">provide that all
    vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required
    by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">provide that stockholders
    seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting
    of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s
    notice; and</span></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="white-space: nowrap; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">not provide for
    cumulative voting rights, thereby allowing the holders of a majority of the shares of Common Stock entitled to vote in any
    election of directors to elect all of the directors standing for election. </span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any of the factors
listed above may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it
more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of
our management.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, because
we are incorporated in Delaware, we are governed by Section 203 of the Delaware General Corporation Law, which may discourage,
delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders.
Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital
stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction.
Any term of our Certificate of Incorporation or Bylaws or Delaware law that has the effect of delaying or deterring a change in
control could limit the opportunity for our stockholders to receive a premium for their shares of our Common Stock and could also
affect the price that some investors are willing to pay for our Common Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related To Our Business Operations
and Managing Growth</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>If our operations
require a full time Chief Medical Officer, and we are not able to hire a full time Chief Medical Officer to manage our clinical
operations or if our current Chief Executive Officer, Chief Financial Officer or key scientific personnel cease to serve, our business
will be harmed. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, our management
team is led by Dr. Mark Dybul, the Chief Executive Officer and Luisa Puche, our Chief Financial Officer. If Dr. Dybul or Ms. Puche
should cease to serve, our business operations may suffer. Additionally, we may in the future require a Chief Medical Officer,
and if we are unable to hire a Chief Medical Officer, our business operations and the continued development of our product candidates
may suffer.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we
are dependent on our continued ability to attract, retain and motivate highly qualified additional management and scientific personnel.
If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the
continued development of our business, we might not be able to sustain our operations or grow.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have limited
corporate infrastructure and may experience difficulties in managing growth. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2021,
we had only 11 full time employees and we rely on third-party contractors for the provision of professional, scientific, regulatory
and other services. As our development and commercialization plans and strategies develop, we may need additional managerial, scientific,
operational, financial, and other resources. Our management may need to divert a disproportionate amount of its attention away
from our day-to-day operations and devote a substantial amount of time to managing these growth activities. We might not be able
to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies,
loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of our
current and potential future product candidates. If our management is unable to effectively manage our growth, our expenses may
increase more than expected, our ability to generate and grow revenue could be reduced and we might not be able to implement our
business strategy. Our future financial performance, our ability to commercialize product candidates, develop a scalable infrastructure
and compete effectively will depend, in part, on our ability to effectively manage any future growth.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>If we, our
service providers, or third parties fail to comply with environmental and health and safety laws and regulations, we could become
subject to fines or penalties or incur costs that could harm our business. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we, our service
providers, or any third parties engaged in development of our product candidates fail to comply with laws regulating the protection
of the environment, health and animal and human safety, we could be subject to enforcement actions and our business prospects could
be adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our research and
development activities, and the research and development activities of our service providers and any third parties engaged in development
of our product candidates, may involve the use of hazardous materials and chemicals or other regulated activities. In conjunction
with our service providers and other third parties, we are also engaged in pre-clinical studies using live animals and samples
of infectious diseases. Failure to adequately handle and dispose of hazardous materials or to meet various standards imposed by
federal, state, local or foreign regulators could lead to liabilities for resulting damages, which could be substantial. We also
may be subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory
procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we, our service
providers, or any third parties engaged in development of our product candidates fail to comply with applicable federal, state,
local or foreign laws or regulations, we could be subject to enforcement actions, which could adversely affect our ability to develop,
market and sell our product candidates successfully and could harm our reputation and lead to reduced acceptance of our product
candidates. These enforcement actions may include:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">restrictions on, or prohibitions against,
marketing our product candidates;</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">restrictions on importation of our product candidates;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">suspension of review or refusal to approve new or pending applications;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">suspension or withdrawal of product approvals;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">product seizures;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">injunctions; and</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">civil and criminal penalties and fines.</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We rely upon
information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security
incidents, could harm our ability to operate our business effectively. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business operations
could suffer in the event of system failure. Despite the implementation of security measures, our internal computer systems and
those of our contract research organizations, and other contractors and consultants are vulnerable to damage from computer viruses,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to
occur and cause interruptions in our operations, it could result in a material disruption of our product development programs.
For example, the loss of formulas or data from completed or ongoing or planned pre-clinical studies could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption
or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential
or proprietary information, we could incur liability and further development of our product candidates could be delayed.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Our business
plan may lead to the initiation of one or more product development programs, the discontinuation of one or more development programs,
or the execution of one or more transactions that you do not agree with or that you do not perceive as favorable to your investment.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are pursuing
a strategy to leverage our clinical experience and expertise for the clinical development and regulatory approval of our gene therapy
product candidates. As part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license
new product candidates and to collaborate on our existing products in development. We cannot be certain that our product candidates
will be successfully developed, or that the early clinical trial results of these product candidates will be predictive of future
clinical trial results. We may determine at any time that one or more of our in-licensed product candidates is not suitable for
continued development due to cost, feasibility of obtaining regulatory approvals or any other reason, and may terminate the related
license.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This business plan
requires us to be successful in a number of challenging, uncertain and risky activities, including pursuing development of our
gene therapy product candidates in indications for which we have limited or no human clinical data, designing and executing a nonclinical
and/or clinical development program for our product candidates, building internal or outsourced gene therapy capabilities, converting
early stage gene therapy research efforts into clinical development opportunities, identifying additional promising new assets
for development that are available for acquisition or in-license and that fit our strategic focus and identifying potential partners
to collaborate on our products. We may not be successful at one or more of the activities required for us to execute this business
plan. In addition, we may consider other strategic alternatives, such as mergers, acquisitions, divestitures, joint ventures, partnerships
and collaborations. We cannot be sure when or if any type of transaction will result. Even if we pursue a transaction, such transaction
may not be consistent with our stockholders’ expectations or may not ultimately be favorable for our stockholders, either
in the shorter or longer term.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our growth prospects
and the future value of our Company are primarily dependent on the progress of our ongoing and planned development programs for
our product candidates as well as the outcome of our ongoing business development efforts and pipeline [expansion activities/progression],
together with the amount of our remaining available cash. The development of our product candidates and the outcome of our ongoing
business development efforts and pipeline [expansion activities/progression] are highly uncertain. We expect to continue to reassess
and make changes to our existing development programs and pipeline strategy. Our plans for our development programs may be affected
by the results of competitors’ clinical trials of product candidates addressing our current target indications, and our business
development efforts and pipeline [expansion activities/progression] may also be affected by the results of competitors’ ongoing
research and development efforts. We may modify, expand or terminate some or all of our development programs, clinical trials or
collaborative research programs at any time as a result of new competitive information or as the result of changes to our product
pipeline or business development strategy.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>If serious
adverse events or other undesirable side effects or safety concerns attributable to our product candidates occur, they may adversely
affect or delay our clinical development and commercialization of some or all of our product candidates. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Undesirable side
effects or safety concerns caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt
our clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval. Although no treatment-related
serious adverse events (“SAEs”) were observed in any clinical trials of any of our product candidates to date, if treatment-related
SAEs or other undesirable side effects or safety concerns, or unexpected characteristics attributable to our product candidates
are observed in any future clinical trials, they may adversely affect or delay our clinical development and commercialization of
the effected product candidate, and the occurrence of these events could have a material adverse effect on our business and financial
prospects. Results of our future clinical trials could reveal a high and unacceptable severity and prevalence of adverse side effects.
In such an event, our trials could be suspended or terminated and the FDA or other regulatory agency could order us to cease further
development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could
affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, if
any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects
or safety concerns caused by these product candidates, a number of potentially significant negative consequences could result,
including:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">regulatory authorities may withdraw, suspend, or limit approvals of
such product and require us to take them off the market;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">regulatory authorities may require the addition of labeling statements,
specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">regulatory authorities may require a medication guide outlining the
risks of such side effects for distribution to patients, or that we implement a REMS or REMS-like plan to ensure that the benefits
of the product outweigh its risks;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">we may be required to change the way a product is distributed or administered,
conduct additional clinical trials or change the labeling of a product;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">we may be required to conduct additional post-marketing studies or
surveillance;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">we may be subject to limitations on how we may promote the product;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">sales of the product may decrease significantly;</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">we may be subject to regulatory investigations,</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">government enforcement actions, litigation or product liability claims;
and</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">our products may become less competitive or our reputation may suffer.</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any of these events
could prevent us or any collaborators from achieving or maintaining market acceptance of our product candidates or could substantially
increase commercialization costs and expenses, which in turn could delay or prevent us from generating revenue from the sale of
our product candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have no
manufacturing experience, and the failure to comply with all applicable manufacturing regulations and requirements could have a
materially adverse effect on our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never manufactured
products in the highly regulated environment of pharmaceutical manufacturing, and our team has limited experience in the manufacture
of drug therapies. There are numerous regulations and requirements that must be maintained to obtain licensure and permitting required
prior to the commencement of manufacturing, as well as additional requirements to continue manufacturing pharmaceutical products.
In addition, we do not have the resources at this time to acquire or lease suitable facilities. If we or our CMO fail to comply
with regulations, to obtain the necessary licenses and knowhow or to obtain the requisite financing in order to comply with all
applicable regulations and to own or lease the required facilities in order to manufacture our products, we could be forced to
cease operations, which would cause you to lose all of your investment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the
FDA and other regulatory authorities require that product candidates and drug products be manufactured according to cGMP. Any failure
by our third-party manufacturers to comply with cGMP could lead to a shortage of our product candidates. In addition, such failure
could be the basis for action by the FDA to withdraw approval, if granted to us, and for other regulatory enforcement action, including
Warning Letters, product seizure, injunction or other civil or criminal penalties.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Product candidates
that we develop may have to compete with other products and product candidates for access to manufacturing facilities. There are
a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing for us and willing
to do so. If we need to find another source of drug substance or drug product manufacturing for our product candidates, we may
not be able to identify, or reach agreement with, commercial-scale manufacturers on commercially reasonably terms, or at all. If
third parties that we engage in the future to manufacture a product for commercial sale or for our clinical trials, should cease
to continue to do so for any reason, we likely would experience significant delays in obtaining sufficient quantities of product
for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for
any reason we are unable to obtain adequate supplies of any product candidate that we develop, or the drug substances used to manufacture
it, it will be more difficult for us to compete effectively, generate revenue, and further develop our products. In addition, if
we are unable to assure a sufficient quantity of the drug for patients with rare diseases or conditions, we may lose any Orphan
Drug exclusivity to which the product otherwise would be entitled.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We may, in
the future, choose to seek FDA Orphan Drug designation for one or more of our current or future CNS product candidates. Even if
we obtain Orphan Drug designation from the FDA for a product candidate, there are limitations to the exclusivity afforded by such
designation. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the U.S., the
company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition receives orphan
drug marketing exclusivity for that drug for a period of seven years. This orphan drug exclusivity prevents the FDA from approving
another application, including a full NDA to market the same drug for the same orphan indication, except in very limited circumstances,
including when the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. For
purposes of small molecule drugs, the FDA defines “same drug” as a drug that contains the same active moiety and is
intended for the same use as the drug in question. To obtain Orphan Drug status for a drug that shares the same active moiety as
an already approved drug, it must be demonstrated to the FDA that the drug is safer or more effective than the approved orphan
designated drug, or that it makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan
drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition,
orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was
materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with
the rare disease or condition or if another drug with the same active moiety is determined to be safer, more effective, or represents
a major contribution to patient care.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_032"></span>1B. Unresolved Staff Comments</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There are no unresolved SEC staff comments.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_033"></span>Item 2. Properties</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company currently leases the following properties:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top; background-color: white">
<td style="border-bottom: black 1pt solid; padding: 0; width: 10%; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Location</span></td>
<td style="padding: 0; width: 1%; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0; width: 10%; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Use</span></td>
<td style="padding: 0; width: 1%; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0; width: 78%; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Terms</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">5901 W. Olympic
Blvd, Suite 419<br> Los Angeles, CA 90036</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Physical
office space</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">On
November 13, 2017, the Company entered into a Lease Agreement for a term of five years and two months from November 1, 2017. The
Leased Premises consist of approximately 2,325 rentable square feet. The base rent for such leased premises increases by 3% each
year over the term, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months
of the sixth year. The Company was entitled to $70,800 in tenant improvement allowance in the form of free rent applied over 10
months in equal installments from January 2018.</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">2080 Century
Park East, Suite 906 <br> Los Angeles, CA 90067</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;Headquarters</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: justify; line-height: 107%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Company entered into a Lease Agreement on June 19, 2018 for our corporate headquarters located at Century City Medical Plaza.
We have a ten-year lease that was for approximately 2,453 square feet at this location. In February 2019, we extended our corporate
headquarters to encompass the adjoining suite for approximately 1,101 square feet, bringing the total workspace to 3,554 square
feet. The new base rent for this leased premises increases by 3% each year over the term, and ranges from $17,770 per month as
of the date of the amendment until the end of the first year to $ 23,186 per month for the tenth year. The additional suite was
in the form of an amendment to the original lease and will expire on the same date as the original lease. The Company was entitled
to a total of $148,168 in contributions toward tenant improvements for both spaces.</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_034"></span>Item 3. Legal Proceedings</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time,
we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We are not
currently a party to any legal proceeding that we believe would have a material adverse effect on our business, financial condition
or operating results.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_035"></span>Item 4. Mine Safety Disclosures.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_036"></span>Item 5. Market for Registrant’s
Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Market Information and Holders of
our Common Stock</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock
trades on the Nasdaq Capital Market under the symbol “ENOB”.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 28, 2021, the Company had 52,219,661 shares of Common Stock issued and outstanding and approximately 227 stockholders of record.
The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners
but whose shares are held in street name by brokers and other nominees.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>	</b>From March 18,
2021 through June 9, 2021, the Company issued 408,164 shares of Common Stock at a price of $3.92 per share pursuant to a private
placement for total proceeds to the Registrant of $1,600,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Company Purchases of Equity Securities</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">[None]</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Dividends</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has
not declared or paid any cash dividends on its Common Stock and does not intend to declare or pay any cash dividend in the foreseeable
future. The payment of dividends, if any, is within the discretion of the Board and will depend on the Company’s earnings,
if any, its capital requirements and financial condition and such other factors as the Board may consider.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_037"></span>Item 6. [Reserved]</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_038"></span>Item 7. Management’s Discussion and Analysis of
Financial Condition and Results of Operations</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>The following
discussion of our financial condition and results of operations should be read in conjunction with our financial statements, and
the related notes to those statements included elsewhere in this report. In addition to the historical financial information, the
following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Our actual results may
differ materially from those anticipated in these forward-looking statements.</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Our Business</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Enochian BioSciences,
Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies
to potentially cure and treat deadly diseases. The company’s gene-modified cell and immune therapy platforms can potentially
be applied to multiple indications, including HIV/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, our operations
have been funded by sales of our securities and debt financing. We have never generated any sales revenue and we expect this to
continue until our therapies or products are approved for marketing in the United States and/or Europe. Even if we are successful
in having our therapies or products approved for sale in the United States and/or Europe, we cannot guarantee that a market for
the therapies or products will develop. We may never be profitable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Recent Developments</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On August 11, 2021, and with an effective
date of July 1, 2021, the Company and Dr. Dybul entered into an Employment Agreement, the form of which was approved and recommended
by the Board on October 30, 2019 and approved by stockholders of the Company with a majority of the voting power of all shares
of the Company’s capital stock entitled to vote on the matter on October 31, 2019. The material terms of the Employment Agreement
are as set forth in the Company’s Information Statement filed with the Securities and Exchange Commission on November 12,
2019.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>COVID-19 </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The COVID-19 pandemic
continues to evolve, and to date has led to the implementation of various mitigation responses, including government-imposed quarantines,
travel restrictions and other public health safety measures, as well as leading to reported adverse impacts on healthcare resources,
facilities and providers across the United States and in other countries. COVID-19 may cause delays in our research activities.
To date, it has not materially affected our operations; however it has caused delays in the conduct of experiments due to limitations
of various organizations, in particular those conducting experiments related to COVID-19. There have also been increases in the
cost to conduct animal studies due to staffing and other limitations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The full extent to
which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult
to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal,
state and local governments could adversely impact our or our partners’ clinical, research and development, regulatory and
manufacturing operations or timelines.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We continue to monitor
the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition,
the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access
capital, which could in the future negatively affect the financial resources available to us.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Year ended June 30, 2021 compared to the year ended June
30, 2020.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
sets forth our revenues, expenses and net income for the years ended June 30, 2021 and 2020. The financial information below is
derived from our audited consolidated financial statements included elsewhere in this Annual Report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Year Ended</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase/(Decrease)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; width: 40%; text-align: left">General and administrative expenses</td><td style="width: 3%; color: black">&nbsp;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 10%; color: black; text-align: right">7,740,130</td><td style="width: 1%; color: black; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">7,120,835</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">619,295</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%; color: black">&nbsp;</td>
    <td style="width: 1%; color: black; text-align: left">&nbsp;</td><td style="width: 10%; color: black; text-align: right">9</td><td style="width: 1%; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Research and development expenses</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">15,538,122</td><td style="color: black; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,694,349</td><td style="text-align: left">&nbsp;</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">10,843,773</td><td style="color: black; text-align: left">&nbsp;</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">231</td><td style="color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Depreciation and amortization</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">123,535</td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">108,584</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">14,951</td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">14</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Operating Expenses</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">23,401,787</td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,923,768</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">11,478,019</td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">96</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(23,401,787</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,923,768</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(11,478,019</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(96</td><td style="padding-bottom: 1pt; color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other Income (Expenses)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Change in fair value of contingent consideration</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(3,048,033</td><td style="color: black; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">274,566</td><td style="text-align: left">&nbsp;</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(3,322,599</td><td style="color: black; text-align: left">)</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(1,210</td><td style="color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest expense</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(379,608</td><td style="color: black; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(104,280</td><td style="text-align: left">)</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(275,328</td><td style="color: black; text-align: left">)</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">264</td><td style="color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Gain (Loss) on currency transactions</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(32,634</td><td style="color: black; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">146,828</td><td style="text-align: left">&nbsp;</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(179,462</td><td style="color: black; text-align: left">)</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(122</td><td style="color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Gain on settlement</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">—</td><td style="color: black; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">140,000</td><td style="text-align: left">&nbsp;</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(140,000</td><td style="color: black; text-align: left">)</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(100</td><td style="color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest income</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">13,179</td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">50,296</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(37,117</td><td style="padding-bottom: 1pt; color: black; text-align: left">))</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(74</td><td style="padding-bottom: 1pt; color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Other Income (Expenses)</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(3,447,096</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">507,410</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(3,954,506</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(779</td><td style="padding-bottom: 1pt; color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Loss Before Income Taxes</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right">(26,848,883</td><td style="color: black; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(11,416,358</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(15,432,525</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">135</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Income Tax Benefit</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">125,276</td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">125,276</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td style="color: black; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(26,723,607</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,416,358</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,307,249</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">134</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Year Ended</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-weight: bold; text-align: left">Net Loss</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(26,723,607</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(11,416,358</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other Comprehensive Income (Loss)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign Currency Translation Gain (Loss), Net of Taxes</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,582</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(143,234</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Comprehensive Loss</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26,693,025</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,559,592</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Revenues</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a pre-revenue,
pre-clinical biotechnology company. We have never generated revenues and have incurred losses since inception. We do not anticipate
earning any revenues until our therapies or products are approved for marketing and sale.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operating expenses
for the years ended June 30, 2021 and 2020 were $23,401,787 and $11,923,768, respectively, representing an increase of $11,478,019,
or 96%. The largest contributor to the increase in operating expenses for the year ended June 30, 2021, was the increase in research
and development expenses of $10,843,773 in connection with the continued growth in our research and development efforts, and an
increase in general and administrative expenses of $619,295.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for the years ended June 30, 2021 and 2020 were $7,740,130 and $7,120,835, respectively, representing an increase of $619,295,
or 9%. General and administrative expenses include audit fees, non-cash compensation expenses, consulting expenses, board compensation,
filing fees, corporate taxes, security expenses, legal fees, office leases, insurance, patent fees, salaries, investor relations,
travel expenses and other general and administrative expenses. The increase in general and administrative expenses are primarily
related to increases of $416,076 in stock-based compensation, $254,512 in salaries, $179,363 related to insurance, and $99,880
in investor relations, partially offset by decreases in legal and security fees and laboratory costs totaling approximately $420,862.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
expenses for the years ended June 30, 2021, and June 30, 2020, were $15,538,122 and $4,694,349, respectively, representing an increase
of $10,843,773 or 231%. Overall research and development expenses remained consistent with the exception of the $10 million upfront
fees related to the Coronavirus and Influenza License Agreement discussed above, and approximately $657,000 in collaboration partner
costs in the development of our product lines ENOB-HV-12 and DC-11 in the year ended June 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Other Income (Expense)</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net other income
(expense) for the years ended June 30, 2021 and 2020 was $(3,447,096) and $507,410, respectively, representing an increase of 3,954,506
or 779%. The increase in other expense was due primarily to the change in the fair value of contingent consideration of $3,322,000,
which is impacted by contingent shares issued during the period and the mark to market adjustments on the remaining contingent
consideration liability, as well as an increase in interest expense of approximately $275,000.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net loss for the
years ended June 30, 2021 and June 30, 2020 was $26,723,607 and $11,416,358, respectively, representing an increase in net loss
of $15,307,249, or 134%. The increase in net loss was primarily due to the upfront fees of $10 million related to the Coronavirus
and Influenza License Agreement recorded in research and development costs, an approximate increase in the change in fair value
of contingent consideration of $3,332,599 and $619,295 increase in general and administrative expenses.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have historically
satisfied our capital and liquidity requirements through funding from shareholders, the sale of our Common Stock and warrants,
and debt financing. We have never generated any sales revenue to support our operations and we expect this to continue until our
therapies or products are approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies
or products approved for sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products
will develop. We may never be profitable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At this time, we
believe we have sufficient liquidity and access to committed funds to fund our operations for the next twelve months. We may need
additional funds for (a) the purchase of equipment, (b) increases in personnel, and, (c) research and development, specifically
to advance towards an Investigational New Drug Application (IND) following Pre-IND readouts from the FDA for ENOB CV-01, ENOB-HB-01,
ENOB-HV-01, and ENOB-HV-21. We will also require additional funding to continue our research and development of ENOB-HV11/12 and
ENOB-DC11 and ENOB-FL-01 and -11 and ENOB-CV-11, to fund the Coronavirus and Influenza Indications License Agreement in furtherance
of the treatment related to all coronaviruses, and for possible future strategic acquisitions of businesses, products or technologies
complementary to our business. If additional funds are required, we may raise such funds from time to time through public or private
sales of our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to
raise capital when needed could materially adversely affect our growth plans and our financial condition and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2021,
the Company had $20,664,410 in cash and working capital of $19,013,100 as compared to $8,696,361 in cash and working capital of
$7,606,411 as of June 30, 2020. The increase in cash of $11,968,049 is primarily due to the proceeds from the various equity raises
throughout the year that totaled approximately $33,066,148, partially offset by the cost of operations primarily related to research
and development costs of $15,500,000 (see Note 8 of the Financial Statements.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 8, 2020,
we entered into a purchase agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC, (“LPC”),
pursuant to which LPC is committed to buy, and we have the right, but not the obligation, to sell to LPC up to an aggregate of
$20,000,000 of our Common Stock, subject to certain limitations and conditions set forth in the LPC Purchase Agreement, including
a limitation on the number of shares of Common Stock we can put to LPC and the pricing parameters for the sales. For the year ended
June 30, 2021, the Company issued 200,000 shares of Common Stock for proceeds of $1,221,350 (see Note 7 of the Financial Statements.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to a private
placement offering, the Company issued 1,275,719 shares of Common Stock resulting in proceeds of $5,000,800. The Company effected
the issuances of the shares of Common Stock from March 15, 2021 to June 9, 2021. The private placement was made directly by the
Company in reliance upon Regulation S of the Securities Act of 1933. No underwriter or placement agent was engaged
by the Company for this private placement (see Note 7 of the Financial Statements.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 14, 2021, the
Company and certain institutional investors entered into a securities purchase agreement (the “Purchase Agreement”),
pursuant to which the Company agreed to sell to such investors an aggregate of 3,866,668 shares of Common Stock, in a registered
direct offering, for gross proceeds of approximately $29 million (the “Financing”). The purchase price for each share of
Common Stock was $7.50. The Company agreed not to issue or enter into any agreement to issue Common Stock from June 14, 2021 until
ninety (90) days after the closing of the Financing. The Company entered into a letter agreement dated June 14, 2021 (the
“Letter Agreement”) with H.C. Wainwright &amp; Co., LLC, as exclusive placement agent (the “Placement
Agent”), pursuant to which the Placement Agent agreed to act as the exclusive placement agent for the Financing. The Company
agreed to pay the Placement Agent an aggregate fee equal to 7.0% of the gross proceeds raised in the Financing. The Company also
agreed to pay the Placement Agent certain expenses. The Company paid $2,090,000 in commissions and incurred offering expenses, and
issuance costs of $66,011, resulting in net proceeds of $26,843,999 in connection with the Financing. The Financing closed on June
16, 2021 (see Note 7 of the Financial Statements.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Warrant Exercises</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 3, 2019,
certain of our warrant holders exercised warrants to purchase 500,000 shares of Common Stock for total proceeds to the Company
of $1,000,000. For the year ended June 30, 2021, the Company issued 63,122 shares of Common Stock for total proceeds of $82,056
upon the exercise of warrants.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Debt</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 6, 2020,
the Company issued two Convertible Notes (the “Convertible Notes”) to an existing stockholder of the Company each with
a face value amount of $600,000, convertible into shares of Common Stock. The holder did not exercise the conversion feature that
expired on February 6, 2021. The outstanding principal amount of the Convertible Notes is due and payable on February 6, 2023.
Interest on the Convertible Notes commenced accruing on the date of issuance at six percent (6%) per annum, computed on the basis
of twelve 30-day months, and is compounded monthly on the final day of each calendar month based upon the principal and all accrued
and unpaid interest outstanding as of such compound date. The interest is payable in cash on a semi-annual basis. For the years
ended June 30, 2021 and 2020, the interest expense amounted to $72,967 and $30,302, respectively (see Note 5 to the Financial Statements.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 30, 2020
(the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $5,000,000 (the “Unsecured
Note”) to Paseco APS (the “Holder”), a Danish limited company and an existing stockholder of the Company. The
principal amount of the Unsecured Note will be payable on November 30, 2021, and bears interest at a fixed rate of 6% per annum,
which was prepaid by the Company in full on the date of issuance through the issuance of 188,485 shares of the Company’s
Common Stock based on the closing market price on that date, valued at $501,370. On February 11, 2021, the Company and the Holder
amended the original Unsecured Note to extend the maturity date to November 30, 2022. The Company prepaid in full all accrued interest
from November 30, 2021 to the new maturity date November 30, 2022, through the issuance of 74,054 shares of Common Stock based
on the closing market price on that date, valued at $299,178. (See Note 5 to the Financial Statements).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash Flows</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Year ended June 30, 2021 compared to the year ended
June 30, 2020</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a summary
of the Company’s cash flows provided by (used by) operating, investing, and financing activities:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Year Ended</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net Cash Used by Operating Activities</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(20,610,723</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(10,459,422</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Cash Used by Investing Activities</td><td>&nbsp;</td>
    <td style="text-align: left"></td><td style="text-align: right">(48,892</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left"></td><td style="text-align: right">(184,463</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Cash Provided by Financing Activities</td><td>&nbsp;</td>
    <td style="text-align: left"></td><td style="text-align: right">32,601,553</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left"></td><td style="text-align: right">7,200,000</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of exchange rates on cash</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right">26,111</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right">(141,978</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Increase (Decrease) in Cash</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,968,049</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,585,863</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2021,
we had cash and cash equivalents of $20,664,410, an increase of $11,968,049, when compared to the June 30, 2020 balance of $8,696,361.
This increase was primarily due to cash provided by financing activities, primarily from equity sale transactions, partially offset
by cash used in operating activities.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We plan to use our
cash and cash equivalents to fund research and development, specifically to open an Investigational New Drug Application (IND)
(the first step in the drug review process by the FDA) for ENOB CV-01, ENOB-HB01, ENOB-HV01, and ENOB-HV21, to continue our research
and development of ENOB-HV11/12 and ENOB-DC11, and to fund the Coronavirus and Influenza Indications License Agreement in furtherance
of the Treatment, and possible future strategic acquisitions of businesses, products or technologies complementary to our business.
These activities will require an increase in staffing and possible additional property, plant and equipment purchases to support
the expected growth.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: black; background-color: white">Cash
used by operating activities represents the cash receipts and disbursements related to all of our activities other than investing
and financing activities. Operating cash flow is derived by adjusting our net income for non-cash items and changes in operating
assets and liabilities. </span>Net cash used by operating activities for the years ended June 30, 2021 and 2020 was $20,610,723
and $10,459,422, respectively, representing an increase of $10,151,301. The increase is primarily related to the increase in our
net loss as adjusted for non-cash items, partially offset by changes in our operating assets and liabilities of $932,133.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash used by
investing activities for the years ended June 30, 2021 and 2020 was $48,892 and $184,463, respectively, representing a decrease
of $135,571. The decrease is primarily due to lower costs incurred in purchases of equipment in the current year.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash provided
by financing activities for the years ended June 30, 2021 and 2020 was $32,601,553 and $7,200,000, respectively, representing an
increase of $25,401,553. The net cash provided by financing activities in the current year consists primarily of $26,843,998 of
net proceeds from the issuance of Common Stock as part of a direct offering, $5,000,800 of proceeds from the issuance of Common
Stock through a private placement, and $1,221,350 proceeds from issuance of Common Stock related to equity line draws. The prior
year net cash from financing activities primarily consisted of $1,200,000 related to a convertible note payable, $5,000,000 related
to a long-term note payable, and $1,000,000 related to warrants exercised.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2021,
and 2020, we had no off-balance sheet arrangements. We are not aware of any material transactions, which are not disclosed in our
consolidated financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Significant Accounting Policies and Critical Accounting
Estimates</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management’s
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses.
On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience
and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results
may differ from these estimates under different assumptions and conditions. Our most critical accounting estimates are detailed
below, and our significant accounting policies are more fully described in Note 1 of the accompanying consolidated financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Intangible Assets - </b>The
<span style="font: 10pt Times New Roman, Times, Serif">Company has both Definite and Indefinite life intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Definite
life intangible assets relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting
Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, <i>Goodwill and Other Intangible
Assets</i>. Intangible assets are recorded at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent.
If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Definite
life intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents
is twenty years from the date of application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Indefinite
life intangible assets include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite
life intangible assets in accordance with ASC 350, License agreement costs represent the fair value of the license agreement on the date
acquired and are tested annually for impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Goodwill
</b>- Goodwill is not amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances
indicate the carrying value may not be recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Impairment
of Goodwill and Indefinite Lived Intangible Assets</b> – We test for goodwill impairment at the reporting unit level, which is
one level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit
to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential
sale of the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting
unit exceeds its fair value, we record an impairment loss for such excess. The carrying value of IPR&amp;D and goodwill at June 30, 2021,
were $154,824,000 and $11,640,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
indefinite-lived intangible assets, such as licenses acquired as an IPR&amp;D asset, on an annual basis we determine the fair value of
the asset and record an impairment less, if any, for the excess of the carrying value of the asset over its fair value. The fair value
analysis performed on the license agreement, and the annual fair value analysis performed on goodwill supported that both indefinite
life intangible assets are not impaired as of June 30, 2021 (see Note 3.)</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair
Value of Financia</b></span><b>l Instruments </b>- The Company accounts for fair value measurements for financial assets and financial
liabilities in accordance with FASB ASC Topic 820. Under the authoritative guidance, fair value is defined as the exit price, representing
the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market
participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance established a three-tier fair value
hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
<td style="width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="padding-right: 8.25pt; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no assets
that use Level 1, 2 or 3 inputs, nor any liabilities that use Level 1 or 2 inputs as of June 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Liabilities that use Level
3 inputs held as of June 30, 2021 consisted of a contingent consideration liability related to the February 16, 2018 acquisition
of Enochian BioPharma Inc. (the “Acquisition”). As consideration for the Acquisition, the stockholders of Enochian
Biopharma received (i) 18,081,962 shares of common stock, and (ii) the right to receive contingent shares pro rata upon the exercise
of warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $21,516,000
at the time of the Acquisition and is subsequently remeasured to fair value at each reporting date. At June 30, 2021, 1,350,000
contingent shares are issuable in connection with the Acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of
the contingent consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual
or observable with the exception being volatility, which is computed based on the value of the Company’s underlying stock.
The key inputs to valuing the contingent consideration liability on the date of acquisition and as of June 30, 2021 include the
Company’s stock price, the exercise price of the warrants of $1.30 per share, the risk-free rate, the expected volatility
of the Company’s common stock and the digital call rate. The fair value measurements are highly sensitive to changes in these
inputs and significant changes in these inputs could result in a significantly higher or lower fair value.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"><b>Stock-Based
Compensation - </b>The Company has granted stock options, restricted share units (“RSUs”) and warrants to certain employees,
officers, directors and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic
718, Compensation – Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted
to certain employees, officers, directors and consultants for the years ended June 30, 2021 and 2020 were $1,444,798 and $1,028,721,
respectively (see Note 7 to the Financial Statements).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes
compensation costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value
of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions
used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are the expected term
of the award, the underlying stock price volatility, the risk-free interest rate and the expected dividend yield.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company records
stock-based compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation—Stock Compensation
Non-Employees</i></b>. All transactions in which goods or services are the consideration received for the issuance of equity instruments
are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever
is more reliably measurable. Equity instruments issued to consultants and the cost of the services received as consideration are
measured and recognized based on the fair value of the equity instruments issued and are recognized over the consultants’
required service period, which is generally the vesting period (see Note 7 to the Financial Statements.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Recently Enacted Accounting Standards</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For a description
of accounting changes and recent accounting standards, including the expected dates of adoption and estimated effects, if any,
on our consolidated financial statements, see “Note 1: Recent Accounting Pronouncements” in the financial statements
included elsewhere in this Annual Report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_039"></span>Item 7A. Quantitative and Qualitative Disclosures about
Market Risk</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Registrant is a smaller reporting
company and is not required to provide this information.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_040"></span>Item 8. Financial Statements and
Supplementary Data</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Index to Consolidated Financial Statements
</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr>
<td style="vertical-align: top; width: 90%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Page
</b>&nbsp;</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_051" tabindex="18">Reports of Independent Registered Public Accounting Firm</a></span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-2</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_052" tabindex="18">Consolidated Balance Sheets at June 30, 2021 and 2020</a></span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-4
- F-5</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_053" tabindex="18">Consolidated
Statements of Operations for the Years Ended June 30, 2021 and 2020</a></span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-6</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_054" tabindex="18">Consolidated Statements of Comprehensive Loss for the Years Ended June 30, 2021 and 2020</a></span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-7</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_055" tabindex="18">Consolidated Statements of Stockholders’ Equity for the Years Ended June 30, 2021 and 2020</a></span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-8</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_056" tabindex="18">Consolidated Statements of Cash Flows for the Years Ended June 30, 2021 and 2020</a></span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-9
- F-10</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_057" tabindex="18">Notes to the Consolidated Financial Statements</a></span></td>
<td style="vertical-align: bottom; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">F-11
- F-29</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 48; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="a_051"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">To the Board of Directors and Shareholders of
Enochian Biosciences, Inc.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Opinion on the Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Enochian Biosciences, Inc. (“the Company”) as of June 30, 2021, and 2020, the related consolidated
statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two-year
period ended June 30, 2021 and the related notes (collectively referred to as the “financial statements”). In our opinion,
the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of
June 30, 2021, and 2020, and the results of its operations and its cash flows for each of the years in the two-year period ended
June 30, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="text-decoration: underline">Basis for Opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based
on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of
internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Critical Audit Matters</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The critical audit matters communicated below
are matters arising from the current period audit of the financial statements that were communicated or required to be communicated
to the audit committee and that: (1) related to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any
way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical matters below, providing
separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Indefinite-Lived Intangible Asset Impairment
Assessment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an indefinite-lived intangible
asset related to an acquired license treated as an in-process research and development asset (“IPR&amp;D”). As of June
30, 2021, the carrying value of the asset is $154,824,000. To assess the carrying value of the IPR&amp;D asset for impairment,
management estimated the fair value of IPR&amp;D annually on its elected assessment date of June 30, 2021, using a multi-period
excess earnings method, which is a specific discounted cash flow method. The determination of the fair value requires management
to make significant estimates including, but not limited to, the discount rate used in the model, the total addressable market
for each potential drug, market penetration assumptions, and for the estimated timing of commercialization of the drugs. Changes
in these assumptions could have a significant impact on the fair value of the IPR&amp;D and a significant change in fair value
could cause a significant impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>How the Critical Audit Matter was Addressed
in the Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We identified the impairment testing of the
IPR&amp;D asset as a critical audit matter because of the significant estimates and assumptions management makes related to the
addressable market, market penetration estimates, commercialization dates of the drugs and selection of the discount rate to determine
the fair value of the goodwill. This required a high degree of auditor judgment and an increased extent of effort when performing
audit procedures to evaluate the selection of the discount rate, the reasonableness of the total addressable market and market
penetration for each drug, and the reasonableness of management’s forecast of the commercialization dates for IPR&amp;D.
In addition, the audit effort involved the use of professionals with specialized skill and knowledge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audit procedures related to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 0.25in">&nbsp;</td>
<td style="width: 0.25in"><span style="font: 10pt Symbol"><span style="font-family: Times New Roman, Times, Serif">●</span></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Testing management’s process for developing the fair value of the IPR&amp;D.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Evaluating the reasonableness and consistency of the selected valuation methodology and assumptions utilized by the Company.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●<span style="font: 10pt Symbol"></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Testing the mathematical accuracy of the model used by management.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●<span style="font: 10pt Symbol"></span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Testing the completeness and accuracy of underlying data used in the fair value estimate.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Evaluating the significant assumptions provided by management or developed by the third-party valuation specialist related to total addressable market, market penetration, commercialization forecasts, and discount rate to discern whether they are reasonable considering (i) current and past performance of the entity; (ii) their consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit.</span></td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, professionals with specialized skill and knowledge
were utilized by the Firm to assist in the performance of these procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill Impairment Assessment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2021, the carrying value of
goodwill was $11,640,000. As described in note 1 to the consolidated financial statements, the Company tests goodwill for impairment
annually at the reporting unit level, or more frequently if events or circumstances indicate it is more likely than not that the
fair value of a reporting unit is less than it’s carrying amount. To assess the carrying value of the goodwill for impairment,
management estimated the fair value of goodwill on its elected assessment date of June 30, 2021, using a discounted cash flow model.
The determination of the fair value requires management to make significant estimates including, but not limited to, the discount
rate used in the model, the total addressable market for each potential drug, market penetration assumptions, and for the estimated
timing of commercialization of the drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>How the Critical Audit Matter was Addressed
in the Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We identified the evaluation of the impairment
analysis for goodwill as a critical audit matter because of the significant estimates and assumptions management makes related
to the addressable market, market penetration, commercialization dates of the drugs and selection of the discount rate to determine
the fair value of the goodwill. This required a high degree of auditor judgment and an increased extent of effort when performing
audit procedures to evaluate the selection of the discount rate, the reasonableness of the total addressable market and market
penetration forecasts for each drug, and the reasonableness of management’s forecast of the commercialization dates for the
drugs. In addition, the audit effort involved the use of professionals with specialized skill and knowledge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audit procedures related to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Testing management’s process for
developing the fair value of the reporting unit.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Evaluating the reasonableness and consistency
of the selected valuation methodology and assumptions utilized by the Company.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Testing the mathematical accuracy of the
model used by management.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Testing the completeness and accuracy of
underlying data used in the fair value estimate.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Evaluating the significant assumptions
provided by management or developed by the third-party valuation specialist related to total addressable market, market penetration,
commercialization forecasts, and discount rate to discern whether they are reasonable considering (i) current and past performance
of the entity; (ii) their consistency with external market and industry data; and (iii) whether these assumptions were consistent
with evidence obtained in other areas of the audit.</span></td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, professionals with specialized skill and knowledge
were utilized by the Firm to assist in the performance of these procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ Sadler, Gibb &amp; Associates, LLC</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have served as the Company’s auditor since 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Draper, UT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: black">September 24, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_052"></span>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_z0pybNNpbo0j" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_497_20210630" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_496_20200630" style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zox3LqIbxT8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zMnuaAiW00J3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">CURRENT ASSETS:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzYE0_z10ljUxbnDDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; width: 56%">Cash</td><td style="width: 8%; color: black">&nbsp;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,664,410</ix:nonfraction></span></td><td style="width: 1%; color: black; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,696,361</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--OtherReceivablesNetCurrent_i02I_maCzYE0_z5DqHpQheEd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Other receivables</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right"><span><ix:nonfraction name="us-gaap:OtherReceivablesNetCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,640</ix:nonfraction></span></td><td style="color: black; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherReceivablesNetCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,982</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_i02I_maCzYE0_zyzywDNJDdXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Prepaid expenses</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">232,943</ix:nonfraction></span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">242,866</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtCzYE0_maCzjFY_zwo73Jq3HUU" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Current Assets</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,898,993</ix:nonfraction></span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,941,209</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzjFY_zkMseuqju6l1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Property and equipment, net</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">719,364</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">778,118</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--AssetsNoncurrentAbstract_i01B_zmfk6TkNiAFd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">OTHER ASSETS</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_maCzeDL_zqRlD14Sm5q4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Definite life intangible assets, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,906</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,323</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_i02I_maCzeDL_zhWZxyeeJYue" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Indefinite life intangible assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">154,824,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">154,824,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--Goodwill_i02I_maCzeDL_zZxSCeognN3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt">Goodwill</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Goodwill" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,640,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Goodwill" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,640,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--DepositsAssetsNoncurrent_i02I_maCzeDL_zEgeWxmLkyZd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Deposits and other assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DepositsAssetsNoncurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,984</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DepositsAssetsNoncurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,550</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzeDL_zpohnqWSB4u8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Operating lease rights-of-use assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,435,978</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,703,859</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCzeDL_maCzjFY_zJkeB0xQFQxk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Other Assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherAssetsNoncurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">167,986,868</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherAssetsNoncurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168,382,732</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--Assets_iTI_mtCzjFY_zkzuivToNzcg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">189,605,225</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">178,102,059</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral
part of these consolidated financial statements.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 51; Options: NewSection; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS (CONTINUED)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zQkaIqKaIbf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">LIABILITIES</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zyrf3OYiGHhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">CURRENT LIABILITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--AccountsPayableTradeCurrent_i02I_maCzvaw_zzjCVabcjNpd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; width: 56%; text-align: left">Accounts payable – trade</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableTradeCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">320,559</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableTradeCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">592,877</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzvaw_zk4n81QrRQj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Accrued expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,182,323</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">470,636</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzvaw_zFgDvy6ArXw6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Other current liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherLiabilitiesCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,602</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0102"><span><ix:nonfraction name="us-gaap:OtherLiabilitiesCurrent" contextref="AsOf2020-06-30" id="fact-identifier-63" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzvaw_zbH1s6XYsbyi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Current portion of operating lease liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">292,409</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">271,285</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_i02TI_mtCzvaw_maCzfpZ_maCzW8O_zdXc3UhKzS3l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Current Liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,885,893</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,334,798</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zFgkxqtzDPM9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt">NON-CURRENT LIABILITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_i02I_maCzfpZ_maCzW8O_zYjObSWVBlwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Contingent consideration liability</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,037,945</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,182,434</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_i02I_maCzfpZ_maCzW8O_zogfvf8gWA14" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Convertible notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--LongTermNotesPayable_i02I_maCzfpZ_maCzW8O_zE1htYxH8iUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Notes payable, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermNotesPayable" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,579,114</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermNotesPayable" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,580,787</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pp0p0_maCzfpZ_z6pssY3nAax6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,239,334</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,531,779</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--LiabilitiesNoncurrent_i02TI_mtCzfpZ_maCz02w_maLASEzb01_zU0sPu8jJzCk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Non-Current Liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesNoncurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,942,286</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesNoncurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,829,798</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_zgSOhYVd4B3k" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&nbsp;Commitments and Contingencies</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128"><span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2021-06-30" id="fact-identifier-78" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0129"><span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2020-06-30" id="fact-identifier-79" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--StockholdersEquityAbstract_i01B_zHyJCyyqx27i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS’ EQUITY:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_maCzVG9_zwXvPTMOhrJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Preferred stock, $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210630_pp4d" title="Preferred stock, par value"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20200630_pp4d" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="4" unitref="USDPShares" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="4" unitref="USDPShares" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value; <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20210630_pdd" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20200630_pdd" title="Preferred stock, shares authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares authorized; <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20210630_zdqfmQAbeec5" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20210630_z7GB3brhCbKc" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_do_c20200630_zWdbslmZaVB2" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20200630_zz9RW3JKeEAl" title="Preferred stock, shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-06-30" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-06-30" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> shares issued and outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0134"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-06-30" id="fact-identifier-88" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-06-30" id="fact-identifier-89" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--CommonStockValue_i02I_maCzVG9_zdCwWz34T0C3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20210630_pp4d" title="Common stock, par value"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20200630_pp4d" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="4" unitref="USDPShares" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="4" unitref="USDPShares" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></ix:nonfraction></span></span></span>, <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20210630_pdd" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20200630_pdd" title="Common stock, shares authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares authorized, <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20210630_pdd" title="Common Stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210630_pdd" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,219,661</ix:nonfraction></span></ix:nonfraction></span></span></span> shares issued and outstanding at June 30, 2021; <span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20200630_pdd" title="Common Stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20200630_pdd" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,497,409</ix:nonfraction></span></ix:nonfraction></span></span></span> shares issued and outstanding at June 30, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,222</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,650</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_i02I_maCzVG9_zv2DBuadPqzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Additional paid-in capital</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">265,580,356</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">230,497,225</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzVG9_zmILgk0CHFme" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accumulated deficit</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,911,805</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64,188,198</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pp0p0_maCzVG9_zQaCgwFPP6uk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accumulated other comprehensive (loss)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,834</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,416</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_mtCzVG9_maCz02w_maLASEzb01_zki4j55JFgX2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Stockholders’ Equity</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">174,662,939</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166,272,261</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_maCz02w_mtLASEzb01_zDivka5xWir5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">189,605,225</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">178,102,059</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral
part of these consolidated financial statements.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 52; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_053"></span>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_zP7Bh9ZySkvi" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_497_20200701_20210630" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_49C_20190701_20200630" style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zBBsBdOaJjT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzaz1_maOEz85V_zukPX6gZEsZ3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; width: 56%; text-align: left">General and administrative</td><td style="width: 8%; color: black">&nbsp;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,740,130</ix:nonfraction></span></td><td style="width: 1%; color: black; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,120,835</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzaz1_maOEz85V_zP9ZDOMIi3Qg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Research and development</td><td style="color: black">&nbsp;</td>
    <td style="color: black; text-align: left">&nbsp;</td><td style="color: black; text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,538,122</ix:nonfraction></span></td><td style="color: black; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,694,349</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzaz1_maOEz85V_zvSeILSSXuxb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Depreciation and amortization</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span><ix:nonfraction name="us-gaap:DepreciationDepletionAndAmortization" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123,535</ix:nonfraction></span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DepreciationDepletionAndAmortization" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,584</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEz85V_zlSMdAher6k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Operating Expenses</td><td style="color: black; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,401,787</ix:nonfraction></span></td><td style="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,923,768</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_maILFCOzqap_zoU2wFPYoTO" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,401,787</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,923,768</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other Income (Expenses)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_ecustom--ChangeInFairValueOfContingentConsideration_i01_maCz2PF_maNIEzjnR_zugO5zxw1gW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Change in fair value of contingent consideration</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="enob:ChangeInFairValueOfContingentConsideration" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,048,033</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ChangeInFairValueOfContingentConsideration" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">274,566</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--InterestExpense_i01N_di_msCz2PF_msNIEzjnR_zJJKQpkBBpFj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">379,608</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104,280</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--ForeignCurrencyTransactionGainLossRealized_i01_maCz2PF_maNIEzjnR_zYB03RnxIkrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Gain (loss) on currency transactions</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,634</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146,828</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maCz2PF_maNIEzjnR_zoxZI4lxrod8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Gain on settlement of debt</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-07-01to2021-06-30" id="fact-identifier-126" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--InvestmentIncomeInterest_i01_maCz2PF_maNIEzjnR_zDpH8EsqMRde" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest income</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:InvestmentIncomeInterest" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,179</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:InvestmentIncomeInterest" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,296</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_mtNIEzjnR_maILFCOzqap_zgRYgK2tufvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Other Income (Expenses)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,447,096</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">507,410</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_maCz9An_mtILFCOzqap_zx8PHAhtEOQ" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Loss Before Income Taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,848,883</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,416,358</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCz9An_z6YCtDqx6er9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income Tax Benefit</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,276</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2019-07-012020-06-30" id="fact-identifier-135" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCz9An_zFIqjoH30BWe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,723,607</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,416,358</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--EarningsPerShareBasicAndDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">BASIC AND DILUTED NET LOSS PER COMMON SHARE</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.57</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">47,167,262</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,330,743</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral
part of these consolidated financial statements.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 53; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_054"></span>CONSOLIDATED STATEMENTS OF COMPREHENSIVE
LOSS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_zEWvns071HPf" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_498_20200701__20210630_zcCUXvUsKK3l" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49E_20190701__20200630_zye5NfyG9YN4" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_maCINOTzHKx_z9QtDsGl3yRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-weight: bold; text-align: left">Net Loss</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,723,607</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,416,358</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_zwNGBGA8TEEc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other Comprehensive Income (Loss)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_iN_pp0p0_di_msCINOTzHKx_zr9qFGbehLRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Foreign currency translation, net of taxes</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,582</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,234</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzHKx_zNQ2s6NRTW77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other Comprehensive Loss</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,693,025</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,599,592</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral
part of these consolidated financial statements.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 54; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_055"></span>CONSOLIDATED STATEMENT OF STOCKHOLDERS’
EQUITY</b>&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended June 30, 2021
and June 30, 2020</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_114_zW40HHaisYo3" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zt4igDDNdCch" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zzXtRCM7k2Cj" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zZjzt8omYVP9" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zOWuf2zsw4vd" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BF_zLBmfVQ5BV7j" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Income (Loss)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
<tr id="xdx_43D_c20190701__20200630_eus-gaap--StockholdersEquity_iS_z5SmWPgLwBl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance July 1, 2019</td><td style="width: 2%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6muGnFAEYw6" title="Beginning Balance, Shares" style="width: 6%; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,273,924</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 2%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,527</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 2%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">225,765,432</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 2%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,771,840</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">101,818</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 2%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">173,099,937</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_ecustom--StockIssuedPursuantToWarrantsExercisedValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock issued pursuant to warrants exercised</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_ecustom--StockIssuedPursuantToWarrantsExercisedShares_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Stock issued pursuant to warrants exercised, Shares" style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedShares" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">999,950</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-157" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-158" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,000,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_ecustom--ContingentShareIssuedPursuantToAcquisitionAgreementValue_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contingent shares issued pursuant to acquisition agreement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_ecustom--ContingentShareIssuedPursuantToAcquisitionAgreementShares_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Contingent Share issued pursuant to Acquisition Agreement, Shares" style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementShares" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,209,950</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-163" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-164" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,210,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_ecustom--RestrictedSharesConvertedToSharesForServicesRenderedValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted shares converted to shares for services rendered</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_ecustom--RestrictedSharesConvertedToSharesForServicesRenderedShares_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZM6IPQqV2c5" title="Restricted shares converted to shares for services rendered,shares" style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedShares" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">143,997</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-169" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-170" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">144,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_ecustom--SharesIssuedInLieuOfInterestOnNotesPayableValue_zGzdz8yclxvb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in lieu of interest on notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_ecustom--SharesIssuedInLieuOfInterestOnNotesPayableShares_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVFe9E5MJI7d" title="Shares issued in lieu of interest on notes payable,shares" style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOnNotesPayableShares" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">188,485</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOnNotesPayableValue" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">19</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOnNotesPayableValue" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">493,173</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0287"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOnNotesPayableValue" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-175" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0288"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOnNotesPayableValue" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-176" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOnNotesPayableValue" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">493,192</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_ecustom--SharesIssuedForFullyVestedRsusValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued for fully vested RSUs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_ecustom--SharesIssuedForFullyVestedRsusShares_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd7cLyIfV3nb" title="Shares issued for fully vested RSUs,shares" style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusShares" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-181" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-182" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2019-07-012020-06-30" id="fact-identifier-183" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td>Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">884,724</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-185" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-186" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">884,724</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Loss</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" id="fact-identifier-188" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-189" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,416,358</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-191" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,416,358</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_ecustom--ForeignCurrencyTranslationLossValue_iN_pp0p0_di_zFNQ8pj1cFug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" id="fact-identifier-193" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2019-07-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-194" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2019-07-012020-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-195" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2019-07-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">143,234</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">143,234</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_433_c20200701__20210630_eus-gaap--StockholdersEquity_iS_z8ykdTdIKL9b" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance June 30, 2020</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCUTfYQlD3Tb" title="Beginning Balance, Shares" style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,497,409</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,650</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">230,497,225</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64,188,198</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,416</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166,272,261</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_ecustom--IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue_iP3us-gaap--SharesOutstanding_zh40BNdMVecc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of commitment shares related to LPC purchase agreement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_ecustom--IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementShares_iP3custom--IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zanGELN5jCig" title="Issuance of commitment shares related to LPC purchase agreement,shares" style="text-align: right"><span><ix:nonfraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">139,567</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329"><span><ix:nonfraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-207" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330"><span><ix:nonfraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-208" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331"><span><ix:nonfraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextref="From2020-07-01to2021-06-30" id="fact-identifier-209" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_ecustom--StockIssuedPursuantToWarrantsExercisedValue_zeaFFfkhMHmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock issued pursuant to warrants exercised</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_ecustom--StockIssuedPursuantToWarrantsExercisedShares_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpzeE8knxZM6" title="Stock issued pursuant to warrants exercised, Shares" style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">63,122</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">82,050</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-213" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-214" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockIssuedPursuantToWarrantsExercisedValue" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">82,056</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_ecustom--ContingentShareIssuedPursuantToAcquisitionAgreementValue_zO6kUfgR3BHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contingent shares issued pursuant to acquisition agreement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_ecustom--ContingentShareIssuedPursuantToAcquisitionAgreementShares_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuUcBg6U9E1c" title="Contingent Share issued pursuant to Acquisition Agreement, Shares" style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">63,122</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">192,516</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0345"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-219" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0346"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-220" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreementValue" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">192,522</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_ecustom--SharesIssuedPursuantTo2021PrivatePlacementValue_iP3custom--ContingentShareIssuedPursuantToAcquisitionAgreementShares_zVLZNXhYvNGe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued pursuant to 2021 private placement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_ecustom--SharesIssuedPursuantTo2021PrivatePlacementShares_iP3custom--SharesIssuedPursuantTo2021PrivatePlacementValue_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbJWGixc7Ks2" title="Shares issued pursuant to 2021 private placement,shares" style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantTo2021PrivatePlacementShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,275,719</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantTo2021PrivatePlacementValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">128</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantTo2021PrivatePlacementValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,000,672</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353"><span><ix:nonfraction name="enob:SharesIssuedPursuantTo2021PrivatePlacementValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-225" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354"><span><ix:nonfraction name="enob:SharesIssuedPursuantTo2021PrivatePlacementValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-226" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantTo2021PrivatePlacementValue" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,000,800</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_ecustom--SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue_iP3custom--SharesIssuedPursuantTo2021PrivatePlacementShares_zZyluI4hrMqg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in lieu of interest on $5 million notes payable extension</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_ecustom--SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionShares_iP3custom--SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUuf6fpK5Eu6" title="Shares issued in lieu of interest on $5 million notes payable extension,shares" style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">74,054</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">298,171</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-231" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-232" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">298,178</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_ecustom--SharesIssuedPursuantToLpcEquityAgreementValue_iP3custom--SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionShares_zcCxUJ9dHeK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued pursuant to LPC equity agreement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_ecustom--SharesIssuedPursuantToLpcEquityAgreementShares_iP3custom--SharesIssuedPursuantToLpcEquityAgreementValue_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJfVFKWpJtY8" title="Shares issued pursuant to LPC equity agreement,shares" style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantToLpcEquityAgreementShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">200,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantToLpcEquityAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantToLpcEquityAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,221,330</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0369"><span><ix:nonfraction name="enob:SharesIssuedPursuantToLpcEquityAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-237" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0370"><span><ix:nonfraction name="enob:SharesIssuedPursuantToLpcEquityAgreementValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-238" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedPursuantToLpcEquityAgreementValue" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,221,350</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_iP3custom--SharesIssuedPursuantToLpcEquityAgreementShares_zhL22lg68vw2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued pursuant to direct offering, net of issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesOther_iP3us-gaap--StockIssuedDuringPeriodValueOther_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwY67USlZpNd" title="Shares issued pursuant to direct offering, net of issuance costs,shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,866,668</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">387</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,843,612</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-243" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-244" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,843,999</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_ecustom--SharesIssuedForFullyVestedRsusValue_zGCNDmBZ90m3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued for fully vested RSUs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_ecustom--SharesIssuedForFullyVestedRsusShares_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSB1cBJt7NNl" title="Shares issued for fully vested RSUs,shares" style="text-align: right"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" id="fact-identifier-247" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-248" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0385"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-249" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0386"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-250" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387"><span><ix:nonfraction name="enob:SharesIssuedForFullyVestedRsusValue" contextref="From2020-07-01to2021-06-30" id="fact-identifier-251" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_ecustom--RestrictedSharesConvertedToSharesForServicesRenderedValue_z2UuSkbUu4t1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted shares converted to shares for services rendered</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_ecustom--RestrictedSharesConvertedToSharesForServicesRenderedShares_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpHNPCEBqTW" title="Restricted shares converted to shares for services rendered,shares" style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">35,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">146,996</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-255" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-256" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedValue" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">147,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--ShareBasedCompensation_zeAIqgG4p1We" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock-based Compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" id="fact-identifier-258" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,297,798</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-260" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-261" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,297,798</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_z82aqs6IySVd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Loss</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" id="fact-identifier-263" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-264" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,723,607</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="fact-identifier-266" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,723,607</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_ecustom--ForeignCurrencyTranslationLossValue_iN_pp0p0_di_zeFHnfHNrT4f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation gain</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" id="fact-identifier-268" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2020-07-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-269" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2020-07-012021-06-30_us-gaap_RetainedEarningsMember" id="fact-identifier-270" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2020-07-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30,582</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="enob:ForeignCurrencyTranslationLossValue" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30,582</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_43A_c20200701__20210630_eus-gaap--StockholdersEquity_iE_zZrRyjKIZpIc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance June 30, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj8jZUTHFAki" title="Ending Balance, Shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,219,661</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,222</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">265,580,356</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,911,805</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,834</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">174,662,939</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;<b>The accompanying
notes are an integral part of these consolidated financial statements.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 55; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_056"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_z9MLiUPzeh7c" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49C_20200701__20210630_zdpcfepAFAki" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_497_20190701__20200630_zPJwPioPOmGe" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zioCJftZxgxk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maCzxH1_maNCPBUzqPe_zQmpgnaGa98g" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Net loss</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,723,607</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,416,358</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH
    USED IN OPERATING ACTIVITIES :</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--DepreciationAndAmortization_i02_maCzxH1_maNCPBUzqPe_zYlAesXuCRM2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DepreciationAndAmortization" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123,534</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DepreciationAndAmortization" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,583</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_i02N_di_msNCPBUzqPe_zvSUqNsOBU2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Change in fair value of contingent consideration</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,048,033</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">274,566</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_ecustom--NonCashCompensation_i02_maCzxH1_maNCPBUzqPe_zxgSKsOmgV9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Non-cash stock-based compensation expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:NonCashCompensation" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,444,798</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:NonCashCompensation" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,028,724</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_maCzxH1_maNCPBUzqPe_zKKn7YkI1t84" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">Amortization of right-of-use assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">267,881</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">257,685</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_ecustom--AmortizationOfDiscountOnNotePayable_i02N_di_msCzxH1_msNCPBUzqPe_zvBTYeCKkABl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Amortization of discount on note payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:AmortizationOfDiscountOnNotePayable" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">296,505</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:AmortizationOfDiscountOnNotePayable" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">73,979</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzxH1_msNCPBUzqPe_zLxaQJzAKVKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Gain on settlement of debt</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-07-01to2021-06-30" id="fact-identifier-291" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_ziogglsZZBng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in assets and liabilities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i03N_pp0p0_di_msNCPBUzqPe_zvKBJlj89dZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Other receivables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">342</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,812</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzxH1_msNCPBUzqPe_zoyVZf2Yuoe4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt">Prepaid expenses/deposits</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">733,739</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,897</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzxH1_maNCPBUzqPe_zY8zuRBqYvn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272,318</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,314</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_i03_maCzxH1_maNCPBUzqPe_zmR4YpPG4uN5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable non-trade</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span><span style="-sec-ix-hidden: xdx2ixbrl0464"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextref="From2020-07-01to2021-06-30" id="fact-identifier-299" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_pp0p0_maNCPBUzqPe_zbUcbTSxoz0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Other current liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,004</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextref="From2019-07-012020-06-30" id="fact-identifier-302" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingLiabilities_i03_maCzxH1_maNCPBUzqPe_z4OEenjHpUVd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Operating lease liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOperatingLiabilities" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">271,321</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOperatingLiabilities" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">251,231</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maCzxH1_maNCPBUzqPe_zXjTjVx9xEEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accrued expenses</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">711,687</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">226,533</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left"></td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_maCz3nv_mtNCPBUzqPe_zROmTi7fw90g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET CASH USED BY OPERATING ACTIVITIES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,610,723</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,459,422</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_iB_z94yjpyu3wM6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzDaz_msNCPBUzOoo_z9We9syWqlTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase of property and equipment</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,892</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">184,463</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzDaz_maCz3nv_mtNCPBUzOoo_zvuJqXspa0W1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET CASH USED BY INVESTING ACTIVITIES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,892</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">184,463</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zEMmDtwWaxSf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--ProceedsFromConvertibleDebt_i01_maCzVf4_maNCPBUzooI_z3yAQmCIqfNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from convertible notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-07-01to2021-06-30" id="fact-identifier-313" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromNotesPayable_i01_maCzVf4_maNCPBUzooI_zOdWzw9FROG1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromNotesPayable" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,272,700</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_ecustom--RepaymentOfFinanceAgreement_i01N_di_msNCPBUzooI_zbi3fp112EA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Repayments of finance agreement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="enob:RepaymentOfFinanceAgreement" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">546,651</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498"><span><ix:nonfraction name="enob:RepaymentOfFinanceAgreement" contextref="From2019-07-012020-06-30" id="fact-identifier-317" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0498" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msNCPBUzooI_z2Uu1pkOR4f1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Repayment of notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272,700</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--ProceedsFromWarrantExercises_i01_maCzVf4_maNCPBUzooI_z3jKdtGESaDe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Proceeds from exercise of warrants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,056</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maNCPBUzooI_zw65cZbAUF2e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from 2021 private placement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,800</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextref="From2019-07-012020-06-30" id="fact-identifier-322" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_ecustom--ProceedsFromDirectOfferingNetOfIssuanceCosts_i01_maNCPBUzooI_zshWUALtjSYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from direct offering, net of issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ProceedsFromDirectOfferingNetOfIssuanceCosts" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">26,843,998</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510"><span><ix:nonfraction name="enob:ProceedsFromDirectOfferingNetOfIssuanceCosts" contextref="From2019-07-012020-06-30" id="fact-identifier-324" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_ecustom--ProceedsFromLpcEquityAgreement_i01N_di_msNCPBUzooI_z9KHcVrKGV1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from LPC equity agreement</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="enob:ProceedsFromLpcEquityAgreement" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,221,350</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513"><span><ix:nonfraction name="enob:ProceedsFromLpcEquityAgreement" contextref="From2019-07-012020-06-30" id="fact-identifier-326" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCz3nv_mtNCPBUzooI_zBDuorgNSiT7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,601,553</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,200,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--EffectOfExchangeRateOnCashAndCashEquivalents_i01_maCz3nv_zFVt92hgVagf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;Effect of exchange rates on cash</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,111</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">141,978</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCz3nv_zAQl5s3rNB97" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET INCREASE (DECREASE) IN CASH</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,968,049</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,585,863</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_z1sprF7PUYM9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">CASH, BEGINNING OF PERIOD</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,696,361</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,282,224</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zpkOgP6DB4ch" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">CASH, END OF PERIOD</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,664,410</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,696,361</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 56; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS
(CONTINUED)</b>&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr id="xdx_400_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zIITpyRHankj" style="vertical-align: bottom; background-color: White">
    <td>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_ecustom--CashPaidDuringPeriodsForAbstract_iB_zc2VNIvHEsz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash Paid during the year for:</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--InterestPaidNet_z8vIl98jdIL" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%">Interest</td>
    <td style="width: 8%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,224</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2019-07-012020-06-30" id="fact-identifier-338" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0537" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxesPaidNet_za27iuJD0HRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income Taxes</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaidNet" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-339" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaidNet" contextref="From2019-07-012020-06-30" id="fact-identifier-340" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING
    AND FINANCING ACTIVITIES </td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_ecustom--ContingentSharesIssuedPursuantWithAcquisitionAgreement_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contingent Shares issued pursuant to Acquisition Agreement</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentSharesIssuedPursuantWithAcquisitionAgreement" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">192,522</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="enob:ContingentSharesIssuedPursuantWithAcquisitionAgreement" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,210,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_ecustom--RightOfUseAssetsInExchangeForOperatingLeaseLiabilitiesUponAdoptionOfAsc842leases_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets in exchange for operating lease liabilities upon adoption of ASC 842-Leases</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548"><span><ix:nonfraction name="enob:RightOfUseAssetsInExchangeForOperatingLeaseLiabilitiesUponAdoptionOfAsc842leases" contextref="From2020-07-01to2021-06-30" id="fact-identifier-343" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="enob:RightOfUseAssetsInExchangeForOperatingLeaseLiabilitiesUponAdoptionOfAsc842leases" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,054,295</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_ecustom--SharesIssuedInLieuOfInterestExpenseOnNotePayable_i01_zhootsmGRPy" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in lieu of interest expense on note payable</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestExpenseOnNotePayable" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">298,178</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="enob:SharesIssuedInLieuOfInterestExpenseOnNotePayable" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">493,192</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_ecustom--FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_i01_z0dhpX2vESb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance agreement entered into in exchange for prepaid assets</td>
    <td style="text-align: right"></td>
    <td style="text-align: left">$&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span><ix:nonfraction name="enob:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">607,250</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555"><span><ix:nonfraction name="enob:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextref="From2019-07-012020-06-30" id="fact-identifier-348" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral
part of these consolidated financial statements.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 57; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_057"></span>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zD843L8oKcLh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 — <span id="xdx_827_zMqiShK53V5j">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="enob:BusinessPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_844_ecustom--BusinessPolicyTextBlock_zM8jE05Sl1Bf" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zUf4LWGa8Cei">Business</span>–
</b>Enochian BioSciences Inc., formerly DanDrit Biotech USA, Inc. (“Enochian”, or “Registrant”, and together
with its subsidiaries, the “Company”, “we” or “us”) engages in the research and development
of pharmaceutical and biological products for the human treatment of HIV, HBV, influenza and coronavirus infections, and cancer
with the intent to manufacture said products.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXujpd8OFFZb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86B_zOyMyKETQIT4">Basis of Presentation</span>-
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United
States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange Commission
(“SEC”).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zbtf9O6tYVL2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86D_zK93yYGizvch">Consolidation</span>
</b>- For the years ended June 30, 2021 and 2020, the consolidated financial statements include the accounts and operations of
the Registrant, and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in
the consolidation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--UseOfEstimates_zxdZ6yHk58Yb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86E_zO7bbQyUsfm5">Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets
and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.
Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible
assets, the fair value of the contingent consideration liability, and fair value of equity instruments issued.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" inside-table="false" id="fact-identifier-354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_844_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zzGtiDN5LWid" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86C_zYRKRymHGvOd">Subsidiaries</span></b>-
Enochian Biopharma Inc. (“Enochian Biopharma”) was incorporated on May 19, 2017 in Delaware and is a 100% owned subsidiary
of the Registrant. Enochian Biopharma owns a perpetual, fully paid-up, royalty-free, sublicensable, and sole and exclusive worldwide
license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain
intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in
humans, and research and development exclusively relating to HIV in humans. As of June 30, 2021 and June 30, 2020, <span id="xdx_907_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_c20210630__srt--ConsolidatedEntitiesAxis__custom--EnochianBiopharmaIncMember_pdd" title="Common shares contingently issuable"><span><ix:nonfraction name="enob:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" contextref="AsOf2021-06-30_custom_EnochianBiopharmaIncMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,350,000</ix:nonfraction></span></span> and
<span id="xdx_906_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_c20200630__srt--ConsolidatedEntitiesAxis__custom--EnochianBiopharmaIncMember_pdd" title="Common shares contingently issuable"><span><ix:nonfraction name="enob:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" contextref="AsOf2020-06-30_custom_EnochianBiopharmaIncMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,438,122</ix:nonfraction></span></span> shares of Common Stock, respectively, remain contingently issuable in connection with the acquisition of Enochian BioPharma
in February 2018 (the “Contingent Shares”).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Enochian Biosciences
Denmark ApS, a Danish corporation was incorporated on April 1, 2001 (“Enochian Denmark”). On February 12, 2014, in
accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Enochian Denmark and it became a 100%
owned subsidiary of the Registrant subject to 185,053 shares of common stock of the Registrant held in escrow according to Danish
law (the “Escrow Shares”). As of June 30, 2021, there are <span id="xdx_905_ecustom--EscrowSharesRemaining_c20200630_pdd" title="Escrow Shares remaining"><span><ix:nonfraction name="enob:EscrowSharesRemaining" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,414</ix:nonfraction></span></span>,
Escrow Shares remaining (see Note 7).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="enob:CovidPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_847_ecustom--CovidPolicyTextBlock_zCbVxJAQOfra" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_866_zgzp4rwc8rPh">COVID-19 Update</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The COVID-19 pandemic
continues to evolve, and to date has led to the implementation of various mitigation responses, including government-imposed quarantines,
travel restrictions and other public health safety measures, as well as leading to reported adverse impacts on healthcare resources,
facilities and providers across the United States and in other countries. COVID-19 may cause delays in our research activities.
To date, it has not materially affected our operations; however, it has caused delays in the conduct of experiments due to limitations
of various organizations, in particular those conducting experiments related to COVID-19. There have also been increases in the
cost to conduct animal studies due to staffing and other limitations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The full extent to
which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult
to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal,
state and local governments could adversely impact our or our partners’ clinical, research and development, regulatory and
manufacturing operations or timelines.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

<ix:exclude><p id="xdx_238_zZc07qws71mj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 58; Value: 4 -->
    <div id="xdx_236_zDbg0mYJIX9k" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zTcM06Y00cHa" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_23C_zlrsTCOnAw57" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_230_zgSGDFemPxh8" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_ztVJjpefEwn7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We continue to monitor
the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition,
the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital,
which could in the future negatively affect the financial resources available to us.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zY0VkJ6PlMU6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_869_zvoEXIms5ipf">Functional
                                                                                                                                                              Currency and Foreign Currency Translation</span> </b>- The functional currency of Enochian Denmark is the Danish Kroner
                                                                                                                                                              (“DKK”). The Company is reporting currency is the U.S. Dollar for the purpose of these financial statements. The
                                                                                                                                                              Company’s consolidated balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all
                                                                                                                                                              revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years ended June 30, 2021
                                                                                                                                                              and 2020. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in
                                                                                                                                                              stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in
                                                                                                                                                              a currency other than the functional currency are included in the statement of operations as incurred.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOhhJ3TViCZ" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_865_zSOJ66rw6mZj">Cash and Cash
Equivalents</span> </b>- The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to
be cash equivalents. The Company’s cash balances at June 30, 2021, and 2020, are $<span id="xdx_90C_eus-gaap--Cash_c20210630_pp0p0" title="Cash balances"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,664,410</ix:nonfraction></span></span> and $<span id="xdx_90B_eus-gaap--Cash_c20200630_pp0p0" title="Cash balances"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,696,361</ix:nonfraction></span></span>, respectively.
The Company had balances held in financial institutions in Denmark and in the United States in excess of federally insured amounts
at June 30, 2021 and 2020 of $<span id="xdx_902_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pp0p0_c20210630_zzwSrbFf7cp" title="Cash held in financial institutions"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,287,212</ix:nonfraction></span></span>, and $<span id="xdx_90E_eus-gaap--CashCashEquivalentsAndShortTermInvestments_c20200630_pp0p0" title="Cash held in financial institutions"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,160,271</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z0ipfBjhakqg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86E_zhPT5y6i7Jae">Property and
Equipment</span> </b>- Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful
lives of property and equipment are capitalized, and depreciated upon being placed in service. Expenditures for maintenance and
repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis
over the estimated useful lives of the assets, which range from four to ten years (see Note 2).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" inside-table="false" id="fact-identifier-366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z4JuXhNyuub6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_866_ziZNEHdeLHTk">Intangible Assets</span>
- </b>The Company has both Definite and Indefinite life intangible assets.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Definite life intangible
assets relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards
Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, <i>Goodwill and Other Intangible Assets</i>.
Intangible assets are recorded at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If
it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Definite
life intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents
is twenty years from the date of application.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indefinite life
intangible assets include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite
life intangible assets in accordance with ASC 350, License agreement costs represent the fair value of the license agreement on
the date acquired and are tested annually for impairment. </p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_23E_zM7KE96k6JIk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 4 -->
    <div id="xdx_238_zEWEdhUGTkB8" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_z3eQclEltu09" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_235_z8lH47KW56Se" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zjoAiou6f2A" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zwDS9rsnPLg4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zCfyF2cHUT7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_238_z9s7BWQAvEi2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zTF9o2Tu6ot9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zP9FJW1YmL9j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z46O0pBcVIB4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zc8YoSLaLqPe" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zw3M6egnZdc6">Goodwill</span></b>
- Goodwill is not amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances
indicate the carrying value may not be recoverable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zs90q8gkHI05" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span><span id="xdx_86D_z6T4VJyQSA9">Impairment
                                                                                                                                                                                        of Goodwill and Indefinite Lived Intangible Assets</span></span></b> – We test for goodwill impairment at the reporting unit
                                                                                                                                                                                        level, which is one level below the operating segment level. Our detailed impairment testing involves comparing the fair value of
                                                                                                                                                                                        each reporting unit to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing
                                                                                                                                                                                        to pay in a potential sale of the reporting unit and is based on discounted cash flows or relative market-based approaches. If the
                                                                                                                                                                                        carrying value of the reporting unit exceeds its fair value, we record an impairment loss for such excess. The carrying value of
                                                                                                                                                                                        IPR&amp;D and goodwill at June 30, 2021, were&nbsp;$<span id="xdx_900_ecustom--InProcessResearchAndDevelopment_iI_c20210630_zJkRrxfTqkU2" title="In-Process Research &amp; Development"><span><ix:nonfraction name="enob:InProcessResearchAndDevelopment" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">154,824,000</ix:nonfraction></span></span> and $<span id="xdx_90F_eus-gaap--Goodwill_iI_pp0p0_c20210630_zu8u2CjSvGIl" title="Goodwill"><span><ix:nonfraction name="us-gaap:Goodwill" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,640,000</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For indefinite-lived intangible
assets, such as licenses acquired as an IPR&amp;D asset, on an annual basis we determine the fair value of the asset and record an impairment
less, if any, for the excess of the carrying value of the asset over its fair value. The fair value analysis performed on the license
agreement, and the annual fair value analysis performed on goodwill supported that both indefinite life intangible assets are not impaired
as of June 30, 2021 (see Note 3.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zVIJ7P6c1MC2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<b><span id="xdx_86F_z9qMG3XddfRi">Impairment
of Long-Lived Assets</span> - </b>Long-lived assets, such as property, plant, and equipment and definite life intangible assets are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset;
significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with
a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset
will more likely than not be sold or disposed of significantly before the end of its estimated useful life.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Recoverability of
assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash
flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash
flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the
asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount
or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue
in use are their respective fair values.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_845_eus-gaap--LesseeLeasesPolicyTextBlock_zKHWnLTFjrLg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<b><span id="xdx_86A_z6GiZh9i8b22">Leases</span>
-</b> In accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets
and lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination
options that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by
using the implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental
borrowing rate based on the information available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Rent expense for
operating leases is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over
the reasonably assured lease term based on the total lease payments and is included in general and administrative expenses in the
consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization
of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included
in general and administrative expenses in the consolidated statements of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has
elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily
related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and
administrative expenses when incurred (see Note 4.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zRlZx80b8bzk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86E_zoNeTf9oTbjb">Research and
Development Expenses</span> - </b>The Company expenses research and development costs incurred in formulating, improving, validating and
creating alternative or modified processes related to and expanding the use of the HIV, HBV, Coronaviruses and Oncology therapies
and technologies for use in the prevention, treatment, amelioration of and/or therapy for HIV, HBV, Coronaviruses and Oncology.
Research and development expenses for the year ended June 30, 2021 and 2020 amounted to $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200701__20210630_zZeh8urPu15c" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,538,122</ix:nonfraction></span></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20190701__20200630_zDGWULhniYOf" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,694,349</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_z778hyEQLXOd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86C_zl72hCmsa7Q4">Income Taxes</span>
</b>- The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an
asset and liability approach for accounting for income taxes (see Note 6.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_237_zEDyrHSf7Eod" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 60; Value: 4 -->
    <div id="xdx_233_zmjfCncNIHk6" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zaSTEKuo5tUj" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_232_zBUnZdqrlEFf" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zkeRCxm735n" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td id="xdx_230_z0txpFGy4sXa" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_z6EUCxJxpN7a" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_238_ziPYVOYx4N1e" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zKrhLY34szTj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z08BOgiTrdP4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zc2Nv6GvrKKd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zVDwD5wUXOwa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z3TgQYqTqCee" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_868_zjnW4IwDJ2I">Loss Per Share</span>
</b>- The Company calculates earnings (loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common
share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings
per common share are based on shares outstanding (computed as for basic EPS) and potentially dilutive common shares. Potential
shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been
granted but have not been exercised. The shares of Common Stock outstanding at June 30, 2021 and 2020 were <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20210630_zToFxfhQnrJa" title="Common Stock outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,219,661</ix:nonfraction></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20200630_zyFDxphlrWLd" title="Common Stock outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,497,409</ix:nonfraction></span></span>,
respectively. Because of the net loss for each of years ended June 30, 2021 and June 30, 2020, dilutive shares for both periods
were excluded from the diluted EPS calculation, as the effect of these potential shares of Common Stock is anti-dilutive. The Company
had <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630_zJ2MMtV3pjKe" title="Potential dilutive shares"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,011,653</ix:nonfraction></span></span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190701__20200630_zUVPuyo10yni" title="Potential dilutive shares"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,091,686</ix:nonfraction></span></span> potential shares of Common Stock excluded from the diluted EPS calculation for the years ended June
30, 2021 and 2020, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgaglbNEdhb2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_867_z8LDm6BZBK8g">Fair Value of
Financial Instruments</span> </b>- The Company accounts for fair value measurements for financial assets and financial liabilities in
accordance with FASB ASC Topic 820, <i>Fair Value Measurements</i>. Under the authoritative guidance, fair value is defined as
the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions,
the guidance established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Level 2. Inputs, other
than quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; line-height: 107%">&nbsp;</td>
    <td style="width: 29px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
    <td style="padding-right: 8.25pt; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no assets
that use Level 1, 2 or 3 inputs, nor any liabilities that use Level 1 or 2 inputs as of June 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Liabilities that use Level
3 inputs held as of June 30, 2021 consisted of a contingent consideration liability related to the February 16, 2018 acquisition
of Enochian BioPharma (the “Acquisition”). As consideration for the Acquisition, the stockholders of Enochian Biopharma
received (i) <span id="xdx_908_ecustom--CommonStockShareIssued_iI_c20210630_zAOEQ9oFs025" title="Common stock shares issued"><span><ix:nonfraction name="enob:CommonStockShareIssued" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18,081,962</ix:nonfraction></span> </span>shares of Common Stock, and (ii) the right to receive contingent shares pro rata upon the exercise of warrants,
which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_902_eus-gaap--AssetsFairValueAdjustment_c20200701__20210630_zdC1vNOUhZO1" title="Fair value"><span><ix:nonfraction name="us-gaap:AssetsFairValueAdjustment" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,516,000</ix:nonfraction></span> </span>at the time
of the Acquisition and is subsequently remeasured to fair value at each reporting date. At June 30, 2021, <span id="xdx_90D_ecustom--ContingentSharesIssuable_c20200701__20210630_zWpTIxJA2rpk" title="Contingent shares issuable"><span><ix:nonfraction name="enob:ContingentSharesIssuable" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,350,000</ix:nonfraction></span></span> contingent
shares are issuable in connection with the Acquisition of Enochian Biopharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of the contingent
consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable
with the exception being volatility, which is computed, based on the Company’s underlying stock. The key inputs to valuing
the contingent consideration liability on the date of acquisition and as of June 30, 2021, include the Company’s stock price
on the valuation date of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20210630_zTO3zmrkl1i4" title="Stock price per share"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.97</ix:nonfraction></span></span>; the exercise price of the warrants of $<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWarrantsExercisePrice_c20200701__20210630_znbhqwvYcPve" title="Warrants exercise price"><span><ix:nonfraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWarrantsExercisePrice" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.30</ix:nonfraction></span></span>, the risk-free rate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630_zXb3ZKDI9Voa" title="Risk-free rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.08</ix:nonfraction></span></span>%, the expected volatility
of the Company’s Common Stock of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630_zDP01G85pEA1" title="Expected volatility rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79.2</ix:nonfraction></span></span>%, and the digital call rate of <span id="xdx_90D_ecustom--DigitalCallRate_dp_c20200701__20210630_zLqCdZriM4r7" title="Digital call rate"><span><ix:nonfraction name="enob:DigitalCallRate" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">90</ix:nonfraction></span></span>%. Fair Value measurements are highly sensitive to
changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise disclosed, the fair
value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses,  accounts payable, accrued
expenses, and notes payable approximate their recorded values due to their short-term nature.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the liabilities at June 30, 2021 and 2020, which are recorded on the balance sheet at fair value on a recurring basis
by level of input within the fair value hierarchy. As required, these are classified based on the lowest level of input that is
significant to the fair value measurement:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zGubdO5w55Q6" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zsxQUAVHCgq" style="display: none">Summary of significant to the fair value measurement</span></td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Fair Value Measurements at Reporting Date Using</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Quoted Prices in <br> Active Markets for Identical Assets Inputs</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Significant Other <br> Observable Inputs</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Significant Other Unobservable &nbsp; Inputs</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(Level 3)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Contingent Consideration Liability at June 30, 2021</td><td style="width: 5%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3AVkak6bNC7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" id="fact-identifier-392" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0658" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="width: 5%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zISM2VIN9HO9" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" id="fact-identifier-393" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0659" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="width: 5%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiability_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Contingent Consideration Liability" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextref="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,037,945</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">The roll forward of the contingent consideration liability is as follows:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance June 30, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iS_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcYE4ORlwuU1" title="Balance at beginning" style="text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextref="AsOf2020-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,182,434</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contingent Shares issued pursuant to the Acquisition Agreement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreement_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbrmAACQI8qf" title="Contingent Shares issued pursuant to the Acquisition Agreement" style="text-align: right">(<span><ix:nonfraction name="enob:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextref="From2020-07-012021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">192,522</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value adjustment</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--EquityFairValueAdjustment_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zk8EAECRIR4j" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666"><span><ix:nonfraction name="us-gaap:EquityFairValueAdjustment" contextref="From2020-07-012021-06-30_us-gaap_FairValueInputsLevel1Member" id="fact-identifier-397" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--EquityFairValueAdjustment_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUot4qlEScOc" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667"><span><ix:nonfraction name="us-gaap:EquityFairValueAdjustment" contextref="From2020-07-012021-06-30_us-gaap_FairValueInputsLevel2Member" id="fact-identifier-398" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0667" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--EquityFairValueAdjustment_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJR0hNvLUDPf" title="Fair value adjustment" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:EquityFairValueAdjustment" contextref="From2020-07-012021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,048,033</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance June 30, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iE_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zyXKOnDpt3o5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextref="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" id="fact-identifier-400" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0670" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iE_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaUNLUOGsT6g" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextref="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" id="fact-identifier-401" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0671" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iE_pp0p0_c20200701__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z734PMA3o6Ke" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextref="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,037,945</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8A2_zkjyzTk8h2ij" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_233_zpZkQluDf0qk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 61; Value: 4 -->
    <div id="xdx_232_zreGtgI3LsFg" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zyUk11zAAiZh" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_238_z6av6A4gWmk4" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zRqziNVFn0yh" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zs15FFttOBG2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zshCyGNllXu7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zAgHkaWnFlqa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zlwZtr7sKg79" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="enob:StockOptionsAndWarrantsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_843_ecustom--StockOptionsAndWarrantsPolicyTextBlock_zzBvLmn22Wlj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"><b><span id="xdx_86F_z6nenK6phami">Stock Options
and Warrants</span> - </b>The Company has granted stock options to certain employees, officers and directors that were subsequently converted
to Grant Warrants. During the years presented in the accompanying consolidated financial statements, the Company has granted stock
options and warrants. The Company accounts for options and warrants in accordance with the provisions of FASB ASC Topic 718, Compensation
– Stock Compensation. Stock-based compensation costs related to employee compensation and consulting fees for the years ended
June 30, 2021 and 2020 were $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20200701__20210630__srt--CounterpartyNameAxis__custom--EmployeeMember_z08KUR1RFbNc" title="Stock-based compensation"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-07-012021-06-30_custom_EmployeeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,444,798</ix:nonfraction></span></span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20190701__20200630__srt--CounterpartyNameAxis__custom--EmployeeMember_zdHLW5bOC6B9"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-07-012020-06-30_custom_EmployeeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,028,724</ix:nonfraction></span></span>, respectively (see Note 7).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z1U9xOSM4VR2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"><b><span id="xdx_86D_zxAbOCbvYYYd">Stock-Based
Compensation</span> </b>—The Company records stock-based compensation for services received from non-employees in accordance with
ASC 718. All transactions in which goods or services are the consideration received for the issuance of equity instruments are
accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever
is more reliably measurable. Equity instruments issued for goods or services and the cost of the services received as consideration
are measured and recognized based on the fair value of the equity instruments issued and are recognized over the consultants’
required service period, which is generally the vesting period. For the year ended June 30, 2021, the Company issued <span id="xdx_906_ecustom--StockIssuedInExchangeForServicesShares_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS59vK03zLA9" title="Stock issued in exchange for services, Shares"><span><ix:nonfraction name="enob:StockIssuedInExchangeForServicesShares" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">35,000</ix:nonfraction></span> </span>shares
at a value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOliCPyK5I53" title="Stock issued in exchange for services, Value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-07-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147,000</ix:nonfraction></span></span>. For the year ended June 30, 2020, the Company issued <span id="xdx_901_ecustom--StockIssuedInExchangeForServicesShares_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSP3v3NwnXz5" title="Stock issued in exchange for services, Shares"><span><ix:nonfraction name="enob:StockIssuedInExchangeForServicesShares" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30,000</ix:nonfraction></span> </span>shares at a value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20190701__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zynV5Tl6kK2k" title="Stock issued in exchange for services, Value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2019-07-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,000</ix:nonfraction></span></span> (see Note 7.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxMbdVVbeR4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_863_zx8TRg7EjIug">Recent Accounting Pronouncements</span>
</b>- The Company adopted ASU 2018-13,&nbsp;<i>Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure
Requirements for Fair Value Measurements, </i>which amends certain disclosures requirements over fair value measurements. Under
the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level
2 inputs of the fair value hierarchy or valuation processes for Level 3 inputs in fair value measurements. However, public companies
will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value
measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this
guidance on July 1, 2020, and there was no material impact to its consolidated financial statement disclosures (see Note 1-Fair
Value of Financial Instruments for more information about the Company’s fair value classifications.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="enob:NewAccountingPronouncementsNotYetAdoptedPolictTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_845_ecustom--NewAccountingPronouncementsNotYetAdoptedPolictTextBlock_z5eRMcu22gy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><span id="xdx_86F_zdneZTL6A9D7">New Accounting Pronouncements Not Yet Adopted</span></b>
- Recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the
Company’s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_231_zdMCb8R8OzV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 62; Value: 4 -->
    <div id="xdx_23F_zjO7m4CXF862" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zwAOnXkvvxcj" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_233_zNqWu7ewAI49" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zu6fqFDVwLSl" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zDIwdufifXV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_232_znIjiF90UoQj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zKeHfVwnUlT7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zauyWjwXxjT8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zHdJH0SOpZzb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zuVv9IbzkmX4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 - <span id="xdx_827_z0ZmtTJCmMr6">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Property and equipment consisted of the
following at June 30, 2021 and 2020:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zAV6MhxezCKl" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B2_zj25omwASt31" style="display: none">Summary of property and equipment</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Lab equipment and instruments</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 11%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200701__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember__srt--RangeAxis__srt--MinimumMember_zYcLRETCgUG6" title="Useful Life"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_LabEquipmentAndInstrumentsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonnumeric></span></span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200701__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember__srt--RangeAxis__srt--MaximumMember_zffmaAbY0Zfj" title="Useful Life"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_LabEquipmentAndInstrumentsMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonnumeric></span></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" title="Total" style="width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-06-30_custom_LabEquipmentAndInstrumentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">583,421</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20200630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" title="Total" style="width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-06-30_custom_LabEquipmentAndInstrumentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">534,527</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200701__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zZuB2wqXddug" title="Useful Life"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">224,629</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20200630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">224,629</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture, fixtures and equipment</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200701__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqVlgsHZQPC" title="Useful Life"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonnumeric></span></span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200701__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zQqRTh1CfrPf" title="Useful Life"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonnumeric></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-06-30_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">171,975</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_c20200630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-06-30_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">171,975</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">980,025</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20200630_pp0p0" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">931,131</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zeKU9zMODU1i" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">260,661</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20200630_zvpJR86Smjh6" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">153,013</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Property and Equipment</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20210630_zMN0IWFjKNY" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">719,364</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20200630_zlBoiJKUJdJd" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">778,118</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table></ix:nonnumeric></span>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Depreciation expense amounted to $<span id="xdx_908_eus-gaap--Depreciation_c20200701__20210630_pp0p0" title="Depreciation expense"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,647</ix:nonfraction></span></span>
and $<span id="xdx_903_eus-gaap--Depreciation_c20190701__20200630_pp0p0" title="Depreciation expense"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,861</ix:nonfraction></span></span> for the years ended June 30, 2021 and 2020, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_232_zuU02T2sc8d5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 4 -->
    <div id="xdx_236_zYhczNLFoAO7" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zuIQmDONNKm8" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_235_zP4HQZwhmivd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zBbgiqCA7L6d" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zbmGXdshlA7c" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zeLvrUjGmid3" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_ztZQIBauulz" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zFLiVayozdF" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS </b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zjXiOqW5Uvj1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_z5DUT6KSScB5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 — <span id="xdx_829_zcnPW64IvQN">INTANGIBLE ASSETS AND GOODWILL</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2021
and 2020, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products
and processes of $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630_pp0p0" title="Definite-life intangible assets"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,906</ix:nonfraction></span></span> and $<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsNet_c20200630_pp0p0" title="Definite-life intangible assets"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,323</ix:nonfraction></span></span>, respectively. The patents are recorded at cost and amortized over twenty years from the date
of application. Amortization expense for the year ended June 30, 2021 and 2020 was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20210630_pp0p0" title="Amortization expense"><span><ix:nonfraction name="us-gaap:AmortizationOfIntangibleAssets" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,888</ix:nonfraction></span></span> and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20200630_pp0p0" title="Amortization expense"><span><ix:nonfraction name="us-gaap:AmortizationOfIntangibleAssets" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,772</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2021
and 2020, indefinite life intangible assets consisted of a license agreement classified as In-Process Research and Development
(“IPR&amp;D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and
goodwill.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2021
and 2020, definite-life and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-439" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zI4XTezkGXAf" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_8B3_zJ1P3h1k2Nba" style="display: none">Schedule of life intangible assets</span></td><td>&nbsp;</td>
    <td style="text-align: left; padding-left: 5.4pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2020</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Period Change</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Effect of Currency Translation</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Definite Life Intangible Assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 15%">Patents</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 15%; text-align: left; padding-left: 5.4pt"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200701__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAEXfNno2eBc" title="Useful Life"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_PatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" inside-table="true" id="fact-identifier-440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonnumeric></span></span> Years</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zyPTqZZeqKIb" title="Definite-life intangible assets" style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextref="AsOf2020-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">299,175</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--PeriodChange_pp0p0_d0_c20200701__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ztzPKHeqzDl3" title="Period Change" style="width: 13%; text-align: right"><span><ix:nonfraction name="enob:PeriodChange" contextref="From2020-07-012021-06-30_us-gaap_PatentsMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20200701__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Effect of Currency Translation" style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextref="From2020-07-012021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,940</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zALaaf0Nbgc1" style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextref="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316,115</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; padding-left: 20pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2uCFynAy8xl" title="Accumulated Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextref="AsOf2020-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">221,852</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--PeriodChange_pp0p0_c20200701__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zb5TrVRb66j7" title="Period Change" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="enob:PeriodChange" contextref="From2020-07-012021-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15,888</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20200701__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_pp0p0" title="Effect of Currency Translation" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextref="From2020-07-012021-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,469</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zjlQPdII57Qi" title="Accumulated Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextref="AsOf2021-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,209</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20200630_zj1Ss1vCe9lj" title="Definite-life intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,323</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--PeriodChange_c20200701__20210630_pp0p0" title="Period Change" style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="enob:PeriodChange" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15,888</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20200701__20210630_pp0p0" title="Effect of Currency Translation" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,471</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20210630_zejiJPwkkT15" title="Definite-life intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-452" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,906</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="padding-left: 5.4pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Indefinite Life Intangible Assets</td><td>&nbsp;</td>
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">License Agreement</td><td>&nbsp;</td>
    <td style="padding-left: 5.4pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iI_pp0p0_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zsClY6k3piui" title="Indefinite Life Intangible Assets" style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextref="AsOf2020-06-30_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">154,824,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$&nbsp;</td><td style="text-align: right">&nbsp;—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zyftVeWRghm9" title="Indefinite Life Intangible Assets" style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextref="AsOf2021-06-30_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-454" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">154,824,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iI_pp0p0_c20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zyoilSIgff74" title="Indefinite Life Intangible Assets" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextref="AsOf2020-06-30_us-gaap_GoodwillMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,640,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z1qK5A06zqxa" title="Indefinite Life Intangible Assets" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextref="AsOf2021-06-30_us-gaap_GoodwillMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,640,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Indefinite Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iI_pp0p0_c20200630_zBle0yUas3Z1" title="Indefinite Life Intangible Assets" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166,464,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iI_pp0p0_c20210630_z4zWZHvWTPHa" title="Indefinite Life Intangible Assets" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166,464,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8AB_zA02U68tEubj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Expected future amortization expense is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z1DIAuaKvHO3" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span id="xdx_8B2_zLz95X10FBAc" style="display: none">Schedule of expected future amortization expense</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_491_20210630_zUpdKnkmz1s2" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years ended&nbsp;June 30,</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_z2lM0WcRSk5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; width: 43%; text-align: left">2022</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 43%; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,154</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_zZrGfBexjRcg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">2023</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-461" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,154</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_zkIWKu4DjmN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">2024</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,154</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_zLZMexzq7phf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">2025</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,154</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_zM1LVkdtQux4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">2026</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,290</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_ztwOCFvL8pa8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0814"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextref="AsOf2021-06-30" id="fact-identifier-465" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0814" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_zn0hXMDwvhs2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); text-align: left">Total</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,906</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>



</ix:nonnumeric></span><p id="xdx_8A7_zGdw8EzRgjO6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During February
2018, the Company acquired a License Agreement (as licensee) to the HIV therapy being developed as ENOB-HV-01 which consists of
a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell,
have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies
for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively
relating to HIV in humans. Because the HIV License Agreement is considered an IPR&amp;D intangible asset, it is classified as an
indefinite life asset that is tested annually for impairment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Impairment –
Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing
a quantitative assessment and determines if it is more than likely than not that, the fair value of the asset is greater than or
equal to the carrying value of the asset. The results of the quantitative assessment supported Management’s conclusion that
an impairment adjustment was not required as of June 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_235_zCgBesG7wZX9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 64; Value: 4 -->
    <div id="xdx_230_zEqG9zm6hxR1" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zNTlaTELlFm2" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_23E_zQWuRf7Ack9h" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zAQaKzvxpW05" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zYySs7vcElBb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zGmfwOhzT7Ng" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zWyxFwul0okj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS </b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zgozdi9zZe78" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zKlUtqoRAF76" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 — <span id="xdx_821_zXj4SJj0j7ca">LEASES</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Operating Leases
</b>—<span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20181101__20181113" title="Lease premises, description"> <span><ix:nonnumeric contextref="From2018-11-012018-11-13" name="us-gaap:LesseeOperatingLeaseDescription" inside-table="false" id="fact-identifier-468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On November 13, 2017, the Registrant entered into a lease agreement for a term of five years and two months from November
1, 2017 with Plaza Medical Office Building, LLC, pursuant to which the Registrant agreed to lease approximately 2,325 rentable
square feet (the “Plaza Lease”). The base rent for the Plaza Lease increases by 3% each year, and ranges from approximately
$8,719 per month, for the first year to $10,107 per month for the two months of the sixth year. The equalized monthly lease payment
for the term of the lease is $7,862. The Registrant was entitled to $70,800 in tenant improvement allowance in the form of free
rent applied over 10 months in equal installments beginning in January 2018.</ix:nonnumeric></span></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20190601__20190619" title="Lease premises, description"><span><ix:nonnumeric contextref="From2019-06-012019-06-19" name="us-gaap:LesseeOperatingLeaseDescription" inside-table="false" id="fact-identifier-469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On June 19, 2018,
the Registrant entered into a lease agreement for a term of ten years from September 1, 2018 with Century City Medical Plaza Land
Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant
entered into an Addendum to the original lease agreement with an effective date of December 1, 2019, where it expanded the lease
area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and
ranges from $17,770 per month as of the date of the amendment to $23,186 per month for the tenth year. The equalized monthly lease
payment for the term of the lease is $20,050. The Company was entitled to $148,168 in contributions toward tenant improvements.</ix:nonnumeric></span></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company identified
and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Expected lease
term </i></b>— The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods
when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms
between 19 months and 74 months. As of June 30, 2021, the weighted-average remaining term is <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210630_zWvq9stMh1S2" title="Weighted-average remaining term"><span><ix:nonnumeric contextref="AsOf2021-06-30" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" inside-table="false" id="fact-identifier-470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.65</ix:nonnumeric></span></span> years.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Incremental
borrowing rate</i></b> — The Company’s lease agreements do not provide an implicit rate. As the Company does not have
any external borrowings for comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S.
Treasury Yield Curve rate that corresponds to the length of each lease. This rate is an estimate of what the Company would have
to pay if borrowing on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic
environment. As of June 30, 2021, the weighted-average discount rate is <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210630_zaUuzL2b1Fn6" title="Weighted-average discount rate"><span><ix:nonfraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span></span>%.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Lease and
non-lease components</i></b> — In certain cases the Company is required to pay for certain additional charges for operating
costs, including insurance, maintenance, taxes, and other costs incurred, which are billed based on both usage and as a percentage
of the Company’s share of total square footage. The Company determined that these costs are non-lease components and they
are not included in the calculation of the lease liabilities because they are variable. Payments for these variable, non-lease
components are considered variable lease costs and are recognized in the period in which the costs are incurred.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For the years ended June 30, 2021, and
2020, the lease expenses charged to general and administrative expenses amounted to $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_c20200701__20210630_pp0p0" title="Lease expense"><span><ix:nonfraction name="us-gaap:OperatingLeaseExpense" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">339,094</ix:nonfraction></span></span>, and $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_pp0p0_c20190701__20200630_zLtRQNrqZOXb" title="Lease expense"><span><ix:nonfraction name="us-gaap:OperatingLeaseExpense" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">395,528</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Below are the lease commitments for the
next 5 years:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeasesTextBlock_zIIqtcxjL9Hl" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span id="xdx_8B5_zSlIfn16fFpc" style="display: none">Lease commitments</span></td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_497_20210630_zxO8xqHmDYYd" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years Ending June 30</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease Expense</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0_maOLFMPzg3T_z55z44MLA7B1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; width: 68%; text-align: left">2022</td><td style="width: 14%; text-align: left">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">348,495</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0_maOLFMPzg3T_zblPBKixjBfb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">2023</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">298,305</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_pp0p0_maOLFMPzg3T_zTuWfIBaMzpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">2024</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">246,004</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_pp0p0_maOLFMPzg3T_zT7vmCjeKZpc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">2025</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-478" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">253,384</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFiveYears_iI_pp0p0_maOLFMPzg3T_zEXnK9yoA1N6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">2026</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">260,985</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueThereafter_iI_pp0p0_maOLFMPzg3T_z0i3FRcfMrg2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313,836</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_ecustom--LessImputedInterest_iNI_pp0p0_msOLFMPzg3T_zwgCErEOAFIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Less imputed interest</span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="enob:LessImputedInterest" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-481" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">189,266</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pp0p0_zPsoTZxRd7B5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,531,743</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</tbody></table></ix:nonnumeric></span>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><p id="xdx_230_z4RclYr2m9o1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 65; Value: 4 -->
    <div id="xdx_236_zvsgjnBQ7Qb1" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_239_zjHeHt2CfYQe" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_230_zcOGAhrFlFv4" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zHIbNVw5A7ki" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zbboy44Lgxl1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z5vJ6GomYiv9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zGvpU1leU6P7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zNLSzb9806jh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:DebtDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zWK2ZnHFrBk8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 — <span id="xdx_82E_zycZdlJQifZe">NOTES PAYABLE</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Convertible Notes
Payable-</b> On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to an existing
stockholder of the Company each with a face value amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20210630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pp0p0" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-06-30_custom_ConvertibleNotesPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">600,000</ix:nonfraction></span></span>, convertible into shares of Common Stock, $<span id="xdx_909_eus-gaap--SharePrice_c20210630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pdd" title="Stock price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-06-30_custom_ConvertibleNotesPayablesMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></span> par value
per share. The outstanding principal amount of the Convertible Notes is due and payable on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_zGSreg6K2tr4" title="Maturity Date"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_ConvertibleNotesPayablesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-486" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">February 6, 2023</ix:nonnumeric></span></span>. Interest on the Convertible
Notes commenced accruing on the date of issuance at six percent (<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_zJ243QKJfvTc" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextref="From2020-07-012021-06-30_custom_ConvertibleNotesPayablesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-487" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span></span>%) per annum, computed on the basis of twelve 30-day months,
and is compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest
outstanding as of such compound date. The interest is payable in cash on a semi-annual basis.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;The holder of the
Convertible Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding
and unpaid principal and all unpaid interest into shares of the Company’s Common Stock. The conversion price is equal to $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-06-30_custom_ConvertibleNotesPayablesMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-488" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.00</ix:nonfraction></span>
</span>per share of Common Stock. The holder did not exercise the conversion feature that expired on February 6, 2021. The Company evaluated
the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not
be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash. All proceeds
received from the issuance have been recognized as a liability on the balance sheet. The Convertible Notes balance as of June 30, 2021
and June 30, 2020, was $<span id="xdx_906_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20210630_zPscQIGl81p"><span><ix:nonfraction name="us-gaap:ConvertibleLongTermNotesPayable" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span></span>.
For the year ended June 30, 2021 and 2020, the Company recorded accrued interest in the amount of $<span id="xdx_902_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20210630_zgiMr3fkwYAg"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,181</ix:nonfraction></span>
</span>and $<span id="xdx_906_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20200630_zJu5KGzrAOo2"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,302</ix:nonfraction></span></span>,
respectively, which is included in accrued expenses. For the years ended June 30, 2021 and 2020, the interest expense related to the
Convertible Notes amounted to $<span id="xdx_90C_eus-gaap--InterestExpenseOther_c20200701__20210630_zaSSzkmdh8Ua"><span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,967</ix:nonfraction></span>
</span>and $<span id="xdx_907_eus-gaap--InterestExpenseOther_c20190701__20200630_zGLFzkPLZkb"><span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,302</ix:nonfraction></span></span>,
respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Note Payable-</b>
On March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20210630__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pp0p0" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-06-30_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-494" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,000</ix:nonfraction></span></span>
(the “Unsecured Note”) to Paseco APS, a Danish limited company and an existing stockholder of the Company. The principal
amount of the Unsecured Note was originally payable on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_zXYzrPcOz5dk" title="Maturity Date"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_NotePayableMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">November 30, 2021</ix:nonnumeric></span></span> (the “Maturity Date”). The Unsecured Note
bore interest at a fixed rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_zpgeGC8dXDwj" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextref="From2020-07-012021-06-30_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-496" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span></span>% per annum, computed based on the number of days between the Issuance Date and the Maturity
Date, which was prepaid by the Company in full on the Issuance Date through the issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pdd" title="Stock issued for debt conversion, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextref="From2020-07-012021-06-30_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-497" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">188,485</ix:nonfraction></span></span> shares of the Company’s
Common Stock based on the closing market price on that date for a total value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pp0p0" title="Stock issued for debt conversion"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2020-07-012021-06-30_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-498" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">501,370</ix:nonfraction></span></span>. The Company evaluated the Unsecured
Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds received
from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount
of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pp0p0" title="Proceeds received from issuance of shares"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2020-07-012021-06-30_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-499" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">493,192</ix:nonfraction></span></span>, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective
interest method. The discount of $493,192 will be accreted over the life of the Unsecured Note.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 11,
2021, the Company entered into an amendment to the Unsecured Note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20210211_zyIrDeEH5NHa" title="Unsecured note principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextref="AsOf2021-02-11" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,000</ix:nonfraction></span> </span>that extends the Maturity
Date out to <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210201__20210211_ziCzzO4R63mg" title="Maturity date"><span><ix:nonnumeric contextref="From2021-02-012021-02-11" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">November 30, 2022</ix:nonnumeric></span></span>. All other terms of the Unsecured Note remain the same. The change in Maturity Date required an additional
year of interest at the fixed rate of <span id="xdx_904_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20210211_zeLtc7vGBgo9" title="Interest at the fixed rate"><span><ix:nonfraction name="us-gaap:DerivativeFixedInterestRate" contextref="AsOf2021-02-11" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span></span>% per annum, which was prepaid by the Company in full on the date of the amendment through
the issuance of <span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200701__20210630_zxzfgrtJA8Gc" title="Issuance of common stock"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74,054</ix:nonfraction></span></span> shares of the Company’s Common Stock based on the closing market price on that date for a total value
of $<span id="xdx_90F_ecustom--MarketPrice_iI_c20210630_zDHlgBm8lVe3" title="Market price"><span><ix:nonfraction name="enob:MarketPrice" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-504" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">298,178</ix:nonfraction></span></span>. For the year ended June 30, 2021 and 2020, discount amortization of $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20200701__20210630_zx7mIQ6PZqf4" title="Discount amortization"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">296,506</ix:nonfraction></span></span> and $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20190701__20200630_zCL26KkqmdNd"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-506" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,979</ix:nonfraction></span> </span>was charged to interest expense.
The Unsecured Note balance, net of discount at June 30, 2021 is $<span id="xdx_906_ecustom--UnsecuredNoteBalanceNetOfDiscount_c20200701__20210630_zKPdS2ipu0Tg" title="Unsecured note balance, net of discount"><span><ix:nonfraction name="enob:UnsecuredNoteBalanceNetOfDiscount" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,579,114</ix:nonfraction></span></span>.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Finance Agreement</b>-<b>
</b>On December 4, 2020, the Company entered into a premium finance agreement (“Agreement”) with a principal amount
of $<span id="xdx_903_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20201204_zdln1ITbDAA"><span><ix:nonfraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextref="AsOf2020-12-04" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">607,250</ix:nonfraction></span></span> and an interest rate of <span id="xdx_900_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20201204_zSQH4jaetGm9"><span><ix:nonfraction name="us-gaap:DerivativeFixedInterestRate" contextref="AsOf2020-12-04" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-509" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.99</ix:nonfraction></span></span>% per annum. The repayment of the Agreement will be made in nine equal monthly installments
of $<span id="xdx_90B_ecustom--MonthlyInstallments_c20201201__20201204_zVlFVtXfycD" title="Monthly installments"><span><ix:nonfraction name="enob:MonthlyInstallments" contextref="From2020-12-012020-12-04" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">62,077</ix:nonfraction></span></span>. The remaining balance at June 30, 2021 is $<span id="xdx_90C_ecustom--MonthlyInstallments_c20200701__20210630_z15C1XurcGK7"><span><ix:nonfraction name="enob:MonthlyInstallments" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-511" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,598</ix:nonfraction></span></span>. The amount is reflected in other current liabilities. Interest expense
related to the Agreement for the year ended June 30, 2021 totaled $<span id="xdx_902_eus-gaap--InterestExpenseRelatedParty_c20200701__20210630_zJIrIHmVgD15" title="Interest expense related to agreement"><span><ix:nonfraction name="us-gaap:InterestExpenseRelatedParty" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,135</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of June 30, 2021 and 2020, the Company recorded a total of $<span id="xdx_901_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20210630_zMokPQnMkhN2" title="Accrued interest"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,181</ix:nonfraction></span></span> and $<span id="xdx_907_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20200630_zhrjetZcWE8l"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,302</ix:nonfraction></span></span> of accrued interest, respectively. Total interest
expense recorded for the years ended June 30, 2021 and 2020, was $<span id="xdx_904_eus-gaap--InterestExpenseDebt_c20200701__20210630_z5jDKj8VSTPg" title="interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">379,608</ix:nonfraction></span></span> and $<span id="xdx_906_eus-gaap--InterestExpenseDebt_c20190701__20200630_zWgyqNcBEcHg"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-516" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104,280</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<ix:exclude><p id="xdx_23E_zmF9Rq94efaa" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 66; Value: 4 -->
    <div id="xdx_236_zdDUfXYosuGh" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zwniL0UCgxwg" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_23B_zxl5ekVA0AY9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_236_zkGE9EAbSYZa" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zxvOT4G0OsLk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zcyaB3qJW4Lh" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zs9MSfwP2YLd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_z1fnbmqbTOVi" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zhtHh8IwgEw7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 — <span id="xdx_82D_zAoOzjlxGA23">INCOME TAXES</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts
for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net
deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between
book and tax accounting and any available operating loss or tax credit carryforwards. The amount of and ultimate realization of
the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s
future earnings, and other future events, the effects of which cannot be determined.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2021
and 2020, the Company had net operating loss carryforwards of approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_c20210630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_pp0p0" title="Net operating loss carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-06-30_custom_UnitedStatesTaxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,327,066</ix:nonfraction></span></span> and $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_c20200630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_pp0p0" title="Net operating loss carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2020-06-30_custom_UnitedStatesTaxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-519" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,247,919</ix:nonfraction></span></span>, respectively, giving rise
to deferred tax assets of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20210630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_pp0p0" title="Deferred tax assets"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextref="AsOf2021-06-30_custom_UnitedStatesTaxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,532,665</ix:nonfraction></span></span> and $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20200630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_pp0p0" title="Deferred tax assets"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextref="AsOf2020-06-30_custom_UnitedStatesTaxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,944,248</ix:nonfraction></span></span>, respectively. The net operating loss carryforwards generated prior to January
1, 2018, expire over various dates from 2031 to 2036. All subsequent net operating loss carryforwards are indefinite.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company files
Danish and U.S. income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2008
for the Danish tax returns and 2012 for the U.S. tax returns.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The temporary differences,
tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at June 30, 2021 and 2020:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zkmO7fEuLGo1" summary="xdx: Disclosure - INCOME TAXES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B7_zjYfx3GRR4bk" style="display: none">Summary of deferred tax asset (liabilities)</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49A_20210630_zeGtEUWfSYv3" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49B_20200630_zdhxi7zd2gQ7" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr id="xdx_404_ecustom--DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_iI_pp0p0_maDTALNzX8q_zhGLEabjaSx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Excess of tax over book depreciation of fixed assets</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="enob:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-523" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,100</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="enob:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,628</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_409_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzX8q_zKX6Qim6nlsi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Excess of tax over book depreciation of patents</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:DeferredTaxAssetExcessTaxOverDepreciationPatents" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,449</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:DeferredTaxAssetExcessTaxOverDepreciationPatents" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,654</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_ecustom--StockoptionsComp_iI_pp0p0_maDTALNzX8q_zSqwB4AQKCYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;Stock/options compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockoptionsComp" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,192,741</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:StockoptionsComp" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">761,613</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzX8q_zjnoKg8QFl02" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:DepreciationAndAmortizations" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">81,140</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:DepreciationAndAmortizations" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">44,278</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzX8q_zCNEOu27z389" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Operating Loss Carryforwards</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,536,884</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,944,248</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_ecustom--ChangeInTaxRate_iI_pp0p0_maDTALNzX8q_zAp5CyLlK1Xi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in tax rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948"><span><ix:nonfraction name="enob:ChangeInTaxRate" contextref="AsOf2021-06-30" id="fact-identifier-533" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0948" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ChangeInTaxRate" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,218</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzX8q_zyAFrB8uww8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-535" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,810,114</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,739,383</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzX8q_zn9kfc39svu4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Total Deferred Tax Assets (Liabilities)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0954"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextref="AsOf2021-06-30" id="fact-identifier-537" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0954" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextref="AsOf2020-06-30" id="fact-identifier-538" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0955" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 405.1pt; text-indent: 491.35pt">&nbsp;</p>

</ix:nonnumeric></span><p id="xdx_8AA_zhbhsoAowFo4" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">In accordance with
prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides
a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain.
The first step is to determine whether the tax position meets the more- likely -than -not condition for recognition, and the second
step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate
realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect,
the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be
estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use
the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation
of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows for
the year ended June 30, 2021 and 2020:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zSyYYW2HnQxb" summary="xdx: Disclosure - INCOME TAXES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B9_z80H3ewtxjuk" style="display: none">Summary of reconciliation of income tax expense at federal statutory rate</span></td><td>&nbsp;</td>
    <td colspan="3" id="xdx_493_20200701__20210630_zN3nchPAiAu4" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_49C_20190701__20200630_zzmW7DbppOVg" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Computed tax at expected statutory rate</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,070,732</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-541" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,828,885</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_di_zxh3O5B3o482" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-US income taxed at different rates</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-542" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,276</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextref="From2019-07-012020-06-30" id="fact-identifier-543" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0963" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses / other items</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextref="From2020-07-01to2021-06-30" id="fact-identifier-544" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0965" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextref="From2019-07-012020-06-30" id="fact-identifier-545" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0966" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zqOH6esjZeQf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,070,732</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,828,885</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_zAw0WuUkfQUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income Tax Expense (Benefit)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,276</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0972"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2019-07-012020-06-30" id="fact-identifier-549" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0972" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8A6_zSSNc99jw9b9" style="font: 10pt/normal Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The components of
income tax expense (benefit) from continuing operations for the year ended June 30, 2021 and 2020 consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-550" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zqwlNPzo8AGh" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B7_zL0t3K02gPMb" style="display: none">Summary of components of income tax expense (benefit) from continuing operations</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_490_20200701__20210630_zDnpU4Q4Becg" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_493_20190701__20200630_zAp2D63s9mhd" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-top: 0; padding-right: 0"></td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; font-weight: bold; text-align: left">Current Tax Expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_maCITEBzXk8_zZRoYQqvIgDc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; width: 56%; text-align: left">Danish income tax (benefit)</td><td style="width: 8%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-551" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,276</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 8%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980"><span><ix:nonfraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextref="From2019-07-012020-06-30" id="fact-identifier-552" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0980" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_mtCITEBzXk8_zg7gzQgYjene" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Current Tax Expense (Benefit)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,276</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983"><span><ix:nonfraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextref="From2019-07-012020-06-30" id="fact-identifier-554" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0983" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred Income Tax Expense (Benefit)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_ecustom--ExcessTaxBenefitOverDepreciationFixedAssets_i01_pp0p0_maDITEBzCiE_zxhYJ04SQSA2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Excess of tax over book depreciation of fixed assets</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="enob:ExcessTaxBenefitOverDepreciationFixedAssets" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,100</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="enob:ExcessTaxBenefitOverDepreciationFixedAssets" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,628</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_ecustom--ExcessTaxBenefitOverDepreciationPatents_i01_pp0p0_maDITEBzCiE_zZ4aHUpJ53hl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Excess of tax over book depreciation of patents</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ExcessTaxBenefitOverDepreciationPatents" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,449</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:ExcessTaxBenefitOverDepreciationPatents" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-558" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,654</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_pp0p0_maDITEBzCiE_zWhkl8USgZV7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt">&nbsp;Stock/options compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,192,741</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">761,613</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization_i01_pp0p0_maDITEBzCiE_zT2Rw3E2zcVg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,140</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-562" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44,278</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_ecustom--IncomeTaxExpenseBenefitOperatingLossCarryforwards_i01_pp0p0_maDITEBzCiE_z0uHBVvMPcyl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Net Operating Loss Carryforwards</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:IncomeTaxExpenseBenefitOperatingLossCarryforwards" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">13,536,884</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:IncomeTaxExpenseBenefitOperatingLossCarryforwards" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,944,248</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_ecustom--DeferredIncomeTaxExpenseChangeInTaxRate_i01_pp0p0_maDITEBzCiE_zFSno9T3WyIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Change in tax rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003"><span><ix:nonfraction name="enob:DeferredIncomeTaxExpenseChangeInTaxRate" contextref="From2020-07-01to2021-06-30" id="fact-identifier-565" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1003" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="enob:DeferredIncomeTaxExpenseChangeInTaxRate" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,218</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0p0_di_msDITEBzCiE_zsuysTgaEWel" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Change in the valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,810,114</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-568" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,739,383</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzCiE_zHpGXF6CiXCk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Deferred Tax Expense</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009"><span><ix:nonfraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="From2020-07-01to2021-06-30" id="fact-identifier-569" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1009" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010"><span><ix:nonfraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="From2019-07-012020-06-30" id="fact-identifier-570" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1010" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8A2_zwM6vPls8ug" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Deferred income tax expense (benefit)
results primarily from the reversal of temporary timing differences between tax and financial statement income.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_230_zRbXJfwuhoM5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 67; Value: 4 -->
    <div id="xdx_239_z8lkNCpfMFC5" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_236_zcTQ2ez02xVk" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_23A_zIverzY5v6B4" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zHwNwB3ygv3d" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zRnckvudtglj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zEX85LwcB9l9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zusey73Qxhg8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zBJIh8Nk2yrb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zOTsdPj5MJjg" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 — <span id="xdx_82C_z7uCdmy4bsFb">STOCKHOLDERS’ EQUITY</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Preferred Stock </b>—
The Company has <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20200630_zSN9W3tUClq1"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span>
</span>authorized shares of Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pp4d_c20200630_zaN3yiOzn8o6"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="4" unitref="USDPShares" inside-table="false" id="fact-identifier-573" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span>
</span>per share. At June 30, 2021 and 2020, there were zero shares issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Common Stock </b>—
The Company has <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_z3IqB96ZSu1k" title="Common stock, shares authorized"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20200630_zmc8kXOxlNj4" title="Common stock, shares authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> authorized shares of Common Stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210630_zQb97bYU2T3k" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200630_zisDijtLKeQk" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-576" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></ix:nonfraction></span></span></span> per share. At June 30, 2021 and 2020, there were
<span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20210630_z1SQCMpqzCgl" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20210630_zve1glqKtmvf" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,219,661</ix:nonfraction></span></ix:nonfraction></span></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20200630_zxD837qyhn92" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20200630_zNbl3FducS7h" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-581" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,497,409</ix:nonfraction></span></ix:nonfraction></span></span></span> shares issued and outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Voting — </b>Holders
of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including
the election of directors, and do not have any right to cumulate votes in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Dividends — </b>Holders
of Common Stock are entitled to receive ratably such dividends as the Company’s Board of Directors from time to time may
declare out of funds legally available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Liquidation Rights —</b>
In the event of any liquidation, dissolution or winding-up of the affairs of the Company, after payment of all of our debts and
liabilities, the holders of Common Stock will be entitled to share ratably in the distribution of any of our remaining assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Purchase Agreement
with Lincoln Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 8, 2020, we entered
into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”),
pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_907_eus-gaap--PurchaseObligation_iI_c20210708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2t6janG1zzg" title="Obligation to purchase"><span><ix:nonfraction name="us-gaap:PurchaseObligation" contextref="AsOf2021-07-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-582" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,000,000</ix:nonfraction></span></span>
of shares of our Common Stock from time to time through <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20210701__20210708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwwIGO1mjkbg" title="Maturity date"><span><ix:nonnumeric contextref="From2021-07-012021-07-08_us-gaap_SubsequentEventMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">August 1, 2023</ix:nonnumeric></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;Under the Purchase Agreement,
we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to <span id="xdx_90D_ecustom--PurchaseOfShares_iI_c20210708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znGwEQN33BU5" title="Purchase of shares"><span><ix:nonfraction name="enob:PurchaseOfShares" contextref="AsOf2021-07-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-584" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">200,000</ix:nonfraction></span>
</span>shares of Common Stock on any business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased
under certain circumstances up to <span id="xdx_909_ecustom--PurchaseOfShares_iI_c20210708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--LincolnParksMember_zzeVwTl8aOG1" title="Purchase of shares"><span><ix:nonfraction name="enob:PurchaseOfShares" contextref="AsOf2021-07-08_us-gaap_SubsequentEventMember_custom_LincolnParksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-585" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">125,000</ix:nonfraction></span>
</span>shares of Common Stock, provided, that Lincoln Park’s committed obligation for Regular Purchases on any business day shall
not exceed $<span id="xdx_906_ecustom--ExceedAmount_iI_c20210708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjMCjcaKcta6" title="Exceed amount"><span><ix:nonfraction name="enob:ExceedAmount" contextref="AsOf2021-07-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,000,000</ix:nonfraction></span></span>.
In the event we direct&nbsp;the purchase of the full amount allowed for a Regular Purchase on any given business day, we may also direct
Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase price of shares of Common
Stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described
in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our sale of shares of Common
Stock to Lincoln Park subsequent to the date of the Purchase Agreement is <span id="xdx_90D_ecustom--PurchaseAgreementDescription_c20200701__20210630_zzDTGVL6zvPk"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="enob:PurchaseAgreementDescription" inside-table="false" id="fact-identifier-587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">limited
to 12,016,457 shares of Common Stock, representing 19.99% of the shares</ix:nonnumeric></span></span> of the Common Stock outstanding on the date of the Purchase
Agreement unless (i) stockholder approval is obtained, (ii) the average price of all applicable sales to Lincoln Park under the Purchase
Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding
the date of the Purchase Agreement or (B) the average of the closing prices on the Nasdaq Capital Market for the five Business Days immediately
preceding the date of the Purchase Agreement or (iii) to the extent it would cause Lincoln Park to beneficially own more than 9.99% of
the Company’s outstanding shares of Common Stock at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration for entering
into the Purchase Agreement, we issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20200721__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zBOpdRFVX439"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2020-07-21_custom_PurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">139,567</ix:nonfraction></span>
</span>shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2021, we issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20210630__srt--TitleOfIndividualAxis__custom--LincolnParkMember_zBQ3lOxWXdj6"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-06-30_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-589" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span>
</span>shares of Common Stock to Lincoln Park under the Purchase Agreement for a purchase price of $<span id="xdx_90E_eus-gaap--SupplementalDeferredPurchasePrice_c20200701__20210630_zQCqvjjrRaxg"><span><ix:nonfraction name="us-gaap:SupplementalDeferredPurchasePrice" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-590" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,221,350</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 68; Value: 4 -->
    <div id="xdx_239_zSJyQVzVRZl6" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zb3T4Meu8Vz4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_23C_z8yhVswO8Ag2" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_233_zRUlUnerd9M1" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zdtF4OcYVb62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Private Placement
</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to a private
placement offering, the Company issued <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20210609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJxm23lQTYqh" title="Shares issued"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-06-09_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-591" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,275,719</ix:nonfraction></span></span> Common Stock resulting in proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20210315__20210709__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z0Ab152lBITc" title="Proceeds from private placement"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextref="From2021-03-152021-07-09_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-592" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,800</ix:nonfraction></span></span>. The Company effected the issuances
of the shares of Common Stock from March 15, 2021 to June 9, 2021. The private placements was made directly by the Company. No
underwriter or placement agent was engaged by the Company for this private placement.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Purchase Agreement
Pursuant to Registered Direct Offering</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 14, 2021,
the Company and certain institutional investors entered into a securities purchase agreement (the “Registered Direct Purchase
Agreement”), pursuant to which the Company agreed to sell to such <span id="xdx_90A_ecustom--PurchaseAgreementDescription_c20210601__20210614_zpX3doDNQ5a2" title="Purchase agreement description"><span><ix:nonnumeric contextref="From2021-06-012021-06-14" name="enob:PurchaseAgreementDescription" inside-table="false" id="fact-identifier-593" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">investors an aggregate of 3,866,668 shares of Common Stock,
in a registered direct offering, for gross proceeds of approximately $29 million (the “Financing”). The purchase price
for each share of Common Stock was $7.50.</ix:nonnumeric></span> </span>Pursuant to the Registered Direct Purchase Agreement, the Company agreed not to issue
or enter into any agreement to issue Common Stock from June 14, 2021 until ninety (90) days after the closing of the Financing.
H.C. Wainwright &amp; Co., LLC, acted as the exclusive placement agent (the “Placement Agent”.) The Financing closed
on June 16, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company agreed
to pay the Placement Agent an aggregate fee equal to <span id="xdx_905_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_dp_c20200701__20210630_z8xgEW5Gty9d" title="Aggregate fee percentage"><span><ix:nonfraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-594" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span></span>% of the gross proceeds raised in the Financing. The Company also agreed
to pay the Placement Agent certain expenses. The Company paid $<span id="xdx_905_eus-gaap--AccruedLiabilitiesForCommissionsExpenseAndTaxes_iI_c20210630_zHeq2XLTeCh3" title="Commissions and incurred offering expenses"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,090,000</ix:nonfraction></span></span> in commissions and incurred offering expenses, and issuance
costs of $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_c20200701__20210630_ze8qeyJnQJLj" title="Issuance costs"><span><ix:nonfraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-596" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,011</ix:nonfraction></span></span>, resulting in net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20200701__20210630_zR9wsSZW1M6b" title="Net proceeds"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,843,998</ix:nonfraction></span></span> in connection with the Financing.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Issuances </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 30, 2021,
the Company issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20210107_zCACHPrH5GNi" title="Issued shares"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-01-07" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></span> shares of Common Stock related to restricted share units that vested on January 7, 2021. These shares
were expensed during the period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 16, 2021, the Company
issued <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20210616_zMT1ro9CG9t8"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-06-16" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,866,668</ix:nonfraction></span></span> shares of Common Stock at a price of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20210616_zy9yUScEQVC" title="Common stock at price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-06-16" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span> </span>per share pursuant to the Registered Direct Purchase Agreement for
total proceeds to the Company of $<span id="xdx_901_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20210601__20210616_zaOHLI9JYvg2"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2021-06-012021-06-16" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-601" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,843,998</ix:nonfraction></span></span> net of $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_c20200601__20200616_zgFAFYQx8Iej"><span><ix:nonfraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextref="From2020-06-012020-06-16" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,156,012</ix:nonfraction></span></span> of issuance costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 14, 2021, the Company
issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20210614__us-gaap--SubsidiarySaleOfStockAxis__custom--LincolnParkMember_z06bO2bNRBWl"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-06-14_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-603" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span> shares of Common Stock at an average price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20210614__us-gaap--SubsidiarySaleOfStockAxis__custom--LincolnParkMember_zGkRTtwptT1j"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-06-14_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-604" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.79</ix:nonfraction></span></span> per share pursuant to the Purchase Agreement with Lincoln Park
for total proceeds to the Company of $<span id="xdx_900_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20210601__20210614__us-gaap--SubsidiarySaleOfStockAxis__custom--LincolnParkMember_z2S0hamAxu91"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2021-06-012021-06-14_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,018,500</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 11, 2021, the Company
issued <span id="xdx_900_eus-gaap--SharesIssued_iI_c20210611__us-gaap--SubsidiarySaleOfStockAxis__custom--LincolnParkMember_zk9HpVtEm6i"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-06-11_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-606" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span> shares of Common Stock at an average price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20210611__us-gaap--SubsidiarySaleOfStockAxis__custom--LincolnParkMember_zzL0cwrjmBWd"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-06-11_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-607" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.057</ix:nonfraction></span></span> per share pursuant to the Purchase Agreement with Lincoln Park
for total proceeds to the Company of $<span id="xdx_90B_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20210601__20210611__us-gaap--SubsidiarySaleOfStockAxis__custom--LincolnParkMember_zNSfS4kQ87ni"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2021-06-012021-06-11_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-608" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">202,850</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From March 18, 2021 through
June 9, 2021, the Company issued <span id="xdx_902_eus-gaap--SharesIssued_iI_c20210609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztNrMVKwg33k"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-06-09_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,275,719</ix:nonfraction></span> </span>shares of Common Stock at a price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20210609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zdXcDG244Yti"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-06-09_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.92</ix:nonfraction></span></span> per share pursuant to a private placement
for total proceeds to the Company of $<span id="xdx_903_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20210318__20210609__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOVKLwMMP9Og"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2021-03-182021-06-09_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,800</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 18, 2021, there
were <span id="xdx_902_eus-gaap--SharesIssued_iI_c20210218_ze9arwBCYHm2"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-02-18" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,000</ix:nonfraction></span></span> restricted share units issued that immediately vested and were converted into shares of Common Stock in exchange for
consulting services valued at $<span id="xdx_900_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20210201__20210218_zlwOeahDrLMh"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2021-02-012021-02-18" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147,000</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 11,
2021, the Company issued <span id="xdx_909_eus-gaap--SharesIssued_iI_c20210211_z0GzARmiluac"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-02-11" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74,054</ix:nonfraction></span></span> shares of Common Stock valued at $<span id="xdx_90C_eus-gaap--CommonStockValue_iI_c20210211_zHtAbzV0fT0d" title="Common stock valued"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-02-11" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">298,178</ix:nonfraction></span></span> based on the closing price on that date, issued in lieu
of prepaid interest related to an amendment that extended the maturity date of the Unsecured Note to November 30, 2022 (see Note
5).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 14, 2020, the
Company issued <span id="xdx_907_eus-gaap--SharesIssued_iI_c20201214_zukOz1OMLtAh"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2020-12-14" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,122</ix:nonfraction></span></span> shares of Common Stock valued at the price of $<span id="xdx_90F_ecustom--DerivativePriceRiskOptionStrikePrices_iI_c20201214_zXZOzQVOGZ88" title="Strike price"><span><ix:nonfraction name="enob:DerivativePriceRiskOptionStrikePrices" contextref="AsOf2020-12-14" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.30</ix:nonfraction></span></span> strike price per share pursuant to the exercise of vested
warrants for total proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20211201__20211214_zoXxaXZxo5F4"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2021-12-012021-12-14" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,056</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 14, 2020, the
Company issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20201214_zcMqVPeFEMCk"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2020-12-14" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,122</ix:nonfraction></span> </span>shares of Common Stock valued at the price of $<span id="xdx_909_eus-gaap--CommonStockNoParValue_iI_c20201214_zoEDjHPscTw2" title="Common stock value price"><span><ix:nonfraction name="us-gaap:CommonStockNoParValue" contextref="AsOf2020-12-14" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.05</ix:nonfraction></span></span> per share in connection with the acquisition of Enochian
Biopharma Inc. This non-cash transaction impacted stockholders’ equity in the amount of $<span id="xdx_908_ecustom--NonCashTransactionImpactedOnStockholdersEquity_iI_c20201214_zO0fgCo07l4c" title="Non cash transaction Impacted on stockholders equity"><span><ix:nonfraction name="enob:NonCashTransactionImpactedOnStockholdersEquity" contextref="AsOf2020-12-14" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">192,522</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_23B_zd4BdSNpWs37" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 69; Value: 4 -->
    <div id="xdx_23D_zy44qvsNUzjb" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zV2DWszc0wsc" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_235_zWTbpTD24KDe" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td id="xdx_239_zjBzpOC0KqBg" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z3BgkckcTK38" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 30, 2020, the
Company issued <span id="xdx_905_eus-gaap--SharesIssued_iI_c20200330_zdnuApxItbyc"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2020-03-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-622" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">188,485</ix:nonfraction></span></span> shares valued at $<span id="xdx_908_eus-gaap--CommonStockValue_iI_c20200330_zRVqybZDpXSj"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-03-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">501,370</ix:nonfraction></span></span> based on the closing share price on that date, in lieu of prepaid interest related
to the $<span id="xdx_900_eus-gaap--PrepaidInterest_iI_pp0n3_dm_c20200330_zENbl9waD8yg" title="Prepaid interest"><span><ix:nonfraction name="us-gaap:PrepaidInterest" contextref="AsOf2020-03-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-624" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span></span> million in principal of the Unsecured Note, which is recorded against the Unsecured Note at its computed relative fair
value of $<span id="xdx_902_eus-gaap--AssetsFairValueDisclosure_iI_c20200330_zWOEy6VdbcWh" title="Unsecured note fair value"><span><ix:nonfraction name="us-gaap:AssetsFairValueDisclosure" contextref="AsOf2020-03-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-625" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">493,192</ix:nonfraction></span></span> (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 9, 2020,
the Company issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20200109_z2rnMXz6kkib"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2020-01-09" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-626" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></span> shares of Common Stock related to restricted share units that vested on January 7, 2020. These shares
were expensed during the period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 27, 2019, there
were <span id="xdx_906_eus-gaap--SharesIssued_iI_c20191227__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5DquzOtQhKc"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2019-12-27_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-627" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,000</ix:nonfraction></span> </span>restricted share units (RSUs) issued with immediate vesting were converted into shares of Common Stock in exchange
for consulting services valued at $<span id="xdx_906_ecustom--CommonStockInExchange_iI_c20191227__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbVSYqO4cWo" title="Common stock in exchange"><span><ix:nonfraction name="enob:CommonStockInExchange" contextref="AsOf2019-12-27_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-628" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">144,000</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 3, 2019, the Registrant
issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20190703__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyALTCkWrQn9"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2019-07-03_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-629" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span> shares of Common Stock valued at the strike price of $<span id="xdx_902_ecustom--DerivativePriceRiskOptionStrikePrices_iI_c20191227__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb1a5Gxe9xO8"><span><ix:nonfraction name="enob:DerivativePriceRiskOptionStrikePrices" contextref="AsOf2019-12-27_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-630" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.00</ix:nonfraction></span></span> per share pursuant to the exercise of vested grant warrants
for total proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pp0n3_dm_c20191201__20191227__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znc14irL0q76"><span><ix:nonfraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextref="From2019-12-012019-12-27_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-631" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 3, 2019, the Registrant
issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20190703_zgqcw1cR0Fxf"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2019-07-03" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-632" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span> shares of Common Stock valued at the price of $<span id="xdx_909_eus-gaap--CommonStockNoParValue_iI_c20190703_z0LD2IIj2tl"><span><ix:nonfraction name="us-gaap:CommonStockNoParValue" contextref="AsOf2019-07-03" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-633" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.42</ix:nonfraction></span></span> per share in connection with the acquisition of Enochian Biopharma.
This non-cash transaction impacted stockholders’ equity in the amount of $<span id="xdx_901_ecustom--NonCashTransactionImpactedOnStockholdersEquity_iI_pp0n3_dm_c20190703_zJgFTIaVtHvg"><span><ix:nonfraction name="enob:NonCashTransactionImpactedOnStockholdersEquity" contextref="AsOf2019-07-03" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-634" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.2</ix:nonfraction></span></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Acquisition of
Enochian Biopharma / Contingently issuable shares</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 16,
2018, the acquisition of Enochian Biopharma was completed. As part of the acquisition, the stockholders of Enochian Biopharma received
(i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise
or conversion of warrants, which were outstanding at closing. As of June 30, 2021, <span id="xdx_90B_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_iI_c20210630__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember_zYxoFfjYGRy9" title="Common shares contingently issuable"><span><ix:nonfraction name="enob:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" contextref="AsOf2021-06-30_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,350,000</ix:nonfraction></span> </span>Contingent Shares are potentially
issuable (see Note 1).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Acquisition of
Enochian Denmark </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At June 30, 2021
and 2020, the Company maintained a reserve of <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630_pdd" title="Common stock reserved for issuance"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-636" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,414</ix:nonfraction></span></span> and <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200630_pdd" title="Common stock reserved for issuance"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-637" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,237</ix:nonfraction></span></span> Escrow Shares, respectively, all of which are reflected as issued
and outstanding in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Enochian Denmark
held by non-consenting shareholders of Enochian Denmark on both June 30, 2021 and 2020, in accordance with Section 70 of the Danish
Companies Act and the Articles of Association of DanDrit Denmark. There have been <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DanDritDenmarkMember_pdd" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-06-30_custom_DanDritDenmarkMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-638" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">167,639</ix:nonfraction></span> </span>shares of Common Stock issued to non-consenting
shareholders of Enochian Denmark as of June 30, 2021. During the year ended June 30, 2021, the Company issued<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20200701__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DanDritDenmarkMember_zoACTBz21juf" title="Common stock issued"> <span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" contextref="From2020-07-012021-06-30_custom_DanDritDenmarkMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-639" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,835</ix:nonfraction></span></span> shares of
Common Stock to such non-consenting shareholders of Enochian Denmark with no impact on the number of outstanding shares as all
Escrow Shares are reflected as issued and outstanding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_232_zNfcaZcHfsH4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 70; Value: 4 -->
    <div id="xdx_23B_zxogjrL6LaZb" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zLY58YlQbAQa" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_230_zN8NLc0Sw5k1" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_234_z1kJTtt4ahC2" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zvBwlIrvQ4Dk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zENcPPBkjXTd" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_231_zatI1rWM1DTi" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zYUFJEx60Wy1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zuMEFb8BxEWi" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 — STOCKHOLDERS’ EQUITY (continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zVBvyPRhHcrb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Stock-based Compensation </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognizes
compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is
estimated on the date of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2021, the weighted-average
assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-640" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJnwi6GEzJS9" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B9_zmlFoRSWbkTh" style="display: none">Summary of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Enochian Biosciences Inc.</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MinimumMember_zWZ3TfLRnsh1" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-641" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.5</ix:nonnumeric></span></span> – <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MaximumMember_zTINgnURo172" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-642" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.50</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MinimumMember_zVPb2JJKPXP6" title="Volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-643" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79.77</ix:nonfraction></span></span> – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MaximumMember_zNh267NDplre" title="Volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-644" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87.77</ix:nonfraction></span></span>%</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MinimumMember_zf3ZgHhGwJ5" title="Risk free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-645" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.26</ix:nonfraction></span></span>%- <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MaximumMember_zEiXhPzq1bla"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-07-012021-06-30_custom_EnochianBiosciencesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-646" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.99</ix:nonfraction></span></span>%</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left">Dividend yield</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 18%; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200701__20210630__dei--LegalEntityAxis__custom--EnochianBiosciencesMember_z2tSkKYrMegf" title="Dividend yield"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2020-07-012021-06-30_custom_EnochianBiosciencesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-647" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span>%</td><td style="width: 1%; text-align: left"></td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8AF_zomvSyXCL2da" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized
stock-based compensation expense related to all equity instruments of $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20210630_pp0p0" title="Stock based compensation expense"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-648" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,444,798</ix:nonfraction></span></span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20200630_pp0p0" title="Stock based compensation expense"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-649" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">884,724</ix:nonfraction></span></span> for the years ended June 30, 2021
and 2020, respectively. At June 30, 2021, the Company had approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20210630_pp0p0" title="Unrecognized compensation costs"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-650" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">388,800</ix:nonfraction></span></span> of unrecognized compensation cost related to non-vested
options.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Grant Warrants</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October of 2017,
the Company issued warrants to APE Invest A/S and N.E. Nielsen, and in January 2018, the Registrant issued a warrant to Eric Leire
(each a “Grant Warrant” and collectively the “Grant Warrants”) for an aggregate of Grant Warrants to purchase
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20171001__20171031_zlkkc34RG5d1" title="Options granted and outstanding"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextref="From2017-10-012017-10-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-651" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">900,000</ix:nonfraction></span> </span>shares of Common Stock. During the year ended June 30, 2020, there were <span id="xdx_90F_ecustom--GrantWarrantsExercised_c20190701__20200630_zveskuwcmAh2" title="Grant Warrants exercised"><span><ix:nonfraction name="enob:GrantWarrantsExercised" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-652" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span></span> Grant Warrants exercised at the strike
price of $<span id="xdx_90B_eus-gaap--OptionIndexedToIssuersEquityStrikePrice1_c20190701__20200630_zm3gAQ4odcL2" title="Strike price"><span><ix:nonfraction name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-653" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.00</ix:nonfraction></span></span> per share, for total proceeds of $<span id="xdx_90B_ecustom--GrantWarrantsExercisedValue_pp0p0_c20190701__20200630_zawWgzm1DtQ2" title="Grant Warrants exercised, value"><span><ix:nonfraction name="enob:GrantWarrantsExercisedValue" contextref="From2019-07-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-654" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,000,000</ix:nonfraction></span></span>. As of June 30, 2021, all Grant Warrants have been exercised.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Plan Options</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;On February
6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved
<span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_zLGckeFcmXh1" title="Common stock reserved for issuance"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2014-02-06_custom_EquityIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-655" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,206,000</ix:nonfraction></span></span> shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 30, 2019,
the Board approved and on October 31, 2019, the Company’s stockholders adopted Enochian’s 2019 Equity Incentive Plan
(the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum
of (1) 6,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the
2014 Plan plus any options related to awards that expire, are terminated, surrendered, or forfeited for any reason without issuance
of shares under the 2014 Plan after the effective date of the 2019 Plan.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the 2019
Plan, the Company granted options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200701__20210630__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_pdd" title="Options granted and outstanding"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextref="From2020-07-012021-06-30_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-656" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,700</ix:nonfraction></span> </span>shares
to employees with a three-year vesting period during the year ended June 30, 2021. For the year ended June 30, 2020, the Company
granted options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20190701__20200630__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zT52XbPpnO0i" title="Options granted and outstanding"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextref="From2019-07-012020-06-30_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-657" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,999</ix:nonfraction></span></span>
shares with a <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zCdMBBSCFMX4" title="Options vesting period" style="display: none"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" inside-table="false" id="fact-identifier-658" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonnumeric></span></span> three-year vesting period under the 2019 Plan. Options are exercisable at the market price of the Company’s
Common Stock on the date of the grant.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years
ended June 30, 2021, and 2020 the Company granted options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200701__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryMembersMember_pdd" title="Options granted and outstanding"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextref="From2020-07-012021-06-30_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-659" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">184,509</ix:nonfraction></span></span> and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20190701__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryMembersMember_pdd" title="Options granted and outstanding"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextref="From2019-07-012020-06-30_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-660" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">587,296</ix:nonfraction></span></span> shares, respectively, to the Board of
Directors and Scientific Advisory Board Members with a one-year vesting period. Options are exercisable at the market price of
the Company’s Common Stock on the date of the grant. To date the Company has granted options under the Plan (“Plan
Options”) to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--PlanOptionsMember_pdd" title="Options granted and outstanding"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextref="From2020-07-012021-06-30_custom_PlanOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-661" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,329,153</ix:nonfraction></span></span> shares of Common Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company issued options
to purchase <span id="xdx_904_ecustom--NumberOfOptionIssued_c20200701__20210630__us-gaap--AwardTypeAxis__custom--BlackScholesMember_z0urS1O9ZrKd" title="Number of option issued"><span><ix:nonfraction name="enob:NumberOfOptionIssued" contextref="From2020-07-012021-06-30_custom_BlackScholesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-662" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15,000</ix:nonfraction></span></span> shares with immediate vesting for services rendered with a Black-Scholes value of $<span id="xdx_904_ecustom--VestingForServices_c20200701__20210630__us-gaap--AwardTypeAxis__custom--BlackScholesMember_z8AY5sWQNz93" title="Vesting for services"><span><ix:nonfraction name="enob:VestingForServices" contextref="From2020-07-012021-06-30_custom_BlackScholesMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-663" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">27,990</ix:nonfraction></span></span>, during the year ended
June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_230_zagYPGEql3J3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 71; Value: 4 -->
    <div id="xdx_23D_zkedCJONaPy1" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zzbUdprhZIml" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_234_zXV0agAYtwy4" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_232_ztza7v4mQIjb" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zBXF9OZ1KB7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zhkt9Vv4xan8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zrQ8Cd9NbLG" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zPclbqDc5Mj6" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A summary of the Plan Options outstanding
at June 30, 2021 is presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-664" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zZyOlMjE3rLb" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B6_ze2vixW6pyZi" style="display: none">Summary of stock options outstanding</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="17" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br>
Price Ranges</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life&nbsp;(years)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number Exercisable</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life&nbsp;(years)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 2%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ExercisePrices_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member__srt--RangeAxis__srt--MinimumMember_zC6P4pP1gWxf" title="Exercise Prices"><span><ix:nonfraction name="enob:ExercisePrices" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-665" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.00</ix:nonfraction></span></span>–<span id="xdx_90D_ecustom--ExercisePrices_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member__srt--RangeAxis__srt--MaximumMember_zXFkzlU8orN1"><span><ix:nonfraction name="enob:ExercisePrices" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.50</ix:nonfraction></span></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zu64Hxjs66t" title="Options Outstanding, Number Outstanding" style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-667" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,543</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zSVBGsGdpGu7" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-668" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.2</ix:nonnumeric></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zMPR74PEpyDf" title="Options Outstanding, Weighted Average Exercise Price" style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-669" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.24</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zGB7e8NyfLgk" title="Options Exercisable" style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-670" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">106,940</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z1o9v42mku5i" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-671" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.72</ix:nonnumeric></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zLswHGaWRUD3" title="Options Exercisable, Weighted Average Exercise Price" style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-672" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.98</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_ecustom--ExercisePrices_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member__srt--RangeAxis__srt--MinimumMember_ztEPRaxOTWBh" title="Exercise Prices"><span><ix:nonfraction name="enob:ExercisePrices" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-673" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.51</ix:nonfraction></span></span>–<span id="xdx_90E_ecustom--ExercisePrices_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member__srt--RangeAxis__srt--MaximumMember_zIOwMBbpWsya"><span><ix:nonfraction name="enob:ExercisePrices" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-674" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.50</ix:nonfraction></span></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-675" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">506,495</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zXdpOdtO5Bc6" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-676" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.74</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-677" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.13</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-678" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">451,999</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_ziNtvXBbok8c" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-679" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.59</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-680" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.18</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ExercisePrices_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member__srt--RangeAxis__srt--MinimumMember_zw8iwQhYQXj4" title="Exercise Prices"><span><ix:nonfraction name="enob:ExercisePrices" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-681" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.51</ix:nonfraction></span></span>–<span id="xdx_90F_ecustom--ExercisePrices_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member__srt--RangeAxis__srt--MaximumMember_zmoe0MoeRbol"><span><ix:nonfraction name="enob:ExercisePrices" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-682" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.00</ix:nonfraction></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-683" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">534,115</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zzBAD2MTAaGd" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-684" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.64</ix:nonnumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-685" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.97</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-686" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">534,115</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zLlOGJb6lZzb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-687" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.64</ix:nonnumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.97</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Total</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-689" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,329,153</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zqnwj0X6qbL3" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-690" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.42</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-691" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.24</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIXxL04po3jd" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,093,053</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zgKoXytRlzGa" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-693" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.21</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-694" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.74</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8AD_z3cSDdNqQX5j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of changes
since July 1, 2020 are presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-695" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zprgdfZQ67e3" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_znrjymsc1fhd" style="display: none">Summary of stock option activity</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic Value</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding at July 1, 2020</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIJxsSxcC8i4" title="Options Outstanding at beginning of period" style="width: 16%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-696" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,105,442</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zBBfsvgSH4Vl" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="width: 16%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-697" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.78</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 15%; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zO6RbOPWviB5" title="Weighted Average remaining life, Outstanding at beginning of period"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="enob:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne" inside-table="true" id="fact-identifier-698" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9.19</ix:nonnumeric></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zJ0Znk6b1pF8" title="Weighted Average Intrinsic Value, Outstanding at beginning of period" style="width: 15%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-699" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,931</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Outstanding, Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-700" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">231,209</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-701" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.65</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSAj1j7WMmB" title="Weighted Average remaining life, Granted"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-702" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.00</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted Average Intrinsic Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246"><span><ix:nonfraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-703" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Outstanding, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-704" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-705" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zHnEAgro6FUc" title="Weighted Average Remaining Life, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1252"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-706" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted Average Intrinsic Value, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-707" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Outstanding, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-708" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1258"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-709" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zzNfCsTeyX35" title="Weighted Average Remaining Life, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1260"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-710" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForForfeitedInPeriodWeightedAverageIntrinsicValue_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted average intrinsic value, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262"><span><ix:nonfraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForForfeitedInPeriodWeightedAverageIntrinsicValue" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-711" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zLYATvzQswE4" title="Options Outstanding, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-712" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,499</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1266"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-713" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zbaqFozzyBz7" title="Weighted Average Remaining Life, expired"><span style="-sec-ix-hidden: xdx2ixbrl1268"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-714" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExpiredInPeriodWeightedAverageIntrinsicValue_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted average intrinsic value, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1270"><span><ix:nonfraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExpiredInPeriodWeightedAverageIntrinsicValue" contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" id="fact-identifier-715" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zeOWmvCAJ8Ek" title="Options Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-716" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,329,153</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zaTJsA8wzSw1" title="Weighted Average Exercise Price, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-717" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.24</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zVUYJI1Auufc" title="Weighted Average remaining life, Outstanding at end of period"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-718" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.42</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z9QXaBTN0xw4" title="Weighted Average Intrinsic Value, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-719" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">511,239</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable at June 30, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zRLElx7jZYp8" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-720" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,093,053</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zPLHI6dF9vDi" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-721" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.74</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z5RELEk7tBd5" title="Weighted Average Remaining Life, Exercisable end of period"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-722" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.21</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted Average Intrinsic Value, Exercisable end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-723" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">233,670</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8AB_zJj8dxveqnA5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2021,
the Company has <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zTzlcM3xZnU" title="Options Exercisable"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-724" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,093,053</ix:nonfraction></span> </span>exercisable Plan Options. The total intrinsic value of options exercisable at June 30, 2021 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionOneMember_zYOVUUMRn0F9" title="Intrinsic value of stock option"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextref="AsOf2021-06-30_custom_EmployeeStockOptionOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-725" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">233,670</ix:nonfraction></span></span>.
Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at June 30, 2021 (for
outstanding options), less the applicable exercise price.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_235_zuCLbdrY2p9g" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 72; Value: 4 -->
    <div id="xdx_234_zxImwMUWZLJ3" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_z8Trg0Xitmi2" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_23E_zKx5bMle6nWk" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_236_zmYf3bJ25Cwd" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zV5gJo0mGw66" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Common Stock Purchase Warrants</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the
warrants outstanding at June 30, 2021, and changes in the warrants in the year ended June 30, 2021 are presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="enob:CommonStockPurchaseWarrantsOutstandingTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-726" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--CommonStockPurchaseWarrantsOutstandingTableTextBlock_zFooaAGSoiFl" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B2_z8nW06LGGAx4" style="display: none">Summary of common stock purchase warrants outstanding</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Underlying &nbsp; Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Life</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding at July 1, 2020</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98F_ecustom--CommonStockPurchaseWarrants_iS_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zpeCUNw4EYbf" title="Outstanding at beginning of period" style="width: 19%; text-align: right"><span><ix:nonfraction name="enob:CommonStockPurchaseWarrants" contextref="AsOf2020-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-727" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,438,122</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z0Odm95vZZc" title="Weighted average exercise price, Outstanding at beginning of period" style="width: 19%; text-align: right"><span><ix:nonfraction name="enob:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextref="AsOf2020-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-728" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.42</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 19%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190701__20200630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zjmmwSXJtxgi" title="Weighted Average remaining life, Outstanding"><span><ix:nonnumeric contextref="From2019-07-012020-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-729" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.99</ix:nonnumeric></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1302"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" id="fact-identifier-730" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Weighted average exercise price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" id="fact-identifier-731" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zQOhu3HFpQz4" title="Weighted Average remaining life, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1306"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" id="fact-identifier-732" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zstEiGkSVvSk" title="Exercised" style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-733" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,122</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zMaykGo0bhK9" title="Weighted average exercise price, Exercised" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-734" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.30</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zA6tbbfduAYh" title="Weighted Average Remaining Life, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1312"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" id="fact-identifier-735" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cancelled/Expired</span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zbPK0722u1Wc" title="Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-736" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Weighted average exercise price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1316"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" id="fact-identifier-737" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm1_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zowj6pwJYRXf" title="Weighted Average Remaining Life, expired"><span style="-sec-ix-hidden: xdx2ixbrl1318"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" id="fact-identifier-738" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_985_ecustom--CommonStockPurchaseWarrants_iE_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z0fJoJhexHL1" title="Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="enob:CommonStockPurchaseWarrants" contextref="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-739" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,350,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zaydYW4zwJq5" title="Weighted average exercise price, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="enob:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextref="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-740" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.30</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z081xbTGeQXa"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-741" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.02</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable at June 30, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Exercisable end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-742" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,350,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Weighted average exercise price, Exercisable end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-743" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.30</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zkiZqXnmS1o8" title="Weighted Average remaining life, Exercisable end of period"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" name="enob:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-744" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.02</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>

</ix:nonnumeric></span><p id="xdx_8A1_zeH6dfwSER07" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-745" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2ygGQUsaTRa" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left"><span id="xdx_8B2_zozxHUgUXrL9" style="display: none">Summary of common stock purchase warrants</span></td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equivalent Shares Exercisable</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Underlying Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (years)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number Exercisable</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePrices_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z4vTIkuZduK8" title="Exercise Prices" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"><span><ix:nonfraction name="enob:ExercisePrices" contextref="From2020-07-012021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-746" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.30</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt; width: 2%">&nbsp;</td>
    <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z5NdplfCME5d" title="Equivalent Shares Underlying Warrants Outstanding, Equivalent Shares" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-747" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,350,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt; width: 2%">&nbsp;</td>
    <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"><span id="xdx_905_ecustom--EquivalentSharesUnderlyingWarrantsOutstandingWeightedAverageRemainingContractualLifeYears_dtY_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zGGWZXTdzgl3" title="Equivalent Shares Underlying Warrants Outstanding, Weighted Average Remaining Contractual Life (years)"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt-sec:duryear" name="enob:EquivalentSharesUnderlyingWarrantsOutstandingWeightedAverageRemainingContractualLifeYears" inside-table="true" id="fact-identifier-748" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.02</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt; width: 2%">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zw1gBJYHQDq8" title="Equivalent Shares Underlying Warrants Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-749" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.30</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt; width: 2%">&nbsp;</td>
    <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zotOy0RLxePk" title="Equivalent Shares Exercisable, Number Exercisable" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-750" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,350,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt; width: 2%">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zCl3s0iBI8Xf" title="Equivalent Shares Exercisable, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-751" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.30</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&nbsp;</td></tr>
</tbody></table>


</ix:nonnumeric></span><p id="xdx_8A5_zEFWrdGJovbb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The exercise price
of certain warrants and the number of shares underlying the warrants are subject to adjustment for stock dividends, subdivisions
of the outstanding shares of Common Stock and combinations of the outstanding shares of Common Stock. For so long as the warrants
remain outstanding, we are required to keep reserved from our authorized and unissued shares of Common Stock a sufficient number
of shares to provide for the issuance of the shares underlying the warrants.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Units (RSUs)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized
stock-based compensation expense related to RSUs of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE23bEQPvCmd" title="Stock based compensation"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-752" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147,000</ix:nonfraction></span></span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20190701__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziH8vTpeQ28h"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-07-012020-06-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-753" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,000</ix:nonfraction></span></span> for the years ended June 30, 2021 and 2020, respectively.
On June 30, 2020, the Company issued <span id="xdx_90D_eus-gaap--SharesIssued_iI_c20210107__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zn1LUpsuj3B3"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2021-01-07_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-754" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></span> shares of Common Stock related to restricted share units that vested on January 7, 2021.
At June 30, 2021, the Company had approximately $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC9i8FHNoPt3" title="Unrecognized compensation cost"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-755" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,209</ix:nonfraction></span></span> of unrecognized compensation cost related to restricted stock units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of Restricted
Stock Units outstanding at June 30, 2020 and changes in the RSUs in the year ended June 30, 2021 are presented below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-756" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zCyEtyBUTaHl" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_zFYf6TKkR33d" style="display: none">Summary of restricted stock units outstanding</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Issuance<br>
    Price</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining
    Life</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Intrinsic<br>
    Value</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding at July 1, 2020</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7wTU8pJR2pf" title="Outstanding at beginning of period" style="width: 16%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextref="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-757" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--RestrictedStockUnitsWeightedAverageExercisePrice_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsoEeipW7ZH" title="Weighted average exercise price, Outstanding at beginning of period" style="width: 16%; text-align: right"><span><ix:nonfraction name="enob:RestrictedStockUnitsWeightedAverageExercisePrice" contextref="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-758" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.15</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 15%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190701__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxpvAknW6XBk" title="Weighted Average remaining life, Outstanding"><span><ix:nonnumeric contextref="From2019-07-012020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-759" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.02</ix:nonnumeric></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN9iCYSlqN77" title="Weighted Average Intrinsic Value, Outstanding at Beginning of period" style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextref="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-760" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-761" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted average exercise price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1363"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-762" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKcCNW8rEAm7" title="Weighted Average remaining life, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1365"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-763" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_ecustom--WeightedAverageIntrinsicValueGranted_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Weighted Average Intrinsic Value, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1367"><span><ix:nonfraction name="enob:WeightedAverageIntrinsicValueGranted" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-764" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwURbSLy9nyk" title="Exercised" style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-765" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted average exercise price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-766" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW9s50nWjX6h" title="Weighted Average Remaining Life, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1373"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-767" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_ecustom--WeightedAverageIntrinsicValueExercised_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Weighted Average Intrinsic Value, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1375"><span><ix:nonfraction name="enob:WeightedAverageIntrinsicValueExercised" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-768" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cancelled/Expired</span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-769" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted average exercise price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1379"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-770" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm1_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIlQVX6mAeJ7" title="Weighted Average Remaining Life, expired"><span style="-sec-ix-hidden: xdx2ixbrl1381"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-771" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm1" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonnumeric></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--WeightedAverageIntrinsicValueCancelledExpired_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Weighted Average Intrinsic Value, cancelled/ expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1383"><span><ix:nonfraction name="enob:WeightedAverageIntrinsicValueCancelledExpired" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-772" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXQwiDxpgd7a" title="Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-773" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--RestrictedStockUnitsWeightedAverageExercisePrice_iE_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXRw9SreRmdb" title="Weighted average exercise price, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="enob:RestrictedStockUnitsWeightedAverageExercisePrice" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.15</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSQdcUDzpjl2" title="Weighted Average remaining life, Exercisable end of period"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-775" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">.52</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJ3RBZiiA9fg" title="Weighted Average Intrinsic Value, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1391"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-776" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>

</ix:nonnumeric></span><p id="xdx_8A5_zZSrzO3ZdO4g" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-777" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zPblCfxzCGdc" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 6)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td colspan="3" style="font-weight: bold; text-align: left"><span id="xdx_8BF_zQzHnQL8Rwd4" style="display: none">Summary of restricted stock units activity</span></td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="5" style="font-weight: bold; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock Units Outstanding</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (years)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Issuance Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zL7y2OclRVoc" title="Stock Units" style="border-bottom: Black 2.5pt double; width: 26%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-778" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="width: 8%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; width: 26%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zM3TH3zOWaO2" title="Weighted Average remaining life, Outstanding"><span><ix:nonnumeric contextref="From2020-07-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-779" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">.52</ix:nonnumeric></span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="width: 8%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_ze2Nk03clXMj" title="Weight Average Issuance Price" style="border-bottom: Black 2.5pt double; width: 26%; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextref="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-780" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.15</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
</tbody></table>





<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

</ix:nonnumeric></span><p id="xdx_8A0_zV7N00jTHxZ4" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_23C_zUIoQd9PA4v2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 73; Value: 4 -->
    <div id="xdx_232_zfZ9tNM9Fe22" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zbhgCa5TOY2k" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_239_zb3PZUtDL3Cd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zFspgHlmlc13" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zJJ5hvS9KvKi" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zoy9uHsuusph" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND
SUBSIDIARIES </b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zzfuEpakDPu2" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zDJCjIB4Rf28" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-781" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHW0P994Qu4d" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;NOTE 8
— <span id="xdx_828_z1WFptqvlbf7">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Consulting Agreement</b>s
- On July 9, 2018, the Company entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company
(“G-Tech”) to assist the Company with the development of the gene therapy and cell therapy modalities for the prevention,
treatment, amelioration of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum
platform for various diseases (including but not limited to cancers and infectious diseases) (the “<span style="text-decoration: underline">G-Tech Agreement</span>”).
G-Tech was entitled to consulting fees for 20 months, a monthly consulting fee of not greater than $<span id="xdx_907_ecustom--ConsultingExpenses_pp0p0_c20190701__20190709__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zCAdfAUacpra" title="Consulting expenses"><span><ix:nonfraction name="enob:ConsultingExpenses" contextref="From2019-07-012019-07-09_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-782" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">130,000</ix:nonfraction></span> </span>per month. Upon the
completion of the 20 months, the monthly consulting fee of $<span id="xdx_909_ecustom--MonthlyConsultingFee_pp0p0_c20200701__20210630__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zBTbi3YeC1A2" title="Monthly consulting fee"><span><ix:nonfraction name="enob:MonthlyConsultingFee" contextref="From2020-07-012021-06-30_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-783" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25,000</ix:nonfraction></span></span> continued for scientific consulting and knowledge transfer on
existing HIV experiments, and will continue until the services are no longer rendered or the agreement is terminated G Tech is
controlled by certain members of Weird Science. For the years ended June 30, 2021 and 2020, $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200701__20210630__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zk2lBhTVYfjj" title="Research and development expenses"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-07-012021-06-30_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-784" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">275,000</ix:nonfraction></span></span> and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20190701__20200630__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zDY6A2vkdTCb" title="Research and development expenses"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-07-012020-06-30_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-785" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,125,000</ix:nonfraction></span></span>, respectively,
was charged to research and development expenses in the accompanying consolidated statements of operations related to this consulting
agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020,
the Company entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company,
G Tech, and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph
Research Institute (“SRI”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV
License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The HBV License Agreement states that
in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other
in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $<span id="xdx_908_eus-gaap--PaymentsForFees_pp0n3_dm_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zgacoaWKLw8l" title="Payment for license"><span><ix:nonfraction name="us-gaap:PaymentsForFees" contextref="From2020-01-012020-01-31_custom_LicenseAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-786" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span> </span>million within 7
days of January 31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology
set forth in the HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License
Agreement provides for cooperation related to the development of intellectual property related to the Treatment and for a <span id="xdx_905_ecustom--RoyaltyPercentage_dp_c20210101__20210131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zck6nn0Unxge" title="Royalty Percentage"><span><ix:nonfraction name="enob:RoyaltyPercentage" contextref="From2021-01-012021-01-31_custom_LicenseAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="USDPShares" inside-table="false" id="fact-identifier-787" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span></span>% royalty
to G Tech on any net sales that may occur under the HBV License. On February 6, 2020, the Company paid the $<span id="xdx_90C_eus-gaap--PaymentsForFees_pp0n3_dm_c20210201__20210206__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zetyyYTQZFNi" title="Payment for license"><span><ix:nonfraction name="us-gaap:PaymentsForFees" contextref="From2021-02-012021-02-06_custom_LicenseAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-788" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span></span> million up-front
payment. The HBV License Agreement contains customary representations, warranties and covenants of the parties with respect to
the development of the Treatment and the HBV License.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cash funding
for research costs pursuant to the HBV License Agreement consists of monthly payments amounting to $<span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_pp0p0_c20200701__20210630__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_z5Kj4UnvkMTb" title="Monthly research costs"><span><ix:nonfraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextref="From2020-07-012021-06-30_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-789" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,500</ix:nonfraction></span></span> that cover scientific
staffing resources to complete the project as well as periodic payments for materials and equipment needed to complete the project.
During the years ended June 30, 2021 and 2020, the Company paid a total of $<span id="xdx_90F_ecustom--PaymentForScientificStaffingResources_pp0p0_c20200701__20210630__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zZgJD5sin2hb" title="Payment for scientific staffing resources"><span><ix:nonfraction name="enob:PaymentForScientificStaffingResources" contextref="From2020-07-012021-06-30_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-790" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,409,000</ix:nonfraction></span></span> and $<span id="xdx_90E_ecustom--PaymentForScientificStaffingResources_pp0p0_c20190701__20200630__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_z79PAFOJo8Gb" title="Payment for scientific staffing resources"><span><ix:nonfraction name="enob:PaymentForScientificStaffingResources" contextref="From2019-07-012020-06-30_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-791" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,022,000</ix:nonfraction></span></span>, respectively for scientific
staffing resources, R&amp;D and IND Enabling studies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b>On April 18,
2021, the Company entered into a Statement of Work and License Agreement (the “License Agreement”), by and among the
Company, G Tech and SRI, whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development License”)
to research, develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus or the
potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza
(the “Prevention and Treatment”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The License Agreement was
entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The License Agreement states
that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement
provides for an up-front payment of $<span id="xdx_909_ecustom--UpfrontPayment_iI_pp0n3_dm_c20191115_zgXUkn8atsI2" title="Up-front payment"><span><ix:nonfraction name="enob:UpfrontPayment" contextref="AsOf2019-11-15" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-792" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span> </span>million and a $<span id="xdx_902_ecustom--PaymentForExpenditures_iI_c20191115_z57OvZSufltl" title="Payment for expenditures"><span><ix:nonfraction name="enob:PaymentForExpenditures" contextref="AsOf2019-11-15" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-793" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">760,000</ix:nonfraction></span></span> payment for expenditures to date prior to the effective date related
to research towards the Prevention and Treatment within 60 days of April 18, 2021. The License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the License Agreement, in
each case subject to the terms of the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><p id="xdx_236_zaCbt3vFTGz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 74; Value: 4 -->
    <div id="xdx_232_zRK62WNyXPtf" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zGUfVoVqS3wd" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_233_ziY2kK8t8jxa" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_234_z15iaf9mRnQe" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zm3KU5lgkL7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The License Agreement provides
for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G Tech on any net sales that may occur under the License Agreement. As of June 30, 2021, the Company paid the $<span id="xdx_90D_ecustom--UpfrontPayment_iI_pp0n3_dm_c20210630_zZvbNGaRH9ai"><span><ix:nonfraction name="enob:UpfrontPayment" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-794" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span> </span>million up-front
payment, and the $<span id="xdx_90F_ecustom--PaymentForExpenditures_iI_c20210630_zJKFFCQpfrSk"><span><ix:nonfraction name="enob:PaymentForExpenditures" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-795" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">760,000</ix:nonfraction></span></span> related to prior research costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">G Tech is controlled
by Dr. Serhat Gümrükcü and Anderson Wittekind, shareholders of the Company, and SRI is controlled by Dr. Serhat
Gümrükcü.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Shares held for
non-consenting shareholders </b><i>– </i>In connection with the share exchange upon the acquisition of Enochian Denmark certain
shareholders of DanDrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section
70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the non-consenting Shareholders that did not
exchange their DanDrit Denmark equity interests for shares of the Company, will be entitled to receive up to <span id="xdx_902_ecustom--CommonStockReceived_c20210630_pdd" title="Common stock received"><span><ix:nonfraction name="enob:CommonStockReceived" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-796" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">185,053</ix:nonfraction></span></span> shares of
Common Stock of the Company that each such non-consenting Shareholder would have been entitled to receive if such shareholder had
consented to the Share Exchange. During the year ended June 30, 2021, the Company issued <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200701__20210630_pdd" title="Common stock issued"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-797" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,835</ix:nonfraction></span></span> shares of Common Stock to such
non-consenting shareholders of DanDrit Denmark. The <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210630_zW7Zvz86JT53" title="Common stock reserved for issuance"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-798" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,414</ix:nonfraction></span></span> remaining shares have been reflected as issued and outstanding in the
accompanying financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Service Agreements
<i>- </i></b><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200701__20210630" title="Compensation description"><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" inside-table="false" id="fact-identifier-799" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Company had an agreement with Dr. Dybul, the Company’s Executive Vice-Chair, whereby he fulfilled the
duties as prescribed by the Company’s bylaws and received annual compensation in the amount of $430,000, plus options to
purchase 300,000 shares of Common Stock that vested immediately. Dr. Dybul was given a one-time grant of options to purchase 450,000
shares of Common Stock at a strike price of $8.00 per share on June 11, 2020. As of July 1, 2021, this agreement was terminated
upon Dr. Dybul becoming the Company’s full-time CEO (see Note 10.) The Company has a consulting agreement for services of
a Senior Medical Advisor for $210,000 per year on a part-time basis.</ix:nonnumeric></span> </span>The Company maintains employment agreements with other staff
in the ordinary course of business<b><i>.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Contingencies
</b>- The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While
any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations
or financial position from such proceedings or claims.</p>

<ix:exclude><p id="xdx_237_zEq0Sn0NJf2f" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<br>
</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 75; Value: 4 -->
    <div id="xdx_23C_zKOLB07BLMAc" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_238_z6XOyFvSWcol" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div id="xdx_23B_zhGsBHvLGlSe" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_239_zbCEzA2QpXhe" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zHatoKLFOc3b" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zh4Bi27H1jK8" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zGXoOB7mB83a" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zLVLF6RS7Fod" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-800" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPBHXefM5aS9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 — <span id="xdx_827_zelONBBdRL2d">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 9, 2018,
the Company entered into a consulting agreement with G-Tech to assist the Company with the development of the gene therapy and
autologous and allogenic cell therapy modalities for the prevention, treatment, amelioration of HIV in humans, and with the development
of a genetically enhanced Allogenic Dendritic Cell for use as a wide spectrum platform for various diseases (including but not
limited to cancers and infectious diseases) (see Note 8.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020,
the Company entered into the HBV License Agreement by and among the Company, G Tech and SRI, whereby the Company acquired the HBV
License for the Treatment (see Note 8.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 18, 2020 the Company
entered into the Flu-CoV License Agreement by and among the Company, G Tech and SRI, whereby the Company acquired the Development
License to research, develop, and commercialize certain formulations, which are aimed at preventing and treating pan-coronavirus
and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (see Note 8.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-07-01to2021-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-801" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zkRxy3PumW2k" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 — <span id="xdx_825_zYPAFiWkvirj">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 11, 2021, and with an effective
date of July 1, 2021, the Company and Dr. Dybul entered into an Employment Agreement, the form of which was approved and recommended
by the Board on October 30, 2019 and approved by the stockholders of the Company with a majority of the voting power of all shares
of the Company’s capital stock entitled to vote on the matter on October 31, 2019. The material terms of the Employment Agreement
are as set forth in the Company’s Information Statement filed with the Commission on November 12, 2019.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 25, 2021, the
Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”)
with Dr. Gumrukcu and SRI whereby Dr. Gumrukcu granted the Company an exclusive, worldwide, perpetual, fully paid-up, royalty-free
license, with the right to sublicense, his proprietary technology subject to a U.S. patent application, to make, use, offer to sell,
sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively for HIV in humans, and
research and development exclusively relating to HIV in humans; provided Dr. Gumrukcu retained the right to conduct HIV research in
the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to Dr. Gumrukcu and SRI, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make,
use, offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV
Comorbidities and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $<span id="xdx_905_ecustom--InitialPayment_c20210801__20210825__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pp0p0" title="Initial payment"><span><ix:nonfraction name="enob:InitialPayment" contextref="From2021-08-012021-08-25_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-802" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">600,000</ix:nonfraction></span>
</span>and agreed to fund future HIV research conducted by Dr. Gumrukcu and SRI, as mutually agreed to by the parties. On September 10,
2021, pursuant to the ALC License Agreement, the Company paid the initial payment of $<span id="xdx_905_ecustom--PaidInitialPayment_c20211001__20211010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pp0p0" title="Paid initial payment"><span><ix:nonfraction name="enob:PaidInitialPayment" contextref="From2021-10-012021-10-10_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-803" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">600,000</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

</ix:nonnumeric></span><p id="xdx_818_zKI75aIxkzel" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 76; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_041"></span>Item 9. Changes in and Disagreements with Accountants
on Accounting and Financial Disclosure</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_042"></span>Item 9A. Controls and Procedures</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Principal Executive
Officer and Principal Financial Officer (the “Certifying Officers”) are responsible for establishing and maintaining
disclosure controls and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures
to ensure that material information is made known to the Certifying Officers, particularly during the period in which this Report
was prepared.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Certifying Officers
conducted a review of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act, Rules
13a-15(e) and 15-d-15(e)) as of the end of the period covered by this Annual Report (the “Evaluation Date”). Based
upon that evaluation, the Certifying Officers concluded that, as of June 30, 2021, our disclosure controls and procedures were
not effective in ensuring that the information we were required to disclose in reports that we file or submit under the SEC Act
of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Management Annual Report on Internal Control over Financial
Reporting</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management is responsible
for establishing and maintaining adequate internal control over financial reporting for the Company. Management used the “Internal
Control over Financial Reporting Integrated Framework” issued by the Committee of Sponsoring Organizations (“COSO”)
to conduct a review of the Company’s internal controls over financial reporting. As of June 30, 2021, Management concluded
that internal controls over financial reporting were not effective, based on COSO’s framework. The deficiencies are attributed
to the fact that the Company does not have an adequate number of people to whom it can segregate accounting tasks within the Company
so as to ensure segregation of duties between those people who approve and issue payment from those people who are responsible
for recording and reconciling such transactions within the Company’s accounting system. These control deficiencies will be
monitored, and attention will be given to this matter as we continue to accelerate through our current growth stage.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report
does not include an attestation report from the Company’s registered public accounting firm regarding internal controls
over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting
firm pursuant to the rules of the SEC that permit the Company to provide only management’s report in this Annual Report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no changes
in our internal control over financial reporting that occurred during the period covered by this report that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_043"></span>Item 9B. Other Information</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Not Applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 43 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART III</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_044"></span>Item 10. Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information
required by this Item 10 will be included under the captions “Directors and Executive Officers”, “Information
as to Nominees and Other Directors”, “Information Regarding Meetings and Committees of the Board”, “Compliance
with Section 16(a) of the Exchange Act”, “Code of Ethics”, “Corporate Governance” and as otherwise
set forth in the Company’s 2021 Proxy Statement and is incorporated herein by reference or, alternatively will be included,
by amendment to this Form 10-K under cover of Form 10-K/A no later than 120-days after the end of our fiscal year covered by this
report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_045"></span>Item 11. Executive Compensation</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This information
will be contained in our definitive proxy statement for our upcoming Annual Meeting of Shareholders, to be filed with the SEC no
later than 120 days after the end of our fiscal year covered by this report, and incorporated herein by reference or, alternatively,
will be included by amendment to this Form 10-K under cover of Form 10-K/A no later than the end of such 120-day period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_046"></span>Item 12. Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This information
will be contained in our definitive proxy statement for our upcoming Annual Meeting of Shareholders, to be filed with the SEC no
later than 120 days after the end of our fiscal year covered by this report, and incorporated herein by reference or, will be included
alternatively, by amendment to this Form 10-K under cover of Form 10-K/A no later than the end of such 120-day period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_047"></span>Item 13. Certain Relationships and Related Transactions
and Director Independence</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This information
will be contained in our definitive proxy statement for our upcoming Annual Meeting of Shareholders, to be filed with the SEC no
later than 120 days after the end of our fiscal year covered by this report, and incorporated herein by reference or, alternatively,
will be included by amendment to this Form 10-K under cover of Form 10-K/A no later than the end of such 120-day period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_048"></span>Item 14. Principal Accounting Fees and Services</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This information
will be contained in our definitive proxy statement for our upcoming Annual Meeting of Shareholders, to be filed with the SEC no
later than 120 days after the end of our fiscal year covered by this report, and incorporated herein by reference or, alternatively,
will be included by amendment to this Form 10-K under cover of Form 10-K/A no later than the end of such 120-day period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 78; Value: 43 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART IV</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_049"></span>Item 15. Exhibits, Financial Statement Schedules</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
No.</b></span></td>
<td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 39%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td>
<td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 48%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Incorporated
by Reference</b></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.1 </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000013/e1079_ex3-1.htm" tabindex="18">Certificate of Incorporation</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000013/e1079_ex3-1.htm" tabindex="18">Incorporated herein by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2018.</a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.2 </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000259/e1349_ex3-1.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Bylaws</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000259/e1349_ex3-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 16, 2019.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000121390017004429/f8k050117ex10ii_dandritbio.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Form
of Warrant</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000121390017004429/f8k050117ex10ii_dandritbio.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on May 1, 2017.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.2</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Promissory
Note</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on March 31, 2020.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.3</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm" tabindex="18"><span style="font-size: 10pt">Description
of Securities</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 4.1 to the Company’s Form 10-K filed with the SEC on September 30, 2020.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.1 </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000121390018000600/f8k011218ex10-1_dandritbio.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Form
of License Agreement</span></a><span style="font-size: 10pt; text-underline-style: none"> </span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000121390018000600/f8k011218ex10-1_dandritbio.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2018.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.2</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000112/e1702_ex10-1.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">2019
Equity Incentive Plan</span></a><span style="font-size: 10pt; text-underline-style: none"> </span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000112/e1702_ex10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 10, 2020.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.3</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000085/e1694_10-1.htm" tabindex="18"><span style="font-size: 10pt">Statement
of Work and License Agreement</span></a><span style="font-size: 10pt"> </span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000085/e1694_10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on February 3, 2020.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.4</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-1.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Note
Purchase Agreement</span></a><span style="font-size: 10pt; text-underline-style: none"> </span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 31, 2020.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.5</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000121390017012297/f8k111317ex10-1_dandritbio.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Lease
Agreement by and between the Company and Plaza Medical Office Building, LLC dated November 13, 2017</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000121390017012297/f8k111317ex10-1_dandritbio.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 17, 2017.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.6</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000021/e1105_10-1.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">General
Office Lease by and between the Registrant and Century City Medical Plaza Land Co., Inc. dated June 19, 2018</span></a><span style="font-size: 10pt; text-underline-style: none">
</span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000021/e1105_10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 25, 2018.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.7</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000575/e1514_10-10.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Consulting
Agreement by and between the Company and G-Tech Bio, LLC July 9, 2018</span></a><span style="font-size: 10pt; text-underline-style: none">
</span></span><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000575/e1514_10-10.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.10 to the Company’s Annual Report on Form 10-K/A filed with the SEC on September 30, 2019.</span></a></span></td></tr>
</tbody></table>


<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 79; Value: 43 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="line-height: 107%; width: 11%"><span style="font: 10pt Times New Roman, Times, Serif">10.8</span></td>
<td style="line-height: 107%; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%; width: 39%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000575/e1514_10-11.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Offer
Letter from the Company to Luisa Puche, dated December 28, 2018</span></a><span style="font-size: 10pt; text-underline-style: none">
</span></span></td>
<td style="line-height: 107%; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%; width: 48%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000575/e1514_10-11.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.11 to the Company’s Annual Report on Form 10-K/A filed with the SEC on September 30, 2019.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.9</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000575/e1514_10-12.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Amended
and Restated Director Agreement by and between the Company and Mark Dybul, as amended, dated May 1, 2019</span></a><span style="font-size: 10pt; text-underline-style: none">
</span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000575/e1514_10-12.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K/A filed with the SEC on September 30, 2019.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.10</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000727/e2021_4-1.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Purchase
Agreement, dated July 8, 2020, by and between the Company and Lincoln Park Capital Fund, LLC</span></a><span style="font-size: 10pt; text-underline-style: none">
</span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000727/e2021_4-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 14, 2020.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.11</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112220000727/e2021_10-1.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Registration
Rights Agreement, dated July 8, 2020, by and between the Company and Lincoln Park Capital Fund, LLC</span></a><span style="font-size: 10pt; text-underline-style: none">
</span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000727/e2021_10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 14, 2020.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.12</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">&nbsp;</span></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221000434/e2548_10-1.htm" tabindex="18"><span style="font-size: 10pt">Form
of Subscription Agreement</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221000434/e2548_10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 24, 2021.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.13</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221000640/e2664_10-1.htm" tabindex="18"><span style="font-size: 10pt">Statement
of Work and License Agreement, dated April 18, 2021, by and among the Company, G-Tech Bio, LLC, and G Health Research Foundation</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221000640/e2664_10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 22, 2021.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.14</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001051/e2853_ex10-2.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Form
of Securities Purchase Agreement, dated June 14, 2021</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001051/e2853_ex10-2.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on June 16, 2021.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.15</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001051/e2853_ex10-1.htm" tabindex="18"><span style="font-size: 10pt">Letter
Agreement, dated June 14, 2021, by and between the Company and H.C. Wainwright</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001051/e2853_ex10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 16, 2021.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.16</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm" tabindex="18"><span style="font-size: 10pt">Employment
Agreement, dated August 11, 2021, by and between the Company and Dr. Mark Dybul</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm" tabindex="18"><span style="font-size: 10pt">Incorporated
herein by reference to Exhibit to 10.1 the Company’s Current Report on Form 8-K/A, filed with the SEC on August 16, 2021.</span></a></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">23.1*&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112221001565/e3109_ex23-1.htm" tabindex="18">Consent of Sadler, Gibb &amp; Associates</a>&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31.1* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112221001565/e3109_ex31-1.htm" tabindex="18"><span style="font-size: 10pt">Certification
of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31.1* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112221001565/e3109_ex31-2.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Certification
of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">32.1** </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112221001565/e3109_ex32-1.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Certification
of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.
Section 1350</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">32.2**</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112221001565/e3109_ex32-2.htm" tabindex="18"><span style="font-size: 10pt; text-underline-style: none">Certification
of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section
1350</span></a></span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">101.INS </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
Calculation Linkbase* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
Definition Linkbase* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
Label Linkbase* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE </span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
Presentation Linkbase* </span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp; &nbsp; &nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
    <td>*</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
    <td colspan="2" style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Provided herewith.</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">**</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Furnished herewith.</span></td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 80; Value: 43 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_050"></span>SIGNATURES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Date: September 24, 2021</span></td>
<td colspan="2" style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>ENOCHIAN BIOSCIENCES INC.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="width: 50%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 5%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 45%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">By: </span></td>
<td style="border-bottom: black 1pt solid; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Mark
Dybul</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Mark Dybul</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer </span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer) </span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">By: </span></td>
<td style="border-bottom: black 1pt solid; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Luisa
Puche</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Luisa Puche</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer </span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)
</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: black 1pt solid; width: 36%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Signature</b></span></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1pt solid; width: 44%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title</b></span></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1pt solid; width: 18%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Dr. Mark Dybul</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer </span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Dr. Mark Dybul</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer) </span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Luisa Puche</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Luisa Puche</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;René Sindlev </span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Director and Chairman of the Board</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">René Sindlev </span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Henrik Grønfeldt-Sørensen</span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Director </span></td>
<td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
<td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Henrik Grønfeldt-Sørensen</span></td>
<td colspan="2" style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="line-height: 107%">&nbsp;</td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 36%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Carl Sandler</span></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 44%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Director </span></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 18%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Carl Sandler</span></td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; padding-left: 25.15pt; text-indent: 40.5pt; line-height: 107%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; padding-left: 25.15pt; text-indent: 40.5pt; line-height: 107%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Gregg Alton</span></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Director </span></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Gregg Alton </span></td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 36%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Jayne McNicol </span></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 44%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Director </span></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 18%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Ms. Jayne McNicol </span></td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 36%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;James Sapirstein </span></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 44%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Director </span></td>
    <td style="width: 1%; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; width: 18%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">James Sapirstein </span></td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
<tr>
    <td style="border-bottom: windowtext 1pt solid; vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Carol Brosgart &nbsp;</span></td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Director </span></td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">September 24, 2021</span></td></tr>
<tr>
    <td style="vertical-align: top; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Carol Brosgart </span></td>
    <td style="vertical-align: bottom; line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="line-height: 107%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; line-height: 107%">&nbsp;</td></tr>
</tbody></table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">47</p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->

</body>
</html>